{"100-1.\n24\u6b72\u7537\u75c5\u4eba\u7f79\u60a3\u50f5\u76f4\u6027\u810a\u690e\u708e\u5df22\u5e74\u591a,\u6700\u8fd1\u534a\u5e74\u4f7f\u7528\u4e0d\u540c\u7a2e\u985e\u4e4b\u975e\u985e\u56fa\u9187\u6d88\u708e\u6b62\u75db\u5291(NSAIDs)\u52a0\u4e0a\u6bcf\u59292\u514b\u4e4bsulfasalazine\u6cbb\u7642,\u75c7\u72c0\u4ecd\u7121\u6cd5\u7372\u5f97\u63a7\u5236,\u8acb\u554f\u6700\u5408\u9069\u4e4b\u4e0b\u4e00\u6b65\u6cbb\u7642\u85e5\u7269\u70ba\u4f55?\nA. Adalimumab\nB. Glucocorticoid\nC. Methotrexate\nD. Thalidomide\nE. Rituximab\n": "(A)", "100-2.\n\u4e00\u4f4d28\u6b72\u7537\u75c5\u60a3,\u6700\u8fd1\u56e0\u5c0f\u4fbf\u707c\u71b1\u75bc\u75db\u5c31\u91ab,\u5c3f\u6db2\u6aa2\u9a57\u8b49\u5be6\u70ba\u62ab\u8863\u83cc(Chlamydia trachomatis)\u5c3f\u9053\u708e.\u7d93\u6297\u751f\u7d20\u6cbb\u7642\u5f8c\u75ca\u7652.\u63a5\u4e0b\u7684\u5e7e\u9031\u4e4b\u9593,\u75c5\u4eba\u53ef\u80fd\u51fa\u73fe\u4e0b\u5217\u4e4b\u75c7\u72c0,\u8acb\u554f\u54ea\u4e00\u7a2e\u53ef\u80fd\u6027\u6700\u5c0f?\nA. \u53f3\u5074\u8db3\u8e1d\u95dc\u7bc0\u708e\nB. \u8461\u8404\u819c\u708e(uveitis)\nC. \u9999\u8178\u6307(dactylitis)\nD. \u8db3\u5e95\u76ae\u819a\u589e\u539a\u89d2\u5316\u75c7(keratodermia)\nE. \u5169\u5074\u624b\u6307proximal interphalangeal joint \u95dc\u7bc0\u708e\n": "(E)", "100-3.\n40\u6b72\u4e4b\u5973\u75c5\u60a32\u500b\u6708\u524d\u5728\u624b\u4e0a\u95dc\u7bc0\u8655(knuckle)\u51fa\u73fe\u8a31\u591a\u7d05\u75b9,\u4e0d\u75db\u4e5f\u4e0d\u7662,\u5f8c\u4f86\u76ae\u819a\u7d05\u75b9\u4e5f\u51fa\u73fe\u5728\u773c\u77bc,\u5169\u9830,\u984d\u982d\u53ca\u80a9\u9838\u90e8.\u53bb\u8a3a\u6240\u5c31\u91ab,\u4e5f\u767c\u73fe\u8ca7\u8840\u53ca\u809d\u6307\u6578(AST/ALT)\u7570\u5e38.\u6700\u8fd1\u5169\u661f\u671f\u51fa\u73fe\u56b4\u91cd\u7121\u75f0\u6027\u4e4b\u54b3\u55fd\u53ca\u547c\u5438\u56f0\u96e3.\u521d\u6b65\u80f8\u90e8X\u5149\u767c\u73fe\u5169\u5074\u80ba\u90e8\u6709\u53b2\u5bb3\u4e4b\u6d78\u6f64\u73fe\u8c61;\u8acb\u554f\u8a72\u75c5\u4eba\u6700\u53ef\u80fd\u51fa\u73fe\u4e0b\u5217\u90a3\u4e00\u7a2e\u81ea\u9ad4\u6297\u9ad4?\nA. Anti-Scl-70\nB. Anti-Sm\nC. Anti-histone\nD. Anti-Jo-1\nE. Anti-SSA\n": "(D)", "100-4.\n\u4e00\u4e9b\u8edf\u7d44\u7e54\u98a8\u6fd5\u75c7(soft tissue rheumatism)\u5bb9\u6613\u56e0\u67d0\u7279\u6b8a\u6d3b\u52d5\u7528\u529b\u4e0d\u7576\u9020\u6210.\u8acb\u554f\u4e0b\u5217\u4e4b\u914d\u5c0d\u4e2d,\u90a3\u4e00\u9805\u8f03\u4e0d\u6070\u7576?\nA. lateral epicondylitis  <------->   carry heavy suitcase\nB. plantar fasciitis <--------> run in hard surface\nC. medial epicondylitis <--------> swing golf club\nD. patellar tendinitis  <-------> jump too much\nE. adhesive capsulitis <-------->mother holds her baby\n": "(E)", "100-5.\n35\u6b72\u4e4b\u7537\u75c5\u4eba\u6bcf\u5e74\u9ad4\u6aa2\u7686\u767c\u73fe\u6709\u5c3f\u9178\u9ad8\u4e4b\u73fe\u8c61(8-9 mg/dl),\u4f46\u5f9e\u7121\u95dc\u7bc0\u708e\u4e4b\u73fe\u8c61.\u6628\u5929\u534a\u591c\u7a81\u7136\u53f3\u8173\u80cc\u53ca\u5927\u8173\u8dbe\u5287\u70c8\u75bc\u75db,\u7121\u6cd5\u5165\u7720.\u5176\u5f9e\u7121\u814e\u81df\u75c5\u53f2.\u8acb\u554f\u6b64\u6642\u4e0b\u5217\u4e4b\u85e5\u7269\u6cbb\u7642\u90a3\u4e00\u9805\u6700\u4e0d\u6070\u7576?\nA. Allopurinol 300mg qd\nB. Colchicine(0.6 mg/tab.) 2 tab. q 8h\nC. Prednisolone 10 mg tid\nD. Diclofenac 75mg bid\nE. ACTH 80 IU intramuscularly\n": "(A)", "100-6.\n\u4e00\u500b60\u6b72\u4e4b\u5973\u75c5\u4eba\u4e3b\u8a34\u624b\u6307\u9047\u51b7\u6703\u8b8a\u7d2b\u8272\u6216\u767d\u8272,\u4e14\u6709\u56b4\u91cd\u53e3\u4e7e\u53ca\u773c\u4e7e\u5df2\u534a\u5e74\u591a,\u4f46\u4e26\u7121\u76ae\u819a\u75c5\u8b8a,\u7121\u95dc\u7bc0\u75db,\u816e\u817a\u53ca\u6dcb\u5df4\u817a\u4e0d\u816b,\u4e5f\u7121\u6162\u6027\u54b3\u55fd\u73fe\u8c61.\u5be6\u9a57\u5ba4\u6aa2\u67e5\u51fa\u73feANA\u53caAnti-SSA(Ro)\u9ad8\u6fc3\u5ea6\u967d\u6027;\u8840\u6e05\u751f\u5316\u53ca\u5c0f\u4fbf\u6aa2\u67e5\u6b63\u5e38;\u80f8\u90e8X\u5149\u4e5f\u6b63\u5e38.\u9664\u7d66\u4e88\u4eba\u5de5\u6dda\u6db2\u5916,\u8acb\u554f\u4e0b\u5217\u4e4b\u6cbb\u7642\u90a3\u4e00\u7a2e\u6700\u6070\u7576?\nA. Prednisolone 10 mg/day + plaquenil 400 mg/day\nB. Methotrexate 10 mg/week + plaquenil 400 mg/day\nC. Pilocaripine 5mg qid + nifedipine 10mg tid.\nD. Rituximab therapy\nE. Cevimelline + azathioprine 100 mg/day\n": "(C)", "100-7.\n\u738b\u5c0f\u59d0\u7f79\u60a3\u5168\u8eab\u6027\u7d05\u6591\u72fc\u7621\u75c7\u4f75\u814e\u7d72\u7403\u708e\u5df24\u5e74\u591a;\u6700\u8fd1\u75c5\u60c5\u7a69\u5b9a,\u7136\u800c\u53f3\u5074\u80a1\u6e9d\u8655(inguinal area)\u6642\u5e38\u75bc\u75db\u5df2\u4e00\u500b\u591a\u6708,\u5c24\u5176\u8d70\u8def\u6642\u66f4\u611f\u4e0d\u9069,\u521d\u6b65\u9aa8\u76e4\u8154(pelvis) X\u5149\u4e26\u7121\u7570\u5e38\u73fe\u8c61;\u8acb\u554f\u4e0b\u5217\u90a3\u4e00\u9805\u6aa2\u67e5\u6700\u53ef\u80fd\u5e6b\u52a9\u8a3a\u65b7\u5176\u554f\u984c?\nA. \u8d85\u97f3\u6ce2(ultrasound)\nB. \u9aa8\u9abc\u6383\u63cf(bone scan)\nC. \u6838\u78c1\u5171\u632f(MRI)\nD. \u62bd\u8840\u6aa2\u9a57ALP\u53caCK\u503c\nE. \u8840\u7ba1\u651d\u5f71(Angiography)\n": "(C)", "100-8.\n\u738b\u5c0f\u59d0\u7f79\u60a3\u5168\u8eab\u6027\u7d05\u6591\u72fc\u7621\u5df23\u5e74\u591a,\u6700\u8fd1\u534a\u5e74\u4f86,\u5b8c\u5168\u8655\u65bc\u7121\u75c7\u72c0\u4e4b\u7de9\u89e3\u72c0\u614b(remission).\u6bcf3\u500b\u6708\u56de\u9580\u8a3a\u8ffd\u8e64\u4e00\u6b21,\u9664\u4e86\u5b8c\u6574\u4e4b\u75c5\u53f2\u8a62\u554f\u53ca\u7406\u5b78\u6aa2\u67e5\u5916,\u4e0b\u5217\u90a3\u4e9b\u5be6\u9a57\u5ba4\u4e4b\u6aa2\u67e5\u4e5f\u662f\u8a55\u4f30\u75be\u75c5\u6d3b\u6027\u4e4b\u5fc5\u8981\u6aa2\u9a57.(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.ANA\r2.Urinalysis\r3.Anti-dsDNA\r4.Anti-Sm\r5.C3 and C4\nA. 1+3+5\nB. 1+4+5\nC. 2+3+5\nD. 3+4+5\nE. 2+3+4\n": "(C)", "100-9.\n38\u6b72\u4e4b\u5973\u75c5\u60a3,\u6700\u8fd12\u661f\u671f\u591a\u6301\u7e8c\u54b3\u55fd\u5e36\u8840\u7d72,\u6f38\u6f38\u611f\u5230\u547c\u5438\u6025\u4fc3\u56f0\u96e3;\u4e00\u661f\u671f\u524d\u51fa\u73fe\u5169\u4e0b\u80a2\u6c34\u816b\u4e14\u5c3f\u91cf\u6e1b\u5c11;\u5be6\u9a57\u5ba4\u6aa2\u67e5\u767c\u73fe\u814e\u529f\u80fd\u4e0d\u5168,\u5c3f\u4e2d\u51fa\u73fe\u86cb\u767d\u5c3f\u53ca\u8840\u5c3f,\u4e14\u80f8\u90e8X\u5149\u51fa\u73fe\u5169\u5074\u80ba\u90e8\u6d78\u6f64\u80ba\u708e\u73fe\u8c61.\u8acb\u554f\u51fa\u73fe\u4e0b\u5217\u90a3\u4e00\u4e9b\u81ea\u9ad4\u6297\u9ad4\u53ef\u4ee5\u89e3\u91cb\u5176\u81e8\u5e8a\u75c7\u5019,\u4e26\u5e6b\u52a9\u8a3a\u65b7? (\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.Anti-proteinase 3\r2.Anti-Jo-1\r3.Anti-myeloperoxidase\r4.Anti-basement membrane\r5.Anti-beta 2 glycoprotein 1\nA. 1+2+3\nB. 1+3+4\nC. 2+3+4\nD. 2+4+5\nE. 3+4+5\n": "(B)", "100-10.\n\u81e8\u5e8a\u8541\u9ebb\u75b9(urticaria)\u4e4b\u767c\u751f,\u56e0\u4e0d\u540c\u539f\u56e0\u6709\u4e0d\u540c\u4e4b\u81f4\u75c5\u6a5f\u8f49,\u8acb\u554f\u4e0b\u5217\u90a3\u4e9b\u539f\u56e0\u9020\u6210\u4e4b\u8541\u9ebb\u75b9,IgE\u6297\u9ad4\u626e\u6f14\u91cd\u8981\u89d2\u8272? (\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.sunlight.\r2.seafood.\r3.radiocontrast media.\r4.anti-C1q inhibitor deficiency.\r5.aspirin and NSAIDs.\nA. 1+2\nB. 1+2+3\nC. 2+4+5\nD. 3+5\nE. 2+5\n": "(A)", "100-1.\n\u4e0b\u5217\u6709\u95dc\u514d\u75ab\u75be\u75c5\u8207\u81ea\u9ad4\u6297\u539f\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u6b63\u78ba\uff1f\nA. Systemic sclerosis--fibronectin\nB. Rheumatoid arthritis--collagen type II\nC. Hashimoto's thyroiditis--asialoglycoprotein receptor.\nD. Sjogren's syndrome--fibrillarin\nE. Dilated cardiomyopathy--F-actin\n": "(B)", "100-2.\n\u4e0b\u5217\u6709\u95dc\u4ee5\u751f\u7269\u88fd\u5291\u6cbb\u7642\u75be\u75c5\u7684\u9069\u61c9\u75c7\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u6070\u7576\uff1f\nA. IVIG--leukocytoclastic vasculitis\nB. Anti-IgE monoclonal antibody--anaphylactic shock\nC. Anti-TNF-  monoclonal antibody--rheumatoid arthritis\nD. Anti-CD20 monoclonal antibody--CREST syndrome\nE. Anti-CD3 monoclonal antibody--systemic lupus erythematosus\n": "(C)", "100-3.\n\u7576\u91ab\u5e2b\u61f7\u7591\u60a3\u8005\u7684T\u7d30\u80de\u514d\u75ab\u529f\u80fd\u6709\u554f\u984c\u6642\uff0c\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u6700\u91cd\u8981\uff1f\nA. Anergy panel skin test\nB. \u8840\u6db2\u4e2dCD3+T\u7d30\u80de\u7684\u6578\u76ee\nC. \u8840\u6e05\u4e2d\u514d\u75ab\u7403\u86cb\u767d\u7684\u6fc3\u5ea6\nD. \u8840\u6db2\u4e2dCD4/CD8 T\u7d30\u80de\u7684\u6bd4\u503c\nE. \u8840\u6e05\u4e2dTNF-alpha \u7684\u6fc3\u5ea6\n": "(A)", "100-4.\n48\u6b72\u7684\u738b\u5c0f\u59d0\u6700\u8fd1\u534a\u5e74\u4f86\uff0c\u6bcf\u5929\u508d\u665a\u958b\u59cb\u6703\u5168\u8eab\u8d77\u8541\u9ebb\u75b9\u3002\u7d93\u91ab\u5e2b\u6aa2\u67e5\u767c\u73fetotal IgE\u53catotal eosinophil count\u5747\u5c6c\u6b63\u5e38\u3002\u8acb\u554f\u4e0b\u5217\u5c0d\u65bc\"\u6162\u6027\u539f\u56e0\u4e0d\u660e\u6027\u8541\u9ebb\u75b9\"\u7684\u63cf\u8ff0\uff0c\u4f55\u8005\u6700\u6b63\u78ba\uff1f\nA. \u91cd\u8907\u76ae\u4e0b\u6ce8\u5c04\u81ea\u9ad4\u8840\u6e05\u6709\u6548\nB. \u6bcf\u5929\u5b9a\u671f\u670d\u7528H1 anti-histamine\u53ef\u4ee5\u75ca\u7652\nC. \u767c\u4f5c\u6642\u5c40\u90e8\u61c9\u5857\u62b9\u8f03\u5f37\u529b\u7684corticosteroid ointment\nD. \u4f7f\u7528hydroxychloroquine \u53cacolchicine\u6709\u52a9\u65bc\u75be\u75c5\u7684\u7de9\u89e3\nE. \u5373\u4f7f\u6c92\u6709urticaric vasculitis\u4e5f\u5fc5\u9808\u670d\u7528\u9ad8\u5291\u91cf\u7684\u985e\u56fa\u9187\n": "(D)", "100-5.\n32\u6b72\u7684\u6797\u5148\u751f\u70baHBV carrier\u3002\u5728\u5169\u9031\u524d\u56e0\u5169\u624b\u7b2cII \u53ca\u7b2cIII\u6307\u7684PIP\u548c MCP\u53ca\u5de6\u624b\u7755\u95dc\u7bc0\u75bc\u75db\u5230\u91ab\u9662\u6c42\u8a3a\u3002\u62bd\u8840\u767c\u73feESR=34 mm/1h, CRP=1.87mg/ml, RF=28.4U/ml (normal<20U/ml)\u3002\u91ab\u5e2b\u61f7\u7591\u70ba\u985e\u98a8\u6fd5\u95dc\u7bc0\u708e\uff0c\u70ba\u4f5c\u9451\u5225\u8a3a\u65b7\uff0c\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u6700\u6709\u5e6b\u52a9\uff1f\nA. Bilateral hands X-film (AP and Lat. view)\nB. Synovial fluid examination\nC. Soft tissue sonography\nD. Serum anti-CCP antibody\nE. Serum IgG4\n": "(D)", "100-6.\n51\u6b72\u7684\u674e\u592a\u592a\u6700\u8fd13\u5e74\u4f86\uff0c\u5728\u51ac\u5929\u6216\u590f\u5929\u5439\u51b7\u6c23\u6642\uff0c\u624b\u6307\u7532\u6703\u8b8a\u767d\u5f8c\u8b8a\u7d2b\u3002\u6700\u8fd1\u5169\u500b\u6708\u4f86\u559d\u6c34\u6642\u5e38\u6703\u55c6\u5230\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73fe\uff1aANA=1:1280 nucleolar+ centromere pattern, C3=107mg/ml, C4=21.4 mg/ml, anti-dsDNA =16 IU/ml (normal <120 IU/ml). hemogram \u53caurinalysis\u5747\u6b63\u5e38\uff0ccryoglobulin (-), RFs=25 IU/ml (normal<20 IU/ml)\u3002\u8acb\u554f\u9019\u4f4d\u60a3\u8005\u7684\u6700\u53ef\u80fd\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Systemic sclerosis\nB. Systemic lupus erythematosus\nC. Rheumatoid arthritis\nD. Raynaud's phenomenon\nE. Cutaneous vasculitis\n": "(A)", "100-7.\n\u4e0b\u5217\u6709\u95dc\u50f5\u76f4\u6027\u810a\u690e\u708e\u7684\u63cf\u8ff0\uff0c\u4f55\u8005\u6700\u6b63\u78ba\uff1f\nA. HLA-B27\u967d\u6027\u662f\u75be\u75c5\u8a3a\u65b7\u7684\u6700\u91cd\u8981\u4f9d\u64da\nB. \u6ce8\u5c04IL-1 receptor antagonist \u6700\u5177\u7642\u6548\nC. \u7167pelvis X-ray (AP-view)\u767c\u73febilateral S-I joint sacroiliitis GrII \u4ee5\u4e0a\u6642\uff0c\u53ef\u4ee5\u78ba\u5b9a\u8a3a\u65b7\nD. \u4e0b\u80cc\u75db\u5728\u904b\u52d5\u6642\u6703\u52a0\u5287\nE. \u521d\u59cb\u75c7\u72c0\u5927\u90fd\u767c\u751f\u572840\u6b72\u4ee5\u4e0a\u7684\u4e2d\u5e74\u4eba\n": "(C)", "100-8.\n\u4e0b\u5217\u6709\u95dc\u9000\u5316\u6027\u95dc\u7bc0\u708e(osteoarthritis, OA)\u7684\u63cf\u8ff0\uff0c\u4f55\u8005\u6700\u6b63\u78ba\uff1f\nA. \u6771\u65b9\u4eba\u7684OA\u5e38\u767c\u751f\u5728\u624b\u8155\u90e8\u53ca\u9ad6\u95dc\u7bc0\nB. \u624b\u90e8OA\u6703\u6709\u907a\u50b3\u56e0\u7d20\u7684\u5b58\u5728\nC. \u624b\u90e8X-\u5149\u6aa2\u67e5\u5e38\u5e38\u53ef\u4ee5\u767c\u73fe\u5728\u95dc\u7bc0\u5468\u908a\u6709\u9aa8\u982d\u4fb5\u8755(bone erosion)\u73fe\u8c61\nD. \u75c5\u7406\u7d44\u7e54\u53ef\u4ee5\u767c\u73fe\u8edf\u9aa8\u7684proteoglycan\u589e\u52a0\uff0c\u4f46\u662f\u8edf\u9aa8\u7d30\u80de\u6578\u76ee\u6e1b\u5c11\nE. \u95dc\u7bc0\u8154\u5167\u6ce8\u5c04hyaluronic acid\u6703\u4f7f\u8edf\u9aa8\u7d44\u7e54\u6062\u5fa9\u6b63\u5e38\n": "(B)", "100-9.\n\u4e0b\u5217\u6709\u95dc\u95dc\u7bc0\u6db2(synovial fluid, SF)\u7684\u6aa2\u67e5\u6240\u898b\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\r1.rheumatoid arthritis(RA)\u7684SF\u4e2dWBC\u6578\u76ee\u901a\u5e38>2000/\u03bcl\r2.RA\u7684SF\u4e2dC3\u53caC4\u6fc3\u5ea6\u6703\u4e0a\u5347\r3.gouty arthritis\u7684SF\u4e2d\u6703\u6709needle-shaped crystal\u5b58\u5728\r4.\u5047\u6027\u75db\u98a8(pseudogout)\u7684SF\u4e2d\u6709birefringency (\u4e00)\u7684 \u83f1\u72c0\u5f62\u7d50\u6676\u9ad4\u5b58\u5728\r5.osteoarthritis\u7684SF\u7684\u7684\u7c98\u7a20\u5ea6\u6703\u964d\u4f4e\r6.\u611f\u67d3\u6027\u95dc\u7bc0\u708e(septic arthritis)\u7684SF\u7684\u7c98\u7a20\u5ea6\u6703\u589e\u52a0\r7.RA\u7684SF\u4e2dmucin test\u6703\u5448\u967d\u6027\u53cd\u61c9\nA. 1+2+3\nB. 4+5+6\nC. 5+6+7\nD. 1+3+7\nE. 2+4+6\n": "(D)", "100-10.\n\u4e0b\u5217\u4f55\u7a2e\u95dc\u7bc0\u75be\u75c5\u6703\u5448\u73feacute monoarthritis\uff1f\r1.rheumatoid arthritis\r2.septic arthritis\r3.osteoarthritis\r4.gouty arthritis\r5.polymyalgia rheumatica\r6.reactive arthritis\r7.psoriatic arthritis\r8.osteonecrosis\nA. 1+3+5\nB. 3+7+8\nC. 2+4+6\nD. 1+6+7\nE. 2+3+4\n": "(C)", "101-1.\n60\u6b72\u4e4b\u5973\u75c5\u4eba,\u4e3b\u8a34\u53f3\u80a9\u75bc\u75db\u50f5\u786c\u5df22\u500b\u6708,\u665a\u4e0a\u6703\u75db\u5f97\u4e0d\u80fd\u5b89\u7720,\u4e26\u7121\u767c\u71d2\u4e4b\u73fe\u8c61,\u4ee5\u524d\u4e5f\u7121\u95dc\u7bc0\u708e\u75c5\u53f2.\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u53f3\u80a9\u8180\u6709\u58d3\u75db,\u4e14\u4e3b\u52d5\u6216\u88ab\u52d5\u7684\u80a9\u95dc\u7bc0\u9748\u6d3b\u5ea6\u7686\u53d7\u9650(restricted active and passive movement)\u3002X\u5149\u6aa2\u67e5\u4e26\u7121\u7279\u5225\u8b8a\u5316.\u8acb\u554f\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u53d7\u4fb5\u72af\u4e4b\u95dc\u7bc0\u7d50\u69cb\u70ba\u4f55?\nA. Bursa\nB. Capsule\nC. Cartilage\nD. Supraspinatus tendon\nE. Synovium\n": "(B)", "101-2.\n50\u6b72\u4e4b\u7537\u75c5\u4eba,\u7f79\u60a3\u75db\u98a8\u77f3\u6027\u95dc\u7bc0\u708e(tophaceous gout)\u5df21\u5e74\u591a,\u5169\u4e0b\u80a2\u6709\u8a31\u591a\u5927\u5c0f\u4e0d\u4e00\u7684\u75db\u98a8\u77f3(tophi);\u540c\u6642\u6709\u6162\u6027\u814e\u529f\u80fd\u4e0d\u5168,\u8840\u4e2dcreatinine\u503c\u70ba2.5 mg/ml,\u4e26\u6709\u814e\u7d50\u77f3.\u5176HLA-B5801\u57fa\u56e0\u70ba\u967d\u6027.\u8acb\u554f\u6700\u5408\u9069\u7684\u964d\u5c3f\u9178\u85e5\u7269\u70ba\u4f55?\nA. Febuxostat\nB. Probenecid\nC. Benzbramarone\nD. Sulfinpyrazone\nE. Allopurinol\n": "(A)", "101-3.\n\u95dc\u7bc0\u708e\u4e4b\u9451\u5225\u8a3a\u65b7\u4e4b\u8981\u9ede\u5305\u62ec\u5176\u70ba\u75c5\u7a0b\u70ba\u6025\u6027(acute)\u6216\u6162\u6027(chronic);\u5176\u4fb5\u72af\u95dc\u7bc0\u6578\u76ee\u70ba\u55ae\u4e00\u95dc\u7bc0(mono-),\u5be1\u95dc\u7bc0(oligo-)\u6216\u591a\u95dc\u7bc0(poly-).\u8acb\u554f\u4e0b\u5217\u90a3\u4e00\u7a2e\u81e8\u5e8a\u95dc\u7bc0\u708e\u985e\u578b(pattern),\u505a\u95dc\u7bc0\u62bd\u6db2(arthrocentesis)\u70ba\u6700\u5fc5\u8981\u7684,\u6700\u6709\u8a3a\u65b7\u50f9\u503c(essential)\u7684\u6aa2\u67e5?\nA. Acute monoarthritis\nB. Acute polyarthritis\nC. Chronic monoarthritis\nD. Chronic polyarthritis\nE. Acute oligoarthritis\n": "(A)", "101-4.\n\u751f\u7269\u88fd\u5291(biologicals)\u4e4b\u7814\u767c\u6210\u529f,\u4f7f\u5f97\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\u4e4b\u6cbb\u7642\u6709\u9577\u8db3\u4e4b\u9032\u6b65.\u8acb\u554f\u4e0b\u5217\u4e4b\u751f\u7269\u88fd\u5291\u53ca\u4f5c\u7528\u6a5f\u5236\u4e4b\u914d\u5c0d\u4e2d\uff0c\u90a3\u4e00\u9805\u662f\u932f\u8aa4\uff1f\nA. adalimumab : TNF-alpha inhibition\nB. abatacept : T cell costimulation blockage\nC. etanercept : TNF-alpha inhibition\nD. rituximab : B cell depletion\nE. tocilizumab : IL-1 inhibition\n": "(E)", "101-5.\n\u70ba\u4f7f\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\u80fd\u66f4\u65e9\u671f\u8a3a\u65b7,\u66f4\u65e9\u4f7f\u7528\"\u75c5\u7a0b\u4fee\u98fe\u85e5\u7269\"(DMARDs),\u7f8e\u570b\u53ca\u6b50\u76df\u98a8\u6fd5\u75c5\u91ab\u5b78\u6703\u65bc\u897f\u51432010\u5e74\u63a8\u51fa\u65b0\u5206\u985e\u8a3a\u65b7\u6a19\u6e96(classification criteria),\u63a1\u8a08\u5206\u6cd5(score),\u8acb\u554f\u4e0b\u5217\u90a3\u4e00\u9805\u4e4b\u7d66\u5206\u6700\u9ad8?\nA. \u75c7\u72c0\u8d85\u904e6\u661f\u671f\nB. CRP\u53caESR\u503c\u7686\u4e0a\u5347\nC. \u5169\u5074\u819d\u95dc\u7bc0\u816b\u75db\u767c\u708e\nD. \u4f4e\u6fc3\u5ea6rheumatoid factor\u967d\u6027\nE. \u5169\u5074wrists\u53ca\u5169\u50743rd proximal interphangeal joints \u767c\u708e\n": "(E)", "101-6.\n\u8541\u75f2\u75b9(urticaria)\u6216\u8840\u7ba1\u6c34\u816b(angioedema)\u6709\u8a31\u591a\u4e0d\u540c\u7684\u81f4\u75c5\u6a5f\u5236;\u8acb\u554f\u4e0b\u5217\u4e4b\u914d\u5c0d\u4e2d,\u90a3\u4e00\u9805\u662f\u932f\u8aa4\uff1f\nA. dermographism : IgE-dependent\nB. C1 inhibitor deficiency : bradykinin-mediated\nC. reaction to blood products : complement-mediated\nD. aspirin : altered arachidonic acid metabolism\nE. solar urticaria : direct mast cell-releasing effect\n": "(E)", "101-7.\n28\u6b72\u5973\u6027\u75c5\u4eba,\u4e3b\u8a34\u96d9\u5074\u624b\u6307\u95dc\u7bc0\u75bc\u75db\u5df2\u4e00\u500b\u591a\u6708,\u9664\u5916\u4e26\u7121\u5176\u4ed6\u75c7\u72c0.\u6700\u8fd1\u516c\u53f8\u9ad4\u6aa2,\u767c\u73fe\u767d\u8840\u7403\u53ca\u8840\u5c0f\u677f\u6578\u76ee\u7a0d\u4f4e,\u5176\u4ed6\u6b63\u5e38.\u5176\u6642\u5e38\u6709\u53e3\u8154\u6f70\u760d\u60c5\u5f62.\u6297\u6838\u6297\u9ad4(ANA)\u6aa2\u9a57\u70ba\u9670\u6027.\u8acb\u554f\u70ba\u78ba\u8a8d\u662f\u5426\u7f79\u60a3\u5168\u8eab\u6027\u7d05\u6591\u72fc\u7621,\u4e0b\u6b21\u7684\u81ea\u9ad4\u6297\u9ad4\u6aa2\u67e5\u90a3\u4e00\u7d44\u662f\u6700\u9069\u7576\u7684?\nA. Repeat ANA + anti-dsDNA + anti-Ro\nB. Repeat ANA + anti-Sm + anti-Ro\nC. Repeat ANA + anti-Sm +anti-RNP\nD. Anti-dsDNA + anti-ribosomal  P + anti-cardiolipin\nE. Anti-Sm + anti-histone +anti-La\n": "(A)", "101-8.\n\u4e00\u500b30\u6b72\u7537\u6027\u4e3b\u8a34\u4e0b\u80cc\u75db\u5df2\u534a\u5e74,X\u5149\u6aa2\u67e5\u4e26\u7121\u660e\u986f\u8b8a\u5316.\u4f46ESR\u53caCRP\u7686\u660e\u986f\u4e0a\u5347.\u6700\u8fd13\u500b\u6708\u5176\u8173\u5f8c\u8ddf(heel)\u4e5f\u6642\u5e38\u75bc\u75db.\u9a57\u5176HLA-B27\u57fa\u56e0\u70ba\u967d\u6027.\u5176\u7236\u89aa\u70ba\u50f5\u76f4\u6027\u810a\u690e\u708e\u4e4b\u60a3\u8005.\u75c5\u4eba\u5f9e\u672a\u63a5\u53d7\u904e\u4efb\u4f55\u85e5\u7269\u6cbb\u7642,\u8acb\u554f\u6700\u9069\u7576\u7684\u8655\u65b9\u70ba\u90a3\u4e00\u9805\u85e5\u7269?\nA. Glucocorticoid\nB. Etanercept\nC. Sulfasalazine\nD. Methotrexate\nE. Non-steroidal anti-inflammatory drugs\n": "(E)", "101-9.\n42\u6b72\u5973\u6027\u75c5\u4eba\u4e3b\u8a34\u5026\u6020,\u5076\u800c\u767c\u71d2\u53ca\u9ad4\u91cd\u6e1b\u8f15\u5df23\u500b\u591a\u6708.\u4e0a\u80a2\u624b\u81c2\u6d3b\u52d5\u7a0d\u4e45,\u5e38\u767c\u4f5c\u6fc0\u70c8\u75bc\u75db.\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u6709\u9ad8\u8840\u58d3\u73fe\u8c61,\u5de6\u5074\u624b\u8155\u8108\u535a(radial pulse)\u6478\u4e0d\u5230.\u62bd\u8840ESR(>100 mm)\u53caCRP\u660e\u986f\u4e0a\u5347,\u4e14\u8840\u4e2dcreatinine\u503c\u504f\u9ad8.\u8acb\u554f\u75c5\u4eba\u6700\u53ef\u80fd\u7f79\u60a3\u4e0b\u5217\u90a3\u4e00\u7a2e\u75be\u75c5?\nA. Henoch-Schonlein purpura\nB. Churg-Strauss syndrome\nC. Takayasu's arteritis\nD. Temporal arteritis\nE. Microscopic polyangitis\n": "(C)", "101-10.\n\u98a8\u6fd5\u75c5\u4e4b\u9451\u5225\u8a3a\u65b7,\u8a73\u7d30\u75c5\u53f2\u8a62\u554f\u53ca\u7406\u5b78\u6aa2\u67e5\u76f8\u7576\u91cd\u8981.\u8acb\u554f\u4e0b\u5217\u90a3\u4e9b\u98a8\u6fd5\u75c5\u4e3b\u8981\u9760\u75c5\u53f2\u53ca\u7406\u5b78\u6aa2\u67e5\u505a\u8a3a\u65b7\u4f9d\u64da,\u62bd\u8840\u6aa2\u9a57\u7121\u751a\u5e6b\u52a9?\r(1)dermatomyositis\r(2)fibromyalgia\r(3)relapsing polychondritis\r(4)Behcet's disease\r(5)Wegener's granulomatosis\nA. (1)+(2)+(3)\nB. (1)+(4)+(5)\nC. (2)+(3)+(4)\nD. (2)+(4)+(5)\nE. (2)+(3)+(5)\n": "(C)", "101-1.\n\u98a8\u6fd5\u53ca\u514d\u75ab\u75be\u75c5\u7684\u81f4\u75c5\u6a5f\u8f49\u8207\u514d\u75ab\u907a\u50b3\u5b78(immunogenetics)\u6709\u76f8\u95dc\u3002\u8acb\u554f\u4e0b\u5217\u7684\u76f8\u95dc\u6027\u4e2d,\u4f55\u8005\u6700\u70ba\u5f37\u70c8?\nA. SLE\u8207HLA-DR2\nB. Ankylosing spondylitis\u8207HLA-B2704\nC. Behcet's disease\u8207HLA-B51\nD. Graves' disease\u8207HLA-B8\nE. Chronic active hepatitis\u8207DR3\n": "(B)", "101-2.\n\u4e00\u4f4d27\u6b72\u7684\u7537\u6027\uff0c\u5f9e\u5c0f\u5c31\u6709\u4e2d\u7b49\u5ea6\u6301\u7e8c\u578b\u7684\u904e\u654f\u6027\u9f3b\u708e(Allergic rhinitis)\uff0c\u5176\u8840\u4e2dtotal IgE 325IU/ml\uff0c\u904e\u654f\u539f\u6aa2\u67e5\u767c\u73fe\u5c0dhouse dust mite Der.P \u5448+++\u3002\u8acb\u554f\u9664\u4e86immunotherapy\u4e4b\u5916\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u9996\u9078\u85e5\u7269?\nA. Intranasal glucocorticoids spray\nB. Moderate dose of oral prednisolone\nC. Anti-IgE antibody injection\nD. Oral pseudoephedrine\nE. Oral H1 antihistamine\n": "(A)", "101-3.\n\u4e00\u4f4d42\u6b72\u5973\u6027\u4e3b\u8a34\u70ba\u6162\u6027\u8541\u9ebb\u75b9\u6709\u5169\u5e74\u4e4b\u4e45\uff0c\u8fd1\u65e5\u4f86\u76ae\u819a\u98a8\u75b9\u584a\u52a0\u5287 ,      \u800c\u4e14\u58d3\u4e86\u4e4b\u5f8c\u4e5f\u4e0d\u6703\u6d88\u5931\uff0c\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u70ba\u301dvasculitic urticaria\u301e\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u6700\u70ba\u9069\u7576?\nA. Topical glucocorticoids\nB. Topical H1 type anti-histamine\nC. Systemic glucocorticoids\nD. Hydroxychloroquine\nE. Cyclosporine\n": "(C)", "101-4.\n\u4e00\u4f4d28\u6b72SLE\u60a3\u8005\u7522\u4e0b\u4e00\u4f4d\u5973\u5b30\uff0c\u4f46\u5176\u5fc3\u8df3\u53ea\u670964\u4e0b/\u5206\uff0c\u8acb\u554f\u4e0b\u5217\u7684\u54ea\u4e00\u7a2e\u81ea\u9ad4\u6297\u9ad4\u6703\u5f15\u8d77\u65b0\u751f\u5152\u7684congenital heart block?\nA. Anti-RNP\nB. Anti-Sm\nC. Anti-histone\nD. Anti-dsDNA\nE. Anti-SSA/Ro\n": "(E)", "101-5.\n\u4e00\u4f4d30\u6b72\u7684\u5973\u6027\u904e\u53bb\u6c92\u6709\u7cd6\u5c3f\u75c5\u3001\u9ad8\u8840\u58d3\u6216\u9ad8\u8840\u8102\u7684\u75c5\u53f2\u3002\u6709\u4e00\u5929\u7a81\u7136\u767c\u751f\u53f3\u4e0b\u80a2\u6df1\u90e8\u975c\u8108\u6813\u585e\uff0c\u88ab\u91ab\u5e2b\u8a3a\u65b7\u70ba\u301d\u6297\u78f7\u8102\u8cea\u6297\u9ad4\u75c7\u5019\u7fa4\u301e(Anti-phospholipid antibody syndrome)\u3002\u8acb\u554f\u4f55\u7a2e\u75c7\u72c0\u6216\u6aa2\u6e2c\u8207\u672c\u75c7\u5019\u7fa4\u6709\u95dc\uff1a\r(1)pulmonary embolism\r(2)anti-B2GPI\r(3)protein C\u7f3a\u4e4f\r(4) recurrent fetal loss\r(5) protein S\u904e\u591a\r(6) livedo reticularis\r(7)aPTT shortening\r(8)increase DRVVT\r(9)subacute cutaneous lupus skin lesion\r(10)interstitial nephritis\nA. (1)+(2)+(5)\nB. (2)+(3)+(4)\nC. (5)+(6)+(7)\nD. (1)+(2)+(9)\nE. (2)+(4)+(6)\n": "(E)", "101-6.\n\u6709\u95dc\u985e\u98a8\u6fd5\u95dc\u7bc0\u708e\u7684\"\u95dc\u7bc0\u5916\u75c7\u72c0\"\u5f88\u591a\uff0c\u4e0b\u5217\u90a3\u4e9b\u75c7\u72c0\u5305\u62ec\u5728\u5167\uff1f\r(1)iritis\r(2)episcleritis\r(3)subcutaneous nodule\r(4)keratoconjunctivitis sicca\r(5)pleural effusion\r(6)thrombocytopenia\r(7)glomerulonephritis\r(8)ischemic necrosis of femoral head\r(9)interstitial lung disease\r(10)cervical myelopathy\nA. (1)+(3)+(5)\nB. (2)+(4)+(9)\nC. (6)+(7)+(8)\nD. (8)+(9)+(10)\nE. (3)+(6)+(9)\n": "(B)", "101-7.\n\u5728\u5065\u4fdd\u7684\u4f7f\u7528\u898f\u7bc4\u4e0a\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u70ba\u6cbb\u7642\u985e\u98a8\u6fd5\u95dc\u7bc0\u708e\u7684\u7b2c\u4e00\u7dda\u751f\u7269\u88fd\u5291\uff1f\nA. Soluble TNF-\u03b1 receptor\nB. Anti-CD20 antibody\nC. Soluble CTLA4\nD. Anti-IL-6 receptor antibody\nE. Anti-LFA1 antibody\n": "(A)", "101-8.\n\u4e0b\u5217\u54ea\u4e00\u7a2e\u8840\u6e05\u5b78\u6216\u5f71\u50cf\u5b78\u6aa2\u67e5\u5728\u8a3a\u65b7\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\u7684\u7279\u7570\u6027\uff08specificity\uff09\u6700\u9ad8\uff1f\nA. Rheumatoid factors\nB. Anti-collagen antibodies\nC. X-ray findings of hands\nD. Anti-CCP antibodies\nE. Soft tissue sonography\n": "(D)", "101-9.\n\u54ea\u4e9b\u81e8\u5e8a\u75c7\u72c0\u6216\u6aa2\u67e5\u8207\u5168\u8eab\u6027\u786c\u5316\u75c7\uff08systemic sclerosis\uff09\u6700\u6709\u76f8\u95dc\uff1f\r(1)anti-centromere antibody\r(2)Raynaud's phenomenon\r(3)active synovitis\r(4)decrease in DLCO\r(5)Gottron's sign\r(6)anti-Scl70 antibody\r(7)photosensitivity\r(8)swallowing disturbance\r(9)uveitis\r(10)peripheral neuropathy\nA. (1)+(2)+(3)\nB. (2)+(4)+(6)\nC. (5)+(6)+(7)\nD. (8)+(9)+(10)\nE. (3)+(6)+(8)\n": "(B)", "101-10.\n\u4e0b\u5217\u4f55\u8005\u53ef\u4ee5\u4f5c\u70ba\u7be9\u9078\u8840\u7ba1\u708e\u7684biomarker\uff1f\nA. Rheumatoid factors\nB. ESR\nC. Thrombocytopenia\nD. Anti-neutrophil cytoplasmic antibodies\nE. Complement C3 levels\n": "(D)", "102-1.\n\u738b\u5973\u58eb45\u6b72\u60a3SLE(systemic lupus erythematosus)\u591a\u5e74\u5408\u4f75\u56b4\u91cd\u8840\u5c0f\u677f\u6e1b\u5c11\u75c7,\u7d93\u985e\u56fa\u9187\u53ca\u5176\u5b83\u7a4d\u6975\u6cbb\u7642\u5f8c\u7121\u6548,\u91ab\u5e2b\u5efa\u8b70\u5979\u63a5\u53d7\u813e\u81df\u5207\u9664\u8853,\u5979\u5728\u624b\u8853\u524d2\u9031\u61c9\u63a5\u53d7\u4f55\u7a2e\u75ab\u82d7\u9810\u9632\u6ce8\u5c04?\nA. A\u578b\u809d\u708e(Hepatitis A)\u75ab\u82d7\nB. \u6c34\u75d8(Varicella)\u75ab\u82d7\nC. \u80ba\u708e(Pneumococcal)\u75ab\u82d7\nD. \u5e36\u72c0\u76b0\u75b9(Herpes zoster)\u75ab\u82d7\nE. \u7834\u50b7\u98a8(Tetanus)\u75ab\u82d7\n": "(C)", "102-2.\n\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(Rheumatoid arthritis)\u6700\u5177\u8a3a\u65b7\u7279\u7570\u6027\u4e4b\u6aa2\u67e5\u70ba\nA. ESR\nB. CRP\nC. Antibodies to cyclic citrullinated peptide\nD. Anti-topoisomerase I antibody\nE. Anti-histone antibody\n": "(C)", "102-3.\n\u738b\u5148\u751f55\u6b72\u6bcf\u5e74\u75db\u98a8\u767c\u4f5c4-5\u6b21,\u6bcf\u6b21\u767c\u4f5c\u6642\u624d\u627e\u91ab\u5e2b\u6cbb\u7642,\u9664\u751f\u6d3b\u7fd2\u6163\u6539\u5584\u5916,\u4e0b\u5217\u4f55\u7a2e\u5efa\u8b70\u662f\u4ed6\u7684\u6700\u597d\u6cbb\u7642\u6216\u6cbb\u7642\u76ee\u6a19?\nA. \u9577\u671fColchicine\u9810\u9632\nB. \u9577\u671fNon-steroid anti-inflammatory drugs\u4f7f\u7528\nC. \u964d\u4f4e\u8840\u4e2d\u5c3f\u9178\u6fc3\u5ea6\u52309-10mg/dl\nD. \u964d\u4f4e\u8840\u4e2d\u5c3f\u9178\u6fc3\u5ea6\u52308-9mg/dl\nE. \u964d\u4f4e\u8840\u4e2d\u5c3f\u9178\u6fc3\u5ea6\u52305-6mg/dl\n": "(E)", "102-4.\n\u6839\u64da2010\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(Rheumatoid arthritis)\u8a3a\u65b7(ACR&EULAR 2010 criteria)\uff0c\u9700\u67096\u5206\u4ee5\u4e0a\u624d\u80fd\u8a3a\u65b7\u985e\u98a8\u6fd5\u95dc\u7bc0\u708e\u3002\u738b\u5c0f\u59d0\u5728\u5169\u624bmetacarpophalangeal\u53caproximal interphalangeal\u5171\u67099\u500b\u5c0f\u95dc\u7bc0\u767c\u708e\uff0c\u5176\u5206\u6578(score)\u6709\uff1a\nA. 1\nB. 2\nC. 3\nD. 4\nE. 5\n": "(C)", "102-5.\n\u738b\u5973\u58eb45\u6b72\u60a3\u6709\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\u591a\u5e74,\u7d93\u50b3\u7d71Disease-modified anti-rheumatic drugs (DMARD)\u6cbb\u7642\u7121\u6548\u5f8c,\u6c7a\u5b9a\u4f7f\u7528\u751f\u7269\u88fd\u5291TNF-\u03b1\u6291\u5236\u5291,\u5979\u4f7f\u7528\u751f\u7269\u88fd\u5291\u524d\u6700\u91cd\u8981\u4e4b\u6aa2\u67e5\u70ba\nA. \u8166\u6ce2(EEG)\nB. \u5fc3\u96fb\u5716(EKG)\nC. Purified peptide derivative (PPD) skin test\nD. \u80ba\u529f\u80fd(pulmonary function tests)\nE. \u808c\u96fb\u5716(EMG)\n": "(C)", "102-6.\nAllopurinol\u5e38\u88ab\u4f7f\u7528\u65bc\u964d\u8840\u4e2d\u5c3f\u9178,\u5176\u526f\u4f5c\u7528\u70ba\u5e38\u767c\u751f\u904e\u654f\u53cd\u61c9,\u53f0\u7063\u5b78\u8005\u5df2\u767c\u73fe\u57fa\u56e0\u8207Allopurinol\u904e\u654f\u6709\u5bc6\u5207\u95dc\u4fc2,\u6b64\u57fa\u56e0\u70ba\nA. HLA DR1\nB. HLA B*5701\nC. HLA B*5801\nD. HLA B*1502\nE. HLA B*1501\n": "(C)", "102-7.\n\u738b\u5148\u751f40\u6b72\u7537\u6027\u6709\u50f5\u76f4\u6027\u810a\u690e\u708e8\u5e74,HLA-B27\u967d\u6027,\u904e\u53bb\u4ed6\u4e26\u6c92\u63a5\u53d7\u9069\u7576\u4e4b\u6cbb\u7642,\u4e8c\u5929\u5f8c\u958b\u59cb\u773c\u775b\u7d05,\u71b1,\u75db\u53ca\u754f\u5149,\u4ed6\u6700\u6709\u53ef\u80fd\u5f97\u5230\u4e0b\u5217\u75be\u75c5\nA. \u904e\u654f\u6027\u7d50\u819c\u708e(Allergic conjunctivitis)\nB. \u524d\u623f\u8461\u8404\u819c\u708e(Anterior uveitis)\nC. \u8996\u7db2\u819c\u7624(Retina tumor)\nD. \u9752\u5149\u773c(Glaucoma)\nE. \u767d\u5167\u969c(Cataract)\n": "(B)", "102-8.\n\u4e0b\u5217\u54ea\u4e9b\u8840\u7ba1\u708e\u75be\u75c5\u8f03\u6613\u7522\u751fanti-neutrophil cytoplasmic antibodies (ANCA) (1)Granulomatosis with polyangiitis (Wegener's) (2)Behcet's disease (3)Microscopic polyangiitis (4)Giant cell arteritis (5)Takayasu's arteritis\nA. (1)+(3)\nB. (2)+(4)\nC. (3)+(5)\nD. (2)+(4)\nE. (4)+(5)\n": "(A)", "102-9.\n\u4e0b\u5217\u4e8c\u7a2e\u5371\u96aa\u56e0\u5b50(Risk factors)\u8207\u9000\u5316\u6027\u95dc\u7bc0\u708e(Osteoarthritis arthritis)\u4e4b\u767c\u751f\u6709\u95dc: (1)\u62bd\u83f8 (2)\u98f2\u98df (3)\u6c23\u5019 (4)\u5e74\u9f61 (5)\u80a5\u80d6\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (1)+(5)\n": "(D)", "102-10.\n\u4e0b\u5217\u7d30\u80de\u6fc0\u7d20(cytokine)\u662f\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(Rheumatoid arthritis)\u4e4b\u4e3b\u8981\u7d30\u80de\u6fc0\u7d20:(1)IL-2 (2)TNF-\u03b1 (3)IL-4 (4)IL-10 (5)IL-17\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (2)+(5)\n": "(E)", "102-1.\n\u4e0b\u5217\u6709\u95dc\u904e\u654f\u6027\u9f3b\u708e\u7684\u63cf\u8ff0\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. \u5b63\u7bc0\u578b\u7684\u60a3\u8005\u8207\u9ef4\u83cc(mold)\u904e\u654f\u539f\u6700\u6709\u95dc\u4fc2\nB. \u7d93\u5e74\u578b\u7684\u60a3\u8005\u8207\u5875\ufffdu(house dust mite)\u904e\u654f\u539f\u6700\u6709\u95dc\u4fc2\nC. \u62bd\u8840\u6aa2\u67e5\u904e\u654f\u539f\u7684\u7279\u7570\u6027\u6297\u9ad4\u6700\u5177\u8a3a\u65b7\u7279\u7570\u6027\nD. \u5b63\u7bc0\u578b\u7684\u60a3\u8005\u8840\u6e05\u4e2d\u7684IgE\u901a\u5e38\u4e0d\u6703\u9ad8\nE. \u5f15\u8d77\u904e\u654f\u6027\u9f3b\u708e\u7684\u904e\u654f\u539f\u7c92\u5b50\u901a\u5e38\u6bd4\u6c23\u5598\u904e\u654f\u539f\u70ba\u5c0f\n": "(B)", "102-2.\n24\u6b72\u7684\u5973\u6027\u60a3\u8005\u7f79\u60a3\u8541\u9ebb\u75b9\u6a23\u7684\u76ae\u819a\u6414\u7662\u6709\u4e00\u5e74\u56db\u500b\u6708\u4e4b\u4e45\uff0c\u6bcf\u6b21\u767c\u4f5c\u6642\u76ae\u819a\u6703\u81a8\u8d77\uff0c\u7d93\u56db\u5929\u4e4b\u5f8c\u624d\u6703\u6d88\u5931\u3002\u76ae\u819a\u5207\u7247\u6aa2\u67e5\u767c\u73fe\u5c0f\u975c\u8108\u6709\u767c\u708e\u7d30\u80de\u7684\u6d78\u6f64\u53cafibrinoid necrosis\u3002\u8acb\u554f\u9577\u671f\u4f7f\u7528\u4e0b\u5217\u4f55\u8005\u85e5\u7269\u6700\u70ba\u9069\u7576\uff1f\nA. H1 anti-histamine\nB. Local application of corticosteroid ointment\nC. Methotrexate\nD. Anti-IgE therapy\nE. Hydroxychloroquine\n": "(E)", "102-3.\n27\u6b72\u7537\u6027\u60a3\u8005\u8fd1\u534a\u5e74\u4f86\u6709\u91cd\u8907\u6027\u7684\u53e3\u8154\u53ca\u820c\u982d\u9ecf\u819c\u7684\u75bc\u75db\u6027\u6f70\u760d\u3002\u4e26\u4e14\u6703\u6709\u591a\u8655\u95dc\u7bc0\u9178\u75db\uff0c\u5176\u9593\u5076\u800c\u4e0b\u80a2\u6703\u51fa\u73fe\u58d3\u75db\u6027\u7684\u7d05\u6591\u3002\u6b64\u7d05\u6591\u75c5\u8b8a\u66fe\u88ab\u91ab\u5e2b\u61f7\u7591\u70ba\u8840\u7ba1\u708e\u3002\u53c8\uff0c\u60a3\u8005\u70ba\u6162\u6027B\u809d\u5e36\u539f\u8005\uff0c\u62bd\u8840\u6aa2\u67e5\u767c\u73feANA 1:160 speckled pattern\u3001rheumatoid factor(RF) 108 IU/ml (normal < 10 IU/ml)\u3001C3\u53caC4\u6b63\u5e38\u3001 HLA-B27 (+)\u3002\u8acb\u554f\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Behcet's disease\nB. SLE\nC. Rheumatoid arthratis (RA)\nD. Leukocytoclastic vasculitis\nE. Chronic urticaria\n": "(A)", "102-4.\n28\u6b72\u7684\u5973\u6027SLE\u60a3\u8005\u6709\u4e09\u6b21\u6d41\u7522\u53ca\u4e00\u6b21\u6b7b\u7522\u4e4b\u61f7\u5b55\u53f2\u3002\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6297\u9ad4\u8207\u7fd2\u6163\u6027\u6d41\u7522\u6700\u6709\u76f8\u95dc\uff1f\nA. Anti-dsDNA\nB. Anti-SSB/La\nC. Anti-Sm/anti-RNP\nD. Anti-\u03b22GPI\nE. Anti-PCNA\n": "(D)", "102-5.\n\u4e00\u4f4d\u7f79\u60a3\u72fc\u7621\u814e\u708e\u7684\u60a3\u8005\u6bcf\u65e5\u6295\u4e88prednisolone 10mg\u53caazathioprine 100mg\u3002\u6709\u4e00\u5929\u5176serum creatinine\u7531\u539f\u672c\u76841.8mg/dL\u5728\u4e8c\u500b\u6708\u4e4b\u5167\u5feb\u901f\u4e0a\u6607\u81f35.3mg/dL\uff0c\u800c\u4e14\u6709\u4e0b\u80a2\u6d6e\u816b\u51fa\u73fe\u3002\u8acb\u554f\u61c9\u8a72\u99ac\u4e0a\u7d66\u4e88\u4f55\u7a2e\u85e5\u7269\u6cbb\u7642\u6700\u70ba\u6070\u7576\uff1f\nA. Methylprednisolone pulse therapy\nB. Oral mycophenolate mofetil\nC. Cyclophosphamide pulse therapy\nD. Rituximab IV infusion\nE. Belimumab IV infusion\n": "(C)", "102-6.\n\u4e00\u4f4d31\u6b72\u7684\u5973\u6027\u5728\u4e8c\u5929\u524d\u53f3\u4e0b\u817f\u7a81\u7136\u767c\u751f\u816b\u8139\u5287\u75db\u3002\u7d93\u62bd\u8840\u6aa2\u67e5\u767c\u73feESR 41 mm/h\u3001CRP 2.3mg/dL\u3001ANA 1:80 speckled pattern, blood culture (-)\u3001PT\u6b63\u5e38\uff0c\u4f46PTT\u5ef6\u9577\u81f353\u79d2\uff08\u6b63\u5e3836\u79d2\uff09\u3001Anti-SSA 34.6 AU/mL (normal < 1.2)\uff0canti-SSB < 1.2 AU/ml\u3001DRVVT\u4e0a\u5347\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u7684\u53ca\u6642\u6cbb\u7642\u6700\u70ba\u6070\u7576\uff1f\nA. Intravenous antibiotics\nB. Low molecular weight heparin infusion\nC. Corticosteroid 1mg/kg/day IV infusion\nD. Oral cylophosphamide 100mg/day\nE. Intravenous immunoglobulin for 5 days\n": "(B)", "102-7.\n58\u6b72\u7684\u5973\u6027\u60a3\u8005\u4e3b\u8a34\u70baRaynaud's phenomenon\u6709\u4e00\u5e74\u4e4b\u4e45\u3002\u8fd1\u4e09\u500b\u6708\u4f86\u5169\u624b\u80cc\u7684\u76ae\u819a\u9010\u6f38\u8b8a\u786c\u3002\u53e6\u5916\uff0c\u5403\u6771\u897f\u5bb9\u6613\u55c6\u5230\u3002\u91ab\u5e2b\u61f7\u7591\u5979\u7f79\u60a3\u786c\u76ae\u75c7\u3002\u514d\u75ab\u5b78\u6aa2\u67e5\u767c\u73feanti-Scl-70\u70ba 126 AU/mL (normal<1.5 AU/mL)\uff0c\u80ba\u529f\u80fd\u53cadiffusion capacity of carbon monoxide(DLCO)\u6aa2\u67e5\u6b63\u5e38\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u70ba\u9996\u9078\u85e5\u7269?\nA. Cyclophosphamide pulse therapy\nB. High dose oral corticosteroids\nC. Colchicine\nD. D-penicillamine\nE. Methotrexate\n": "(D)", "102-8.\n\u6709\u95dc\u50f5\u76f4\u6027\u810a\u690e\u708e\u7684\u8840\u6db2\u53ca\u8840\u6e05\u5b78\u6aa2\u67e5\u6578\u64da\u5982\u4e0b\uff0c\u8acb\u554f\u4f55\u8005\u6700\u70ba\u6b63\u78ba?(1) ANA(+)  (2) ESR\u4e0a\u5347( 3) CRP\u4e0a\u5347  (4) RF (+) (5)Anti-CCP (-)  (6) HLA-B27(+)  (7) ANCA(+)\nA. (1)+(2)+(3)\nB. (4)+(5)+(6)\nC. (2)+(4)+(7)\nD. (3)+(4)+(5)\nE. (3)+(5)+(6)\n": "(E)", "102-9.\n\u4e0b\u5217\u6709\u95dc\u5404\u7a2evasculitis syndromes\u7684\u75be\u75c5\u7279\u5fb5\u7684\u63cf\u8ff0\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f(1)Granulomatosis with polyangiitis--cANCA (+) (2)\tHenoch-Schonlein purpura--serum IgE\u4e0a\u5347 (3)Polyarteritis nodosa-paranasal sinusitis (4)Takayasu's arteritis--pulseless disease (5)Leukocytoclastic vasculitis--pANCA (+) (6)Churg-Strauss syndrome--allergic manifestations (7)Temporal arteritis--serum IgA\u4e0a\u5347\nA. (1)+(4)+(6)\nB. (1)+(2)+(3)\nC. (3)+(4)+(5)\nD. (2)+(6)+(7)\nE. (3)+(5)+(7)\n": "(A)", "102-10.\n\u4e0b\u5217\u6709\u95dc\u5404\u7a2e\u95dc\u7bc0\u708e\u7684\u75be\u75c5\u7279\u5fb5\u63cf\u8ff0\uff0c\u4f55\u7a2e\u7d44\u5408\u6700\u70ba\u6b63\u78ba\uff1f\r(1)\tOsteoarthritis--osteophyte formation\r(2)\tRheumatoid arthritis--marginal bone erosion\r(3)\tPsoriatic arthropathy--osteonecrosis\r(4)\tPseudogout--monosodium urate deposit\r(5)\tAnkylosing spondylitis--chronic synovitis\r(6)\tFrozen shoulder--tendinitis\r(7)\tReactive arthritis--enthesitis\nA. (1)+(3)+(5)\nB. (2)+(6)+(7)\nC. (3)+(4)+(5)\nD. (1)+(4)+(7)\nE. (2)+(5)+(6)\n": "(B)", "103-1.\n\u9673\u5c0f\u59d0\uff0c 28\u6b72\uff0c\u672a\u5a5a\uff0c\u56e0\u70ba\u4e0b\u80a2\u6c34\u816b\u4f86\u4f4f\u9662\uff0c \u4e26\u7121\u5176\u4ed6\u81e8\u5e8a\u8868\u5fb5 (\u5305\u62ec:\u96d9\u9830\u7d05\u75b9\u3001\u5634\u7834\u53ca\u6389\u9aee\u7b49)\uff0c\u6aa2\u9a57\u5831\u544a\u53ea\u670924\u5c0f\u6642\u86cb\u767d\u5c3f3.2g\uff0c \u8840\u6db2\u767d\u86cb\u767d2.0 mg/dl , ANA(+) (Antinuclear antibodies) 1:1280X speckled pattern\uff0canti-double strand DNA Ab(-) \u8acb\u554f\u63a5\u4e0b\u4f86\u8981\u505a\u4ec0\u9ebc\u6aa2\u67e5\u4f86\u8a3a\u65b7\u8f03\u70ba\u5408\u9069?\nA. \u4e09\u5929\u5f8c\u518d\u62bd\u4e00\u6b21anti-double strand DNA Ab, \u8981\u9023\u7e8c3\u6b21.\nB. \u5b89\u6392\u814e\u81df\u5207\u7247\nC. \u5b89\u6392\u773c\u5e95\u93e1\u6aa2\u67e5\nD. \u62bd\u8840\u6aa2HLA typing\nE. \u4ee5\u4e0a\u7686\u5fc5\u8981.\n": "(B)", "103-2.\n\u5433\u5c0f\u59b9\u59b9\uff0c16 \u6b72\uff0c 1 \u5e74\u524d\u8a3a\u65b7\u6709SLE\uff0c\u6700\u8fd13\u5929\u5abd\u5abd\u767c\u73fe\u5979\u6027\u683c\u6539\u8b8a\uff0c \u958b\u59cb\u4e82\u7f75\u4eba\uff0c\u53c8\u6709\u4e9b\u767c\u71d2\uff0c \u4f46\u7121\u8116\u5b50\u50f5\u786c\uff0c \u56e0\u6b64\u4f86\u4f4f\u9662\u3002 \u8acb\u554f\u63a5\u4e0b\u4f86\u8981\u505a\u4ec0\u9ebc\u8840\u6e05\u6aa2\u67e5\u4f86\u8a3a\u65b7\u8f03\u70ba\u5408\u9069?\nA. Anti-cardiolipin Ab + Anti-Ribosomal P Ab\nB. Anti-Ribosomal P Ab + Anti-Smith Ab\nC. Anti-smooth-muscle antibody (ASMA)\nD. Antithyroglobulin antibody\nE. \u4ee5\u4e0a\u7686\u5c0d\n": "(A)", "103-3.\n42\u6b72\u5973\u6027\u75c5\u60a3\u6709primary systemic sclerosis\u75c5\u53f23\u5e74\uff0c\u56e0\u5168\u8eab\u62bd\u6410\u88ab\u9001\u81f3\u6025\u8a3a\u3002\u5230\u9662\u6642\u8840\u58d3200/106 mmHg\uff0c\u8a3a\u65b7\u70bastatus epilepticus\u3002\u75c5\u60a3\u524d\u4e00\u9031\u66fe\u81f3\u773c\u79d1\u9580\u8a3a\u5c31\u91ab\uff0c\u4e3b\u8a34\u70ba\u8996\u529b\u6a21\u7cca\uff0c\u773c\u5e95\u93e1\u6240\u898b\u70ba\u8996\u7db2\u819c\u51fa\u8840\u4e26\u6709cotton wool spots\u3002\rHb\t10.1 g/dL\rWBC\t6450/\u03bcL\rPlatelets\t204,000/\u03bcL\rBUN\t50 mg/dL\rCreatinine\t2.0 mg/dL\rESR\t77 mm/hr\rUrine protein\t+++\rUrine RBC\t10-20/HPF\r\u4ee5\u4e0b\u54ea\u7a2e\u6cbb\u7642\u6700\u9069\u7576\uff1f\nA. \u7d66\u4e88oral captopril\nB. \u7d66\u4e88IV labetalol (Trandate)\nC. \u7d66\u4e88oral methotrexate\nD. \u7d66\u4e88IV phenytoin\nE. \u5b89\u6392plasma exchange\n": "(A)", "103-4.\n69\u6b72\u9000\u4f11\u8b77\u7406\u5e2b\uff0c\u5973\u6027\uff0c\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\u75c5\u53f215\u5e74\uff0c\u65bc\u534a\u5e74\u524d\u63a5\u53d7\u751f\u7269\u88fd\u5291adalimumab Q2W\u4f75\u7528methotrexate 15mg QW\u53caprednisolone 10mg QD\u6cbb\u7642\u3002\u8fd1\u4e09\u9031\u51fa\u73fe\u75b2\u5026\u3001\u9ad4\u91cd\u6e1b\u8f155\u516c\u65a4\u3001\u53ca\u591c\u9593\u76dc\u6c57\u4e4b\u60c5\u5f62\u3002\u7406\u5b78\u6aa2\u67e5\u4e26\u7121\u95dc\u7bc0\u767c\u708e\u53caDAS28\u70ba3.1\u5206\u3002\u5176\u4ed6\u7406\u5b78\u6aa2\u67e5\u4e26\u7121\u76ae\u75b9\u6dcb\u5df4\u816b\u5927\u6216\u809d\u813e\u816b\u5927\u3002\u80f8\u90e8\uff38\u5149\u7121\u767c\u73fe\u7570\u5e38\u3002\rHb\t13.1 g/dL\rWBC\t7200/\u03bcL\rPlatelets\t204,000/\u03bcL\rRF\t320 U/L\rANA\tnegative\rESR\t72 mm/hr\rCRP\t5.5 mg/dL\rLDH\u53cabeta-2 microglobulin\tBoth within normal ranges\r\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u70ba\u6700\u9069\u7576\u4e4b\u6aa2\u67e5\uff1f\nA. bone marrow biopsy\nB. CT scan of thorax, abdomen and pelvis\nC. PPD test\nD. QuantiFeron test for tuberculous infection\nE. Creatine kinase (CK)\n": "(D)", "103-5.\n27\u6b72\u5973\u6027\uff0c\u67095\u5e74\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\u75c5\u53f2\uff0c\u65bc1\u5e74\u524d\u958b\u59cb\u63a5\u53d7\u751f\u7269\u88fd\u5291etanercept\u6cbb\u7642\uff0c\u76ee\u524d\u4e26\u7121\u95dc\u7bc0\u816b\u75db\u53ca\u6668\u9593\u50f5\u786c\uff0cDAS28\u70ba2.2\u5206\u3002\u6700\u8fd1\u4e00\u500b\u6708\u767c\u73fe\u81c9\u4e0a\u6709\u7d05\u6591\u53ca\u6389\u9aee\u60c5\u5f62\uff0c\u81c9\u4e0a\u7d05\u6591\u65bc\u65e5\u66ec\u5f8c\u66f4\u70ba\u660e\u986f\u3002\u8fd1\u5169\u9031\u51fa\u73fe\u5de6\u80f8\u75bc\u75db\uff0c\u5c24\u5176\u5728\u5438\u6c23\u6642\u66f4\u70ba\u75db\u695a\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u7a2e\u6aa2\u67e5\u6700\u70ba\u6709\u8a3a\u65b7\u6027\uff1f\nA. anti-cardiolipin antibodies\nB. anti-dsDNA\nC. anti-histone antibodies\nD. ANCA\nE. anti-SSA and anti-SSB\n": "(B)", "103-6.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u8ef8\u5fc3\u578b\u810a\u690e\u95dc\u7bc0\u708eAxial spondyloarthritis\u7684\u8a3a\u65b7\u689d\u4ef6\u4e4b\u4e00\uff1f\nA. \u5bb6\u65cf\u53f2\u6709\u810a\u690e\u95dc\u7bc0\u708e\u4e4b\u4efb\u4e00\u7a2e\nB. \u4f7f\u7528NSAID\u5f8c\u6709\u9032\u6b65\nC. MRI\u6709sacroiliitis\nD. ESR\u5347\u9ad8\nE. HLA-B27\u967d\u6027\n": "(D)", "103-7.\n\u4e00\u4f4d40\u6b72\u5bb6\u5ead\u4e3b\u5a66\uff0c\u56e0\u5de6\u53f3\u624b\u8108\u640f\u5f37\u5ea6\u4e0d\u540c\u800c\u5230\u91ab\u9662\uff0c10\u5e74\u524d\u4ed6\u66fe\u6709\u4e09\u500b\u6708\u7684\u767c\u71d2\u3001\u5b50\u5bae\u808c\u7624\u8207\u9ad4\u91cd\u6e1b\u8f15\u4e4b\u75c5\u53f2\uff0c\u7576\u6642\u8840\u58d3120/70 mmHg\uff0c\u9ad4\u6eab37.8\u2103\uff0c\u8108\u640f80/min\uff0c\u76ae\u819a\u6c92\u7d05\u6591\uff0c\u7121\u53e3\u8154\u6f70\u760d\uff0c\u5fc3\u81df\u7121\u96dc\u97f3\uff0c\u4f46\u5728\u5de6\u908asupraclavicular fossa\u6709Bruit\uff0c\u5176\u4ed6\u6b63\u5e38\uff0c10\u5e74\u4f86\u5979\u4e26\u4e0d\u518d\u770b\u91ab\u5e2b\uff0c10\u5e74\u524d\u7684\u5be6\u9a57\u5ba4\u6aa2\u67e5\u70ba\uff1a\u8840\u6bd4\u5bb928 %\uff0c\u767d\u8840\u74037,600/\u03bcL\uff0c\u8840\u5c0f\u677f480,000/\u03bcL\uff0cESR 80 mm/hr\uff0c CRP 4.5mg/dL\uff0cCK\u3001serum creatinine\u3001RF\u3001ANCA\u3001ANA\u7686\u9670\u6027\u3002\u9019\u75c5\u4eba\u6700\u6709\u53ef\u80fd\u662f\u4f55\u7a2e\u75be\u75c5\nA. Adult onset Still's disease\nB. Microscopic polyangiitis\nC. polyarteritis nodosa\nD. Rheumatoid arthritis\nE. Takayasu's arteritis\n": "(E)", "103-8.\n\u767c\u708e\u6027\u4e0b\u80cc\u75db(Inflammatory low back pain)\u7684\u7279\u5fb5\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f(1)\u767c\u75c5\u5e74\u9f61\u5c0f\u65bc40\u6b72 (2)\u6f38\u9032\u767c\u751f (3)\u904b\u52d5\u904e\u5f8c\u53ef\u6e1b\u8f15 (4)\u6668\u9593\u50f5\u786c (5)\u53d7\u50b7\u5f15\u8d77 (6)high CRP\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (5)+(6)\nE. (1)+(6)\n": "(D)", "103-9.\n\u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621\u75c5\u4eba\u9808\u61f7\u5b55\u6642\u4f7f\u7528\u4e0b\u5217\u85e5\u7269\u5c0d\u5f71\u97ff\u80ce\u5152\u6700\u5c0f(1)Glucocorticoid (2)Tacrolimus (3)Rituximab (4)Cyclosporine (5)Methotrexate (6)Low-dose aspirin\nA. (1)+(2)\nB. (3)+(4)\nC. (5)+(6)\nD. (1)+(3)\nE. (1)+(6)\n": "(E)", "103-10.\n\u4e0b\u5217\u85e5\u7269\u6700\u5e38\u898b\u5f15\u8d77\u7d05\u6591\u6027\u72fc\u7621\uff08Lupus-like disease\uff09\u70ba(1)Procainamide (2)Disopyramide (3)Furosemide (4)Glucocorticoid\r(5)Azathioprine (6)Methotrexate\nA. (1)+(2)\nB. (3)+(4)\nC. (5)+(6)\nD. (1)+(5)\nE. (1)+(6)\n": "(A)", "103-1.\n\u4e0b\u5217\u6709\u95dc\u75be\u75c5\u8207\u514d\u75ab\u529f\u80fd\u7570\u5e38\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Mycobacterial infection - antibody deficiency\nB. Recurrent Streptococcus pneumoniae infection- cellular deficiency\nC. Recurrent skin pyogenic infections - phagocytic defect\nD. Recurrent Neisseria infection - antibody deficiency\nE. Inflammatory diseases - complement deficiency\n": "(C)", "103-2.\n\u4e0b\u5217\u6709\u95dc\u751f\u7269\u88fd\u5291\u8207\u75be\u75c5\u6cbb\u7642\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Soluble CTLA-4 protein - T cell lymphoma\nB. Anti-TNF-\u03b1 monoclonal antibody - rheumatoid arthritis\nC. IVIG - multiple myeloma\nD. Anti - CD20 monoclonal antibody - acute B cell leukemia\nE. Anti-IL-6 receptor monoclonal antibody - SLE\n": "(B)", "103-3.\n\u4e0b\u5217\u6709\u95dc\u904e\u654f\u6027\u9f3b\u708e\u6cbb\u7642\u7684\u63cf\u8ff0\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Immunotherapy\u5c0d\u4efb\u4f55\u5c6c\u6027\u7684\u904e\u654f\u6027\u9f3b\u708e\u90fd\u662f\u6700\u597d\u7684\u6cbb\u7642\u9078\u64c7\nB. \u55ae\u682a\u6297IgE\u6297\u9ad4\u5c0dallergen-specific IgE\u5347\u9ad8\u7684\u9f3b\u708e\u60a3\u8005\u6700\u6709\u6548\nC. \u53e3\u670d\u03b1-adrenergic agonist\u662f\u9996\u9078\u6cbb\u672c\u7684\u85e5\u7269\nD. Intra-nasal high-potency glucocorticoids\u7684\u4f7f\u7528\u5c0d\u904e\u654f\u75c7\u72c0\u6700\u6709\u6548\nE. \u8f15\u5ea6\u3001\u9593\u6b47\u6027\u7684\u904e\u654f\u6027\u9f3b\u708e\u767c\u4f5c\u6642\u53ef\u4ee5\u77ed\u671f\u4f7f\u7528\u9ad8\u5291\u91cf\u7684\u53e3\u670d\u985e\u56fa\u9187\u6cbb\u7642\n": "(D)", "103-4.\n\u4e00\u4f4d57\u6b72\u5973\u6027\uff0c\u8fd1\u4e8c\u5e74\u4f86\u767c\u73fe\u51ac\u5b63\u5929\u51b7\u6642\uff0c\u53f3\u624b\u7b2c\u4e09\u53ca\u7b2c\u56db\u6307\u7684\u6307\u7532\u6703\u8b8a\u767d\u8b8a\u7d2b\u3002\u6700\u8fd1\u4e00\u5e74\u4f86\u5169\u5074\u624b\u80cc\u7684\u76ae\u819a\u8b8a\u539a\u8b8a\u786c\u3002\u559d\u6c34\u6642\u5076\u800c\u6703\u55c6\u5230\u53ca\u6709\u4e7e\u54b3\u767c\u751f\u3002\u5230\u8a3a\u6240\u62bd\u8840\u767c\u73feANA 1:5120 speckled + 1:320 centromere pattern\uff0cC3 109 mg/dL\uff0cC4 21.4 mg/dL\uff0canti-dsDNA 42.5 IU/mL (normal < 120 IU/mL)\u3001anti-SSA 25.4 U/mL (< 12.0 U/mL)\uff0canti-SSB 8.6 U/mL (< 12.0 U/mL)\u3002\u8acb\u554f\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\uff1a\nA. SLE\nB. Systemic sclerosis\nC. Sjogren's syndrome\nD. Psoriasis\nE. Cutaneous vasculitis\n": "(B)", "103-5.\n\u4e00\u4f4d46\u6b72\u7684\u7537\u6027\uff0c\u904e\u53bb\u6709\u91cd\u8907\u6027\u7684\u5de6\u5074\u816e\u817a\u816b\u5927\u3002\u6700\u8fd1\u534a\u500b\u6708\u4f86\u6709\u660e\u986f\u7684\u6d88\u5316\u4e0d\u826f\u53ca\u98df\u617e\u4e0d\u632f\u3002\u53e6\u5916\uff0c\u4e5f\u6709\u773c\u4e7e\u53ca\u53e3\u4e7e\u767c\u751f\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73feANA: 1:80 speckled\uff0cAST 38 U/L\uff0cALT 62 U/L\uff0canti-SSA 8 U/mL (<12 U/mL)\uff0canti-SSB 11 U/mL (<12 U/mL)\uff0camylase 185 U/L\u3002\u8179\u90e8\u8d85\u97f3\u6ce2\u767c\u73fe\u80f0\u81df\u982d\u90e8\u816b\u5927\u4e14\u6709\u7e96\u7dad\u5316\u3002\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u75be\u75c5\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f\nA. Serum IgG4\nB. Serum electrophoresis\nC. Anti-aquaporin 4 antibodies\nD. Minor salivary gland biopsy\nE. Sialoscintigraphy\n": "(A)", "103-6.\n\u4e00\u4f4d21\u6b72\u7684\u7537\u6027\uff0c\u65e9\u6668\u8d77\u4f86\u6709\u4e0b\u80cc\u75db\u90545\u500b\u6708\u4e4b\u4e45\u3002\u8d77\u5e8a\u4ee5\u5f8c\u7a0d\u4e8b\u904b\u52d520\u5206\u4e4b\u5f8c\uff0c\u4e0b\u80cc\u7684\u50f5\u786c\u53ca\u75e0\u75db\u5f88\u5feb\u5c31\u6703\u7de9\u89e3\u3002\u7d93\u591a\u5bb6\u91ab\u9662\u6aa2\u67e5\u5305\u62ec\uff0cESR 2 mm/1h\u3001CRP<0.3 mg/dL\u3001\u9aa8\u76c6X-\u5149\u7167\u76f8\u7121\u660e\u986f\u7684sacroiliitis\u3002\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u65bc\u8a3a\u65b7axial spondyloarthropathy\u6700\u6709\u5e6b\u52a9\uff1f\nA. Soft tissue sonography\nB. Inflammatory bone scan\nC. Dynamic MRI test\nD. HLA-B27 genotyping\nE. Lumbar spine mobility test\n": "(C)", "103-7.\n\u4e00\u4f4d69\u6b72\u7684\u75db\u98a8\u60a3\u8005\uff0c\u904e\u53bb\u6709\u5c3f\u8def\u7d50\u77f3\u7684\u75c5\u53f2\u3002\u56e0\u7d93\u5e38\u4f7f\u7528NSAIDS\u4ee5\u81f4\u814e\u529f\u80fd\u53d7\u640d\u3002\u8840\u6db2\u6aa2\u67e5\u767c\u73feBUN 34 mg/dL\uff0ccreatinine 2.3 mg/dL\uff0curic acid 9.1 mg/dL\u3002\u53e6\u5916\u6aa2\u6e2cHLA\u767c\u73fe\u70baHLA-B*5801\u5e36\u539f\u8005\u3002\u8acb\u554f\u4f7f\u7528\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u4f86\u964d\u5c3f\u9178\u6700\u70ba\u9069\u7576\uff1f\nA. Allopurinol\nB. Probenecid\nC. Benzbromarone\nD. Febuxostat\nE. Colchicine\n": "(D)", "103-8.\n\u5728SLE\u60a3\u8005\u7684\u8840\u6e05\u4e2d\u542b\u6709\u5404\u5f0f\u5404\u6a23\u7684\u6297\u9ad4\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u624d\u662f\u6700\u6b63\u78ba\u7684\u7d44\u5408\u6297\u9ad4\uff1f (1) ACPA  (2) ANCA  (3) anti-SSA/anti-SSB  (4) anti-histone  (5) anti-Sm/ anti-RNP  (6) anti-lymphocyte  (7) anti-mitochondria  (8) anti-LKM  (9) anti-centromere\nA. (1)+(3)+(9)\nB. (2)+(6)+(8)\nC. (3)+(4)+(7)\nD. (1)+(5)+(8)\nE. (4)+(5)+(6)\n": "(E)", "103-9.\n\u8207rheumatoid arthritis\u76f8\u95dc\u7684\u56e0\u5b50\u5f88\u591a\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e9bcytokines/ chemokines \u8207rheumatoid pathogenesis\u6700\u6709\u76f8\u95dc\uff1f\r(1) IL-2  (2) IL-1  (3) IL-6  (4) TGF-\u03b2  (5) TNF-\u03b1  (6) IL-4  (7) G-CSF  (8) IFN-\u03b3  (9) IL-10\nA. (1)+(2)+(4)\nB. (3)+(5)+(8)\nC. (4)+(6)+(7)\nD. (2)+(8)+(9)\nE. (1)+(5)+(7)\n": "(B)", "103-10.\n\u4e0b\u5217\u7684\u54ea\u7a2e\u8840\u7ba1\u708e\u6709\u53ef\u80fd\u6703\u7522\u751fanti-neutrophil cytoplasmic antibodies (ANCAs) ? (1) giant cell arteritis  (2) polyarteritis nodosa  (3) idiopathic cutaneous vasculitis (4) granulomatosis with polyangiitis  (5) hepatitis C-associated cryoglobulinemic vasculitis  (6) microscopic polyangiitis  (7) Kawasaki disease (8) Churg-Strauss syndrome  (9) Takayasu's arteritis\nA. (1)+(2)+(4)\nB. (2)+(5)+(7)\nC. (4)+(6)+(8)\nD. (3+(5)+(9)\nE. (5)+(6)+(7)\n": "(C)", "104-1.\n\u4e00\u4f4d65\u6b72\u786c\u76ae\u75c7\u5973\u6027\u75c5\u4eba\uff0c\u9577\u671f\u4ee5\u514d\u75ab\u6291\u5236\u5291\u63a7\u5236\u75c5\u60c5\uff0c\u6700\u8fd1\u958b\u59cb\u611f\u89ba\u8d70\u8def\u6703\u547c\u5438\u56f0\u96e3\u53ca\u75b2\u5026\uff0c\u91ab\u5e2b\u61f7\u7591\u6709\u80ba\u52d5\u8108\u9ad8\u8840\u58d3\uff0c\u4e0b\u5217\u6aa2\u67e5\u662f\u8a3a\u65b7\u80ba\u52d5\u8108\u9ad8\u58d3\u4e4b\u5e38\u7528\u65b9\u6cd5\uff1f\r(1)\u80f8\u90e8X\u5149 (Chest X-ray) ; (2)\u53f3\u5fc3\u5c0e\u7ba1\u6aa2\u67e5 (R't Heart Catheterization) ; (3)\u5de6\u5fc3\u5c0e\u7ba1\u6aa2\u67e5 (L't Heart Catheterization) ; (4)\u6297\u6838\u6297\u9ad4 (ANA) ; (5)\u8d85\u97f3\u6ce2\u6aa2\u67e5 (Echocardiography)\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (1)+(2)+(5)\nD. (1)+(4)+(5)\nE. (3)+(4)+(5)\n": "(C)", "104-2.\n\u4e00\u4f4d28\u6b72\u7537\u6027\u4e3b\u8a34\u767c\u71d2\u3001\u982d\u75db\u3001\u8179\u7009\u53ca\u76ae\u819a\u7d05\u75b9\u6709\u5169\u9031\uff0c\u75c5\u4eba\u4e8c\u500b\u6708\u524d\u5230\u5b5f\u52a0\u62c9\u7d93\u5546\u4e00\u9031\uff0c\u66fe\u6709\u6c34\u72c0\u8179\u7009\u591a\u5929\uff0c\u4e0b\u5217\u6aa2\u67e5\u8f03\u4e0d\u5177\u8a3a\u65b7\u50f9\u503c\uff1f\nA. \u8840\u6db2\u57f9\u990a\nB. \u9aa8\u9ad3\u57f9\u990a\nC. \u672a\u7d93\u6cbb\u7642\u75c5\u4eba\uff0c\u611f\u67d3\u4e00\u9031\u4e4b\u5927\u4fbf\u57f9\u990a\nD. \u672a\u7d93\u6cbb\u7642\u75c5\u4eba\uff0c\u611f\u67d3\u4e09\u9031\u4e4b\u5927\u4fbf\u57f9\u990a\nE. Widal test\n": "(E)", "104-3.\n\u4e0b\u5217\u95dc\u7bc0\u708e\u5e38\u9700\u505a\u95dc\u7bc0\u8154\u6db2\u6aa2\u67e5(Synovial fluid analysis)\u4ee5\u78ba\u5b9a\u8a3a\u65b7\nA. \u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e (RA)\nB. \u7d05\u6591\u6027\u72fc\u7621 (SLE)\nC. \u611f\u67d3\u6027\u95dc\u7bc0\u708e (septic arthritis)\nD. \u9000\u5316\u6027\u95dc\u7bc0\u708e (OA)\nE. \u7e96\u7dad\u808c\u75db\u75c7 (fibromyalgia)\n": "(C)", "104-4.\n\u4e0b\u5217\u75be\u75c5\u5e38\u4ee5\u55ae\u4e00\u95dc\u7bc0\u708e\u8868\u73fe?\r(1) \u9000\u5316\u6027\u95dc\u7bc0\u708e; (2)\u75db\u98a8\u95dc\u7bc0\u708e ; (3)\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e ; (4)\u7d30\u83cc\u611f\u67d3\u6027\u95dc\u7bc0\u708e ; (5)\u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (2)+(3)+(4)\nD. (2)+(4)+(5)\nE. (3)+(4)+(5)\n": "(B)", "104-5.\n\u4e0b\u5217\u4f55\u7a2e\u6297\u9ad4\u8207\u65b0\u751f\u5152\u72fc\u7621 (Neonatal lupus)\u5408\u4f75\u5148\u5929\u6027\u7d05\u6591\u53ca\u5148\u5929\u6027\u5fc3\u81df\u50b3\u5c0e\u969c\u7919\u6709\u95dc?\nA. La\u6297\u9ad4 (anti-La)\nB. Ro\u6297\u9ad4 (anti-Ro)\nC. Scl-70\u6297\u9ad4 (anti-Scl-70)\nD. U1 RNP (anti-U1 RNP)\nE. Sm\u6297\u9ad4 (anti-Sm)\n": "(B)", "104-6.\n\u6709\u95dc\u50f5\u76f4\u6027\u810a\u690e\u708e\u4e4b\u76f8\u95dc\u57fa\u56e0\uff0c\u4e0b\u5217\u4f55\u8005\u8f03\u4e0d\u76f8\u95dc?\nA. HLA-B27\nB. HLA-B61\nC. DR4\nD. ERAP-1\nE. IL23R\n": "(C)", "104-7.\n40\u6b72\u7537\u6027\uff0c\u53cd\u8986\u767c\u751f\u8e1d\u95dc\u7bc0\u708e\uff0c\u5e38\u4f75\u6709\u53e3\u8154\u6f70\u760d\u53ca\u5c3f\u9053\u708e\uff0c\u5076\u6709\u8ddf\u8171\u816b\u75db\uff0c\u8840\u4e2dESR=30 hr/min, HLA-B27 negative, Rheumatoid factor: negative\uff0c\u4e0b\u5217\u4f55\u7a2e\u75be\u75c5\u662f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\uff1a\nA. \u75db\u98a8\nB. \u7d05\u6591\u6027\u72fc\u7621\nC. \u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e (rheumatoid arthritis)\nD. \u810a\u690e\u95dc\u7bc0\u708e (spondyloarthritis)\nE. \u9aa8\u95dc\u7bc0\u708e (osteoarthritis)\n": "(D)", "104-8.\n38\u6b72\u7537\u6027\uff0c\u6709\u767c\u708e\u6027\u4e0b\u80cc\u75db\u7d04\u534a\u5e74\uff0cESR=30 mm/1hr\uff0c\u4f46X-ray\u7121\u660e\u986fSacroiliitis\uff0c\u4e0b\u5217\u8a3a\u65b7\u6b65\u9a5f\u4f55\u8005\u4e0d\u5408\u7406?\nA. \u8a62\u554f\u6709\u7121\u810a\u690e\u95dc\u7bc0\u708e\u5bb6\u65cf\u53f2\nB. \u7406\u5b78\u6aa2\u67e5\nC. \u6838\u91ab\u9aa8\u9abc\u6383\u63cf (Bone Scan)\nD. \u62bd\u8840\u6e2cHLA-B27\nE. \u8003\u616eSI joints MRI\n": "(C)", "104-9.\n\u767c\u708e\u6027\u4e0b\u80cc\u75db (Inflammatory low back pain)\u7684\u7279\u5fb5\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e?\nA. \u767c\u75c5\u5e74\u9f61\u5c0f\u65bc40\nB. \u6f38\u9032\u767c\u751f\nC. \u904b\u52d5\u904e\u5f8c\u53ef\u6e1b\u8f15\nD. \u6668\u9593\u50f5\u786c\nE. \u8840\u4e2dRF\u9670\u6027\n": "(E)", "104-10.\n\u4e0b\u5217\u54ea\u4e9b\u4e0d\u662f\u5c6c\u65bc\u6297\u5438\u6536\u7684 (anti-resorptive)\u6297\u9aa8\u8cea\u758f\u9b06\u85e5\u7269\nA. selective estrogen receptor modulator (raloxifene)\nB. bisphosphonqate\nC. RANKL inhibitor (Denosumab)\nD. parathyroid homone (teriparatide)\nE. hormone replacement therapy\n": "(D)", "104-1.\n\u4e0b\u5217\u6709\u95dcspecific autoantibody\u8207\u81ea\u9ad4\u514d\u75ab\u75be\u75c5\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u6b63\u78ba\uff1f\nA. Anti-collagen type II--Goodpasture's syndrome\nB. Anti-aminoacyl-tRNA histidyl synthetase--Myositis\nC. Anti-thyroid peroxidase--Graves' disease\nD. Anti-myeloperoxidase--Granulomatosis with polyangiitis\nE. Anti-keratin--SLE\n": "(B)", "104-2.\n\u4e00\u4f4d23\u6b72\u5973\u6027\uff0c\u5f9e5\u6b72\u958b\u59cb\u76ae\u819a\u6301\u7e8c\u767c\u7662\u81f3\u4eca\u3002\u5c31\u8a3a\u6642\u81c9\u90e8\u3001\u9838\u90e8\u3001\u80cc\u90e8\u3001\u8179\u90e8\u53ca\u56db\u80a2\u76ae\u819a\u5df2\u5448\u82d4\u766c\u5316(lichenification)\u3002\u8acb\u554f\u5c0d\u672c\u60a3\u8005\u6700\u6709\u7528\u7684\u6aa2\u67e5\u9805\u76ee\u70ba\uff1a\nA. Serum specific IgE\nB. Dermatography\nC. Total eosinophil count\nD. Serum complement C1 inhibitor levels\nE. Skin pathology\n": "(A)", "104-3.\n\u4e00\u4f4d26\u6b72\u7684SLE\u60a3\u8005\u904e\u53bb\u66fe\u67093\u6b21\u6d41\u7522\u7d00\u9304\uff0c\u8acb\u554f\u8207\u4e0b\u5217\u7684\u4f55\u7a2e\u81ea\u9ad4\u6297\u9ad4\u6700\u6709\u76f8\u95dc\uff1f\nA. Anti-dsDNA\nB. Anti-SSA/Ro\nC. Anti-Sm\nD. Anti-histone\nE. Anti-phospholipid\n": "(E)", "104-4.\n41\u6b72\u7684\u5973\u6027\u4f86\u9662\u6c42\u8a3a\u7684\u4e3b\u8a34\u70ba\u624b\u3001\u8173\u591a\u8655\u95dc\u7bc0\u75e0\u75db\u6709\u4e09\u5e74\u4e4b\u4e45\u3002\u6700\u8fd1\u4e8c\u500b\u6708\u4f86\u767c\u73fe\u5de6\u624b\u7b2c2\u30013\u6307\u7684\u8fd1\u7aef\u6307\u9593\u95dc\u7bc0\u816b\u8139.\u5728\u8a3a\u6240\u62bd\u8840\u6aa2\u67e5\u767c\u73fe\uff1aESR 32 mm/h\u3001CRP 1.8 mg/dL\u3001C3 89 mg/dL\u53caC4 17.1 mg/dL\uff0c\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\uff0c\u5c0d\u8a3a\u65b7\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\u6700\u6709\u5e6b\u52a9\uff1f\nA. Rheumatoid factors\nB. ANAs\nC. Anti-CCP antibodies\nD. Bilateral hand X-ray examination\nE. Bilateral hand sonographic examination\n": "(C)", "104-5.\n48\u6b72\u5973\u6027\u767c\u73fe\u8fd1\u4e09\u5e74\u4f86\u5169\u5074\u624b\u6307\u5728\u51ac\u5929\u6703\u8b8a\u767d\u53ca\u8b8a\u7d2b\uff0c\u7d93\u4fdd\u6696\u4e4b\u5f8c\u6703\u6062\u5fa9\u3002\u6700\u8fd1\u89ba\u5f97\u541e\u56a5\u6709\u9ede\u56f0\u96e3\uff0c\u53ca\u767c\u73fe\u96d9\u5074\u624b\u6307\u7684\u76ae\u819a\u8b8a\u539a\u3001\u8b8a\u786c\u3002\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u8a3a\u65b7systemic sclerosis\u6700\u6709\u5e6b\u5fd9\uff1f\nA. Anti-U1RNP\nB. Nailfold capillaroscopy\nC. Pulmonary function test + DLCO\nD. Anti-centromere antibody\nE. Anti-topoisomerase-1\n": "(E)", "104-6.\n68\u6b72\u7684\u7537\u6027\u60a3\u8005\u572815\u5e74\u524d\u56e0\u5169\u624b\u8098\u53ca\u982d\u76ae\u76ae\u819a\u75c5\u8b8a\uff0c\u88ab\u76ae\u819a\u79d1\u91ab\u5e2b\u8a3a\u65b7\u70ba\"\u4e7e\u766c\"\uff0c\u7d93\u6cbb\u7642\u4e4b\u5f8c\u76ae\u819a\u75c7\u72c0\u7a69\u5b9a\u3002\u6700\u8fd1\u4e00\u500b\u6708\u4f86\u767c\u73fe\u5169\u624b\u591a\u6307\u7684\u9060\u7aef\u6307\u9593\u95dc\u7bc0\u816b\u8139\u75bc\u75db\u3002\u800c\u4e14\u6709\u591a\u6839\u624b\u6307\u8b8a\u6210\"\u9999\u8178\u6307\u6a23\"(sausage-like finger)\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73feESR 48 mm/1h\u3001CRP 3.8 mg/dL\u3001Rheumatoid factor 14.3 IU/ml (normal < 10 IU/ml)\u3001uric acid 8.1 mg/dL\uff0cX-\u5149\u6aa2\u67e5\u767c\u73fe\u624b\u90e8\u9060\u7aef\u6307\u9593\u95dc\u7bc0\u6709\u7834\u58de\u8b8a\u578b\u3002\u56e0\u53e6\u6709\u8170\u90e8\u75e0\u75db\u7d93pelvic X-ray\u6aa2\u67e5\u767c\u73feS-I\u95dc\u7bc0\u6709\u660e\u986f\u767c\u708e\u53cd\u61c9\uff0c\u8acb\u554f\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\uff1a\nA. Rheumatoid arthritis\nB. Gouty arthritis\nC. Osteoarthritis\nD. Psoriatic arthropathy\nE. Ankylosing spondylitis\n": "(D)", "104-7.\n\u4e0b\u5217\u6709\u95dc\u6cbb\u7642\u98a8\u6fd5\u75c5/\u81ea\u9ad4\u514d\u75ab\u75be\u75c5\u7684\u85e5\u7269\u8207\u5176\u526f\u4f5c\u7528\u7684\u914d\u5c0d\u4e2d\uff0c\u5728\u81e8\u5e8a\u4e0a\u4f55\u8005\u6700\u70ba\u56b4\u91cd\uff1f\nA. Glucocorticoids--leukocytosis\nB. Azathioprine--neutropenia\nC. Methotrexate--oral mucosal ulcer\nD. Intravenous cyclophosphamide pulse therapy-teratogenicity\nE. Hydroxychloroquine--retinal detachment\n": "(B)", "104-8.\nRheumatoid arthritis\u7684\u95dc\u7bc0\u5916\u7684\u81e8\u5e8a\u8868\u5fb5\u5f88\u591a\uff0c\u4e0b\u5217\u7684\u4f55\u7a2e\u7d44\u5408\u6700\u70ba\u6b63\u78ba\uff1f(1) keratoconjunctivitis sicca (2) iritis/uveitis (3) periodontitis (4) cerebral vasculitis (5) \u9838\u690eC1-C2 subluxation (6) pleuritis (7) renal tubular acidosis (8) cutaneous vasculitis (9) thrombocytopenia (10) intestinal mucositis\nA. (1)+(4)+(7)\nB. (4)+(6)+(7)\nC. (1)+(5)+(6)\nD. (3)+(5)+(7)\nE. (2)+(9)+(10)\n": "(C)", "104-9.\n\u8840\u7ba1\u708e\u75c7\u5019\u7fa4(vasculitis syndrome)\u7684\u6a19\u5e5f\u6297\u9ad4\u70baANCA\uff0c\u8acb\u554f\u4e0b\u5217\u90a3\u4e9b\u8840\u7ba1\u708e\u662fANCA(+) vasculitis\uff1f(1) drug-induced vasculitis (2) granulomatosis with polyangiitis (3) cancer-associated vasculitis (4) Churg-Strauss syndrome (5) Behcet's disease (6) microscopic polyangiitis (7) Kawasaki disease (8) idiopathic crescentic glomerulonephritis (9) giant cell arteritis (10) polyarteritis nodosa\nA. (1)+(3)+(5)+(7)\nB. (1)+(2)+(3)+(4)\nC. (2)+(5)+(6)+(7)\nD. (2)+(4)+(6)+(8)\nE. (3)+(8)+(9)+(10)\n": "(D)", "104-10.\nChronic polyarthritis\u53ef\u4ee5\u5305\u62ec\u4e0b\u5217\u4f55\u7a2e\u75be\u75c5\uff1f(1) gouty arthritis (2) rheumatoid arthritis (3) pyogenic arthritis (4) calcium pyrophosphate deposition disease (5) osteoarthritis (6) Lyme arthritis (7) pigmented villonodular synovitis (8) reactive arthritis (9) hemophilic hemarthrosis (10) sarcoidosis\nA. (1)+(2)+(3)\nB. (2)+(5)+(10)\nC. (3)+(5)+(9)\nD. (4)+(6)+(8)\nE. (5)+(7)+(8)\n": "(B)", "105-1.\n\u50f5\u76f4\u6027\u810a\u690e\u708e(Ankylosing spondylitis ) (AS)\u4e4b\u767c\u751f\u8207\u57fa\u56e0\u6709\u5bc6\u5207\u95dc\u4fc2\uff0c\u4e0b\u5217\u57fa\u56e0\u8207AS\u4e4b\u767c\u751f\u6709\u95dc?\r1. HLA-B27\r2. HLA-DR4\r3. HLA-B8\r4. IL-23R\r5. HLA-B47\nA. 1+2\nB. 1+3\nC. 1+4\nD. 1+5\nE. 3+5\n": "(C)", "105-2.\n\u985e\u98a8\u6ebc\u6027\u95dc\u7bc0\u708e(Rheumatoid arthritis)\u70ba\u56b4\u91cd\u4e4b\u95dc\u7bc0\u708e\uff0c\u4e0b\u5217\u6558\u8ff0\u70ba\u6b63\u78ba?\r1. \u6297\u816b\u7624\u58de\u6b7b\u751f\u7269\u88fd\u5291\u70ba\u5e38\u7528\u4e4b\u6cbb\u7642\r2. \u5e38\u4fb5\u72af\u9060\u7aef\u6307\u95dc\u7bc0\r3. \u6297\u74b0\u74dc\u6c28\u9178\u6297\u9ad4(anti-CCP)\u70ba\u5176\u7279\u5fb5\u4e4b\u4e00\r4. \u5e38\u767c\u751f\u5728HLA-B8\u4e4b\u75c5\r5. \u62bd\u83f8\u7121\u95dc\nA. 1+2\nB. 1+3\nC. 1+4\nD. 1+5\nE. 3+5\n": "(B)", "105-3.\n\u4e0b\u5217\u70ba\u50f5\u76f4\u6027\u810a\u690e\u708e(AS)\u5e38\u898b\u4e4b\u95dc\u7bc0\u5916\u4e4b\u75c7\u72c0\u6216\u75be\u75c5\r1. \u524d\u8461\u8404\u819c\u708e(\u5f69\u8679\u708e)\r2. Giant cell arteritis ( temporal arteritis)\r3. \u904e\u654f\u6027\u76ae\u819a\u708e\r4. \u8178\u708e ( inflammatory bowel disease)\r5. \u80ba\u764c\nA. 1+2\nB. 1+3\nC. 1+4\nD. 1+5\nE. 2+4\n": "(C)", "105-4.\n\u6839\u64da2010\u7f8e\u570b\u98a8\u6fd5\u75c5\u91ab\u5b78\u6703\u8207\u6b50\u6d32\u98a8\u6fd5\u75c5\u806f\u76df\u5236\u5b9a\u985e\u98a8\u6ebc\u6027\u95dc\u7bc0\u708e\u4e4b\u8a3a\u65b7\u5206\u985e\u6e96\u5247\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u8f03\u91cd\u8981\u4e4b\u8a3a\u65b7\u8981\u4ef6\nA. \u4fb5\u72af\u5927\u95dc\u7bc0\nB. \u4fb5\u72af\u5c0f\u95dc\u7bc0\nC. \u53cd\u61c9\u86cb\u767d\u6fc3\u5ea6(C-reactive protein)\nD. \u7d05\u8840\u7403\u4e0b\u964d\u901f\u7387(ESR)\nE. \u767c\u75c5\u6642\u9593\u4e4b\u9577\u77ed\n": "(B)", "105-5.\n\u4e00\u4f4d22\u6b72\u7537\u6027\u9000\u4f0d\u5f8c\uff0c\u56e0\u5026\u6020\u5230\u6aa2\u9a57\u6240\u62bd\u8840\u6aa2\u67e5\uff0c\u767c\u73fe\u6885\u6bd2\u8a66\u9a57(venereal disease research laboratory test) (VDRL)\u967d\u6027\u4e0b\u5217\u4f55\u8005\u70ba\u6709\u53ef\u80fd\u4e4b\u539f\u56e0\nA. \u75c5\u4eba\u6709\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0(RA)\nB. \u75c5\u4eba\u6709\u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621(SLE)\nC. \u75c5\u4eba\u6709\u50f5\u76f4\u6027\u810a\u9ad3\u708e(AS)\nD. \u75c5\u4eba\u6709\u4e7e\u766c\nE. \u75c5\u4eba\u6709\u4e7e\u766c\u6027\u95dc\u7bc0\u708e\n": "(B)", "105-6.\n\u4e00\u4f4d55\u6b72\u5973\u6027\u75c5\u4eba\u60a3\u6709\u786c\u76ae\u75c7\u591a\u5e74\uff0c\u6700\u8fd1\u8d70\u8def\u6642\u6703\u5598\uff0c\u4e0b\u5217\u6aa2\u67e5\u8f03\u9069\u7576\nA. \u6aa2\u67e5\u6297\u9ad4anti-Scl-70\nB. \u6e2c\u80ba\u52d5\u8108\u8840\u58d3\nC. \u6aa2\u67e5\u6297\u78f7\u9178\u8102\u6297\u9ad4(anti phospholipid antibody)\nD. \u6e2c\u5fc3\u808c\u9175\u7d20(CK-MB)\nE. \u80ba\u90e8\u5207\u7247\u6aa2\u67e5\n": "(B)", "105-7.\n\u4e00\u4f4d64\u6b72\u7537\u6027\u4e3b\u8a34\u5de6\u624b\u7b2c4\u6307\u816b\u75db\u53ca\u53f3\u624b\u7b2c3\u6307\u9060\u7aef\u6307\u9593\u816b\u75db3\u500b\u6708(\u5982\u5716)\uff0c\u75c5\u4eba\u81ea\u8ff0\u4e0b\u80cc\u75db\u591a\u5e74\uff0c\u4e0b\u5217\u6aa2\u67e5\u6700\u9069\u7576\nA. \u6297\u6838\u6297\u9ad4(ANA)\nB. HLA-B27\nC. \u6297dsDNA\u6297\u9ad4(anti-dsDNA)\nD. Anti-Scl-70 \u6297\u9ad4\nE. \u8840\u4e2d\u5c3f\u9178\n": "(B)", "105-8.\n\u4e0b\u5217\u85e5\u7269\u6cbb\u7642\u5c0d\u7d05\u6591\u6027\u72fc\u7621(SLE)\u4e4bdiffuse proliferative lupus Nephritis\u6700\u9069\u7576\nA. azathioprine\nB. Plasmaphersis\nC. Cyclosporin\nD. Mycophenolate\nE. Methotrexate\n": "(D)", "105-9.\n\u4e0060\u6b72\u7537\u6027\u60a3\u8005\u6709\u7cd6\u5c3f\u75c5\u53f25\u5e74 \u7a81\u7136\u53f3\u5074\u95dc\u7bc0\u816b\u75db3\u5929\uff0cX\u5149\u50c5\u986f\u793a\u51fa\u53f3\u819d\u8edf\u7d44\u7e54\u816b\u8139\uff0c\u95dc\u7bc0\u6db2\u5206\u6790\u986f\u793aWBC 85000\uff0cN/L\uff1a85/15\uff0cMSU(-)\uff0cCPPD(-)\uff0c\u4ee5\u4e0b\u4f55\u8005\u81c6\u6e2c\u8a3a\u65b7\u6700\u6709\u53ef\u80fd\uff1f\nA. \u75db\u98a8\u6027\u95dc\u7bc0\u708e\nB. \u5047\u6027\u75db\u98a8\nC. \u9000\u5316\u6027\u95dc\u7bc0\u708e\nD. \u7d30\u83cc\u6027\u95dc\u7bc0\u708e\nE. \u985e\u98a8\u6ebc\u6027\u95dc\u7bc0\u708e\n": "(D)", "105-10.\nSjogren's syndrome \u5e38\u5408\u4f75\u6dcb\u5df4\u7624(Lymphoma) \u4e4b\u767c\u751f, Sjogren's syndrome\u75c5\u4eba\u6709\u4e0b\u5217\u6aa2\u67e5\u5e38\u5408\u4f75\u6dcb\u5df4\u7624\nA. ANA\u967d\u6027\nB. Anti-SS/A\u6297\u9ad4\u967d\u6027\nC. Anti-SS/B\u6297\u9ad4\u967d\u6027\nD. \u8840\u4e2d\u4f4e\u88dc\u9ad4\nE. \u767d\u8840\u7403\u589e\u52a0\n": "(D)", "105-1.\n21\u6b72\u7684\u5973\u6027\u60a3\u8005\uff0c\u5f9e3\u6b72\u958b\u59cb\u5c31\u6709\u6162\u6027\u5168\u8eab\u76ae\u819a\u6414\u7662\u3002\u5176\u7236\u6bcd\u5747\u6709\u904e\u654f\u6027\u75be\u75c5\u7684\u5bb6\u65cf\u53f2\u3002\u5c31\u8a3a\u6642\u767c\u73fe\u5979\u7684\u81c9\u90e8\u53ca\u5169\u624b\u8098\u7684\u76ae\u819a\u6709\u82d4\u861a\u5316\u73fe\u8c61\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73feIgE 3750IU/mL (normal<300IU/mL)\u3002\u76ae\u819a\u6414\u7662\u5c0d\u985e\u56fa\u9187\u85e5\u818f\u7684\u6cbb\u7642\u6709\u6548\uff0c\u4f46\u59cb\u7d42\u7121\u6cd5\u6cbb\u7652\u3002\u8acb\u554f\u9019\u4f4d\u60a3\u8005\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Psoriasis\nB. Chronic urticaria\nC. Atopic dermatitis\nD. Licken planus\nE. Contact dermatitis\n": "(C)", "105-2.\n\u4e0b\u5217\u6709\u95dc\u514d\u75ab\u7570\u5e38\u8207\u7f79\u60a3\u75be\u75c5\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Complement deficiency--autoimmune disorders\nB. Antibody deficiency--frequent influenza infections\nC. Cellular immunodeficiency--chronic skin infections\nD. Phagocytic deficiency--chronic fungal infections\nE. NK cell dysfunction--carcinogenesis\n": "(A)", "105-3.\n\u4e0b\u5217\u6709\u95dc\u5168\u8eab\u6027\u7d05\u6591\u72fc\u7621\u60a3\u8005\u7684\u8840\u6e05\u81ea\u9ad4\u6297\u9ad4\u8207\u81e8\u5e8a\u75c7\u72c0\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55 \u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Anti-Sm--neuropsychiatric manifestation\nB. Anti-ribosomal P--serositis\nC. Anti-SSB/La--lupus nephritis\nD. Anti-histone--drug-induced SLE\nE. Anti-RNP--vasculitis\n": "(D)", "105-4.\n\u4e00\u4f4d41\u6b72\u5973\u6027\u70ba\u6162\u6027\u809d\u708e\u60a3\u8005\u3002\u4e3b\u8a34\u70ba\u5169\u624b\u624b\u6307\u53ca\u5169\u624b\u8098\u95dc\u7bc0\u50f5\u786c\u3001\u9178\u75db\u6709\u5169\u500b\u6708\u4e4b\u4e45\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73feESR 28mm/h, CRP 1.4mg/mL\u3002\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u5c0dRA\u7684\u9451\u5225\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f\nA. Rheumatoid factors\nB. Complement C3 and C4\nC. ANA\nD. Anti-neutrophil cytoplasmic antibodies\nE. Anti-citrullinated peptide antibodies\n": "(E)", "105-5.\n54\u6b72\u5973\u6027\u60a3\u8005\u4e3b\u8a34\u51ac\u5929\u6642\u5169\u624b\u591a\u6307\u6703\u8b8a\u767d\u3001\u8b8a\u7d2b\u3002\u53e6\u5916\uff0c\u81c9\u90e8\u6709\u8774\u8776\u6591\u3001\u808c\u8089\u7121\u529b\u3001\u53ca\u559d\u6c34\u6642\u5bb9\u6613\u55c6\u5230\u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u6709\u9999\u8178\u6307\u53ca\u624b\u80cc\u76ae\u819a\u8b8a\u786c\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73fe\uff1aC3 65mg/mL, C4 14.6mg/mL, ANA 1:1280 speckled+1:640 nucleoli, RF 54U/mL, anti-dsDNA 354 IU/mL (normal <300IU/mL), anti-Scl-70<20 IU/L, anti-RNP 2476 IU/mL. proteinuria (++), CK 786 IU/mL, ESR 37mm/h, CRP 0.81mg/mL, AST 121 U/mL. ALT 18U/mL. \u8acb\u554f\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. MCTD\nB. SLE\nC. PSS\nD. RA\nE. DM/PM\n": "(A)", "105-6.\n56\u6b72\u7537\u6027\u60a3\u8005\u4e3b\u8a34\u70ba\u773c\u4e7e\u3001\u53e3\u4e7e\u3001\u5169\u5074\u816e\u817a\u816b\u8139\u3001\u53ca\u773c\u76ae\u6d6e\u816b\u6709\u4e09\u500b\u6708\u4e4b\u4e45\u3002\u4e00\u5e74\u524d\u7684\u5065\u5eb7\u6aa2\u67e5\u767c\u73feserum amylase\u6607\u9ad8\uff0c\u8179\u8d85\u6aa2\u67e5\u767c\u73fe\u80f0\u81df\u982d\u90e8\u816b\u8139\u53ca\u81bd\u7ba1\u3001\u81bd\u56ca\u6709\u7e96\u7dad\u5316\u3002\u8840\u6e05\u5b78\u6aa2\u67e5\u767c\u73fe\uff1aanti-SSA\u53caanti-SSB\u6b63\u5e38\uff0cANA 1:160 speckled, Schirmer's test: OD 4mm/5min, OS: 6mm/5min. \u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u75be\u75c5\u7684\u9451\u5225\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f\nA. Serum lipase\nB. Sialoscintigraphy\nC. Anti-mitochondrial antibodies\nD. Anti-smooth muscle antibodies\nE. Serum IgG4 level\n": "(E)", "105-7.\n56\u6b72\u7537\u6027\u60a3\u8005\u904e\u53bb\u4e09\u5e74\u4f86\u6642\u5e38\u6709\u9f3b\u7ac7\u708e\u53ca\u5169\u6b21\u6d41\u9f3b\u8840\u3002\u6700\u8fd1\u767c\u73fe\u814e\u529f\u80fd\u6709\u7570\u5e38\u53ca\u5580\u8840\u3002\u80f8\u90e8X\u5149\u6aa2\u67e5\u767c\u73fe\u80ba\u91ce\u6709\u6578\u9846\u7d50\u7bc0\u3002\u8840\u6e05\u5b78\u6aa2\u67e5\u767c\u73fe\uff1aESR \u53caCRP\u589e\u52a0\uff0cANA 1: 80 speckled, \u8840\u6db2\u5e38\u898f\u6b63\u5e38\uff0cproteinurea (++). Urine RBC 10-15/HPF, WBC 7-9/HPF, cANCA 148 IU/mL (normal<10 IU/ml). \u8acb\u554f\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Polyarteritis nodosa\nB. Eosinophilia with polyangiitis\nC. Sarcoidosis\nD. Granulomatosis with polyangiitis\nE. Paragonimiasis\n": "(D)", "105-8.\n\u4e0b\u5217\u6709\u95dc\u75c5\u56e0\u8207\u95dc\u7bc0\u708e\u5c6c\u6027\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Staphylococcus aureus--chronic monarticular arthritis\nB. Reactive arthritis--acute monarticular arthritis\nC. Rheumatoid arthritis--chronic polyarticular arthritis\nD. Mycobacterium tuberculosis--acute polyarticular arthritis\nE. Neisseria gonorrhoeae--acute monarticular arthritis\n": "(C)", "105-9.\n\u4e0b\u5217\u6709\u95dcRA\u60a3\u8005\u7684\u95dc\u7bc0\u5916\u8868\u73fe(extra-articular manifestations)\u7684\u7d44\u5408\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\r(1)\tkeratoconjunctivitis sicca (2) pleural effusion (3) thromboembolism (4) oral ulceration (5) panniculitis (6) ascites (7) erythema nodosum (8) uveitis (9) interstitial lung disease (10) IgA nephropathy\nA. 1+3+5\nB. 1+2+9\nC. 3+4+5\nD. 2+7+8\nE. 5+9+10\n": "(B)", "105-10.\n\u4e0b\u5217\u6709\u95dcanti-phospholipid antibody syndrome\u7684\u6558\u8ff0\u4e2d\uff0c\u4f55\u7a2e\u7d44\u5408\u6700\u70ba\u6b63\u78ba\uff1f\r(1) Bleeding tendency (2) aPTT prolongation (3) PT shortening (4) \u6703\u5f15\u8d77deep vein thrombosis (5) \u8207SLE recurrent abortion\u6709\u76f8\u95dc (6) \u5e38\u5e38\u6703\u5f15\u767ccutaneous vasculitis (7) \u5c0dgluco- corticoids\u7684\u6cbb\u7642\u6709\u6548 (8) \u8207SLE\u60a3\u8005\u7684 VDRL (venereal disease research laboratory) false positive\u6709\u95dc (10) \u8207SLE\u60a3\u8005\u7684leukopenia\u6709\u95dc\nA. 1+3+6\nB. 2+4+8\nC. 5+7+9\nD. 2+8+9\nE. 4+5+6\n": "(B)", "106-1.\n\u767d\u7d30\u80de\u4ecb\u7d2017 (Interleukin 17)\u626e\u6f14\u4e0b\u5217\u75be\u75c5\u91cd\u8981\u4e4b\u89d2\u8272\uff1f(1)\u75db\u98a8\u95dc\u7bc0\u708e \uff1b(2)\u9000\u5316\u6027\u95dc\u7bc0\u708e\uff1b(3)\u4e7e\u766c\u6027\u95dc\u7bc0\u708e(Psoriatic arthritis)\uff1b(4)\u50f5\u76f4\u6027\u810a\u690e\u708e(Ankylosing spondylitis)\uff1b(5)\u5168\u8eab\u6027\u786c\u5316\u75c7(Systemic sclerosis)\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (5)+(1)\n": "(C)", "106-2.\n\u95dc\u7bc0\u6db2\u62bd\u53d6\u6aa2\u67e5\u5e38\u5728\u4e0b\u5217\u75be\u75c5\u57f7\u884c\uff1f(1)\u75db\u98a8\u95dc\u7bc0\u708e\uff1b(2)\u611f\u67d3\u6027\u95dc\u7bc0\u708e\uff1b(3)\u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621 (SLE)\uff1b(4)\u5168\u8eab\u6027\u786c\u5316\u75c7 ( Systemic sclerosis)\uff1b(5)\u50f5\u76f4\u6027\u810a\u690e\u708e(Ankylosing spondylitis)\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (5)+(1)\n": "(A)", "106-3.\n\u4e00\u4f4d61\u6b72\u7537\u6027\u6709\u591a\u5e74\u559d\u9152\u7fd2\u6163\uff0c\u5168\u8eab\u6709\u75db\u98a8\u77f3\u7d50\u6676(\u5982\u5716)\uff0c\u6cbb\u7642\u7684\u76ee\u6a19\u662f\uff1f\nA. \u5916\u79d1\u624b\u8853\u53bb\u9664\u75db\u98a8\u77f3\nB. \u98f2\u98df\u63a7\u5236\nC. \u964d\u4f4e\u8840\u4e2d\u5c3f\u9178\u503c\u81f32 mg/dL\u4ee5\u4e0b\nD. \u964d\u4f4e\u8840\u4e2d\u5c3f\u9178\u503c\u81f35 mg/dL\u4ee5\u4e0b\nE. \u964d\u4f4e\u8840\u4e2d\u5c3f\u9178\u503c\u81f37 mg/dL\u4ee5\u4e0b\n": "(D)", "106-4.\n\u514d\u75ab\u7403\u86cb\u767dG4\u76f8\u95dc\u75be\u75c5(IgG4-related disease)\u5728\u7e96\u7dad\u5316\u7d44\u7e54\u5207\u7247\u6aa2\u67e5\u4e2d\u4e3b\u8981\u4e4b\u7d30\u80de\u6d78\u6f64\u70ba\uff1f\nA. \u5de8\u566c\u7d30\u80de (Macrophage)\nB. NK\u7d30\u80de\nC. \u6a39\u72c0\u7a81\u7d30\u80de(Dendritic cell)\nD. \u6f3f\u7d30\u80de(Plasma cell)\nE. B\u7d30\u80de(B cell)\n": "(D)", "106-5.\n\u50f5\u76f4\u6027\u810a\u690e\u708e(Ankylosing spondylitis)\u6700\u5e38\u898b\u7684\u95dc\u7bc0\u5916\u75c7\u72c0(extra-articular symptom)\u662f\uff1f\nA. \u8178\u80c3\u708e\nB. \u524d\u8461\u8404\u819c\u708e(Anterior uveitis)\nC. \u53e3\u8154\u6f70\u760d\nD. \u76ae\u819a\u7d05\u6591\nE. \u80ba\u90e8\u7e96\u7dad\u5316\n": "(B)", "106-6.\n\u6cbb\u7642\u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621(SLE)\u4e4b\u85e5\u7269\u4e2d\uff0c\u4e0b\u5217\u662f\u6700\u5c11\u5f15\u8d77\u80ce\u5152\u6bd2\u6027\u4e4b\u526f\u4f5c\u7528\uff1f(1)\u585e\u514b\u7f85\u9081\u5f97Cyclophosphamide (Endoxan)\uff1b(2)\u74b0\u5b62\u9748Cyclosporine\uff1b(3)\u5fc5\u8cf4\u514b\u5ed4Hydroxychloroquine\uff1b(4)\u7cd6\u76ae\u8cea\u6fc0\u7d20Glucocorticoid\uff1b(5)\u83ab\u9808\u7624Rituximab\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (5)+(1)\n": "(C)", "106-7.\n\u4e0b\u5217\u4f55\u7a2e\u6297\u9ad4\u5728\u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621(SLE)\u5e38\u5408\u4f75\u6182\u9b31\u75c7(depression)\u6216\u7cbe\u795e\u75c5(psychosis)\uff1f\nA. anti-Sm\nB. anti-RNP\nC. anti-SS-A/Ro\nD. anti-SS-A/La\nE. anti-ribosomal P\n": "(E)", "106-8.\n\u4e00\u4f4d55\u6b72\u5bb6\u5ead\u4e3b\u5a66\u4e3b\u8a34\u54b3\u55fd\u53ca\u547c\u5438\u56f0\u96e31\u500b\u6708\uff0c\u80f8\u90e8X\u5149\u986f\u793a\u9593\u8cea\u6027\u80ba\u75c5(interstitial lung disease)\uff0c\u75c5\u4eba\u66fe\u78ba\u8a3a\u70ba\u591a\u767c\u6027\u808c\u708e(polymyositis)\u3002\u4e0b\u5217\u4f55\u7a2e\u6297\u9ad4\u70ba\u51fa\u73fe\u5728\u6b64\u75be\u75c5\u6700\u5e38\u898b\u7684\u6297\u9ad4\uff1f\nA. anti-dsDNA\nB. anti-histidyl-tRNA synthetase\nC. anti-melanoma differentiation-associated gene 5\nD. anti-DNA topoisomerase 1\nE. anti-centromere\n": "(B)", "106-9.\n\u4e0b\u5217\u767d\u7d30\u80de\u4ecb\u7d20( interleukin)\u53ef\u7528\u4f86\u8a3a\u65b7\u80ba\u7d50\u6838\u611f\u67d3\u4e4b\u53ef\u80fd\uff1f\nA. \u816b\u7624\u58de\u6b7b\u56e0\u5b50-\u03b1 (Tumor Necrosis Factor-\u03b1, TNF-\u03b1)\nB. \u767d\u7d30\u80de\u4ecb\u7d2010 (IL-10)\nC. \u5e72\u64fe\u7d20-\u03b1 (Interferon-\u03b1)\nD. \u5e72\u64fe\u7d20-\u03b2 (Interferon-\u03b2)\nE. \u5e72\u64fe\u7d20-\u03b3 (Interferon-\u03b3)\n": "(E)", "106-10.\nHepcidin\u53ef\u4ee5\u5f15\u8d77\u767c\u708e\u76f8\u95dc\u4e4b\u8ca7\u8840\uff0c\u5176\u4f5c\u7528\u6a5f\u8f49\u662f\u5f71\u97ff\uff1f\nA. \u9435\u4e4b\u5438\u6536\nB. \u8449\u9178\u4e4b\u5438\u6536\nC. \u7dad\u4ed6\u547dB12\u4e4b\u5438\u6536\nD. \u7dad\u4ed6\u547dD\u4e4b\u5438\u6536\nE. \u81bd\u56fa\u9187\n": "(A)", "106-1.\n\u4e0b\u5217\u6709\u95dc\u904e\u654f\u539f\u5f15\u767c\u8541\u75f2\u75b9\u81f4\u75c5\u6a5f\u8f49\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u6b63\u78ba\uff1f\nA. Pollens\uff0dbradykinin-mediated\nB. Radiocontrast media\uff0dmast cell-mediated\nC. Opiate\uff0dIgE-dependent\nD. NSAIDs\uff0dcomplement-mediated\nE. Cold exposure\uff0dmacrophage activation\n": "(B)", "106-2.\n32\u6b72\u5973\u59d3\u60a3\u8005\u904e\u53bb\u6709\u4e8c\u6b21\u6d41\u7522\u8a18\u9304\u3002\u4e8c\u5929\u524d\u53f3\u4e0b\u817f\u7a81\u7136\u816b\u8139\u75bc\u75db\uff0c\u88ab\u61f7\u7591\u70ba\u8702\u7aa9\u7d44\u7e54\u708e\u3002\u4f46\u7d93\u6297\u751f\u7d20\u6cbb\u7642\u4e09\u5929\u4e4b\u5f8c\u7121\u986f\u8457\u6539\u5584\u3002\u8840\u6e05\u5b78\u6aa2\u67e5\u767c\u73feANA1:1280 speckled pattern, C3 57.6 mg/dL, C4 7.5 mg/dL, anti-dsDNA 473 IU/mL, \u8840\u6db2\u5b78\u6aa2\u67e5\u767c\u73fepancytopenia\u3002\u8acb\u554f\u9019\u4f4d\u60a3\u8005\u53f3\u4e0b\u817f\u7a81\u7136\u816b\u8139\u7684\u6700\u53ef\u80fd\u539f\u56e0\u70ba\u4f55\uff1f\nA. Lupus nephritis\nB. Cellulitis\nC. Anti-phospholipid syndrome\nD. Lymphoedema\nE. Sciatica\n": "(C)", "106-3.\n49\u6b72\u5973\u59d3\u60a3\u8005\uff0c\u4e8c\u5e74\u524d\u958b\u59cb\u767c\u73fe\u96d9\u5074\u624b\u6307\u5728\u51ac\u5929\u6703\u8b8a\u767d\u5f8c\u8b8a\u7d2b\u3002\u6700\u8fd1\u4e09\u500b\u6708\u96d9\u624b\u6709\u95dc\u7bc0\u9178\u75db\u53ca\u50f5\u786c\uff0c\u5634\u5df4\u5f35\u958b\u53d7\u9650\u53ca\u5403\u6771\u897f\u6709\u6642\u6703\u55c6\u5230\u3002\u5728\u61f7\u7591\u7f79\u60a3\u81ea\u9ad4\u514d\u75ab\u75be\u75c5\u4e4b\u4e0b\uff0c\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u81ea\u9ad4\u6297\u9ad4\u6aa2\u67e5\u5c0d\u75be\u75c5\u7684\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f\nA. Anti-double stranded DNA\nB. Anti-Sjogren's-syndrome-related antigen A\nC. Anti-cyclic citrullinated peptide antibody (Anti-CCP antibody)\nD. Anti-topoisomerase 1\nE. Anti-phospholipid\n": "(D)", "106-4.\n24\u6b72\u7537\u6027\u60a3\u8005\uff0c\u5728\u9577\u9014\u958b\u8eca\u6642\u6703\u6709\u8170\u9178\u80cc\u75db\u3002\u4e0b\u8eca\u6d3b\u52d520\u5206\u9418\u4e4b\u5f8c\u6703\u6539\u5584\u3002\u53e6\u5916\uff0c\u65e9\u4e0a\u525b\u8d77\u5e8a\u6642\u5168\u8eab\u6703\u50f5\u786c\u3002\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u75be\u75c5\u7684\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f\nA. HLA-B27\nB. Whole body bone scan\nC. Rheumatoid factors (RFs)\nD. Anti-nuclear antibodies (ANAs)\nE. MRI\n": "(E)", "106-5.\n61\u6b72\u5973\u59d3\u767c\u89ba\u6700\u8fd1\u81c9\u90e8\u53ca\u624b\u90e8\u6307\u7bc0\u8655\u6709\u7d05\u6591\u51fa\u73fe\u3002\u8d77\u5e8a\u6642\u7121\u6cd5\u7acb\u5373\u7ad9\u8d77\u4f86\uff0c\u5fc5\u9808\u4ee5\u96d9\u624b\u652f\u6490\u624d\u80fd\u7ad9\u8d77\u4f86\u3002\u62bd\u8840\u767c\u73feAST 108U/L, ALT 32U/L, CK 659 U/L\u3002\u8acb\u554f\u8981\u78ba\u5b9a\u8a3a\u65b7\uff0c\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u75be\u75c5\u7684\u8a3a\u65b7\u6700\u5177\u6c7a\u5b9a\u6027\uff1f\nA. MRI\nB. Electromyolography (EMG)\nC. Muscle biopsy\nD. Myoglobulin\nE. Whole body CT scan\n": "(C)", "106-6.\n82\u6b72\u7537\u6027\u60a3\u8005\uff0c\u5728\u534a\u591c\u7761\u89ba\u6642\u7a81\u7136\u767c\u751f\u5de6\u819d\u84cb\u5287\u75db\u3002\u5728\u6025\u8a3a\u62bd\u8840\u767c\u73feuric acid 6.1 mg//dL, ESR 42 mm/1h, CRP 4.6 mg/dL\u3002\u95dc\u7bc0\u6db2\u6aa2\u67e5\uff1aWBC 8480/HPF,\u767c\u73fe\u6709 rhomboid and plate-like crystal (+),\u4f46\u7121needle-shaped crystal.\u8acb\u554f\u6700\u6709\u53ef\u80fd\u7684\u75be\u75c5\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Acute gouty arthritis\nB. Pseudo-gout\nC. Septic arthritis\nD. Osteoarthritis\nE. Polymyalgia rheumatica\n": "(B)", "106-7.\n\u4ee5xanthine oxidase inhibitor \"Allopurinol\"\u6cbb\u7642\u75db\u98a8\u6642\uff0c\u5fc5\u9808\u4e8b\u524d\u6aa2\u6e2c\u4f55\u7a2e\u57fa\u56e0\uff1f\nA. HLA-B*5801\nB. HLA-DR4\nC. HLA-B*1502\nD. HLA-B27\nE. HLA-B51\n": "(A)", "106-8.\n45\u6b72\u7537\u6027\u60a3\u8005\u70baB\u809d\u5e36\u539f\u8005\u3002\u6700\u8fd1\u4e94\u5929\u5168\u8eab\u6709\u591a\u8655\u95dc\u7bc0\u75db\u767c\u751f\u3002\u5230\u91ab\u9662\u6aa2\u67e5\u767c\u73feESR 34 mm/1h, CRP 2.1 mg/dL, RF 84 IU/mL\u3002\u88ab\u61f7\u7591\u6709rheumatoid arthritis\u3002\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u75be\u75c5\u7684\u9451\u5225\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f\nA. Ferritin\nB. Bilateral hand X-ray film\nC. Cryoglobulin\nD. IgG RFs\nE. Anti-CCP\n": "(E)", "106-9.\n\u4e0b\u5217\u6709\u95dc\u8840\u7ba1\u708e\u75c7\u5019\u7fa4(vasculitis syndrome)\u8207\u81e8\u5e8a\u76f8\u95dc\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u6b63\u78ba\uff1f(1)Granulomatosis with polyangiitis\uff0dusually cANCA (+)\uff1b(2)Takayasu arteritis\uff0ddifference in bilateral. brachial blood pressure\uff1b(3)Giant cell arteritis\uff0dhigh incidence in young age group\uff1b(4)Eosinophilic granulomatosis with polyangiitis\uff0dhigh incidence in old age group\uff1b(5)Henoch-Schonlein purpura\uff0dincrease in serum IgA\uff1b(6)Polyarteritis nodosa\uff0dchronic pancreatitis\uff1b(7)Cryoglobulinemic vasculitis\uff0dassociated with hepatitis\rC\uff1b(8)Behcet's disease\uff0dusually pANCA (+)\uff1b(9)Microscopic polyangiitis\uff0dusually associated with sinusitis\nA. (1)+(2)+(3)\nB. (3)+(4)+(6)\nC. (1)+(5)+(7)\nD. (2)+(7)+(8)\nE. (1)+(3)+(9)\n": "(C)", "106-10.\n\u539f\u767c\u6027Sjogren's syndrome \u6709\u591a\u7a2e\u553e\u6db2\u817a\u4ee5\u5916\u7684\u75c7\u72c0\u8868\u73fe\u3002\u8acb\u554f\u4e0b\u8ff0\u7684\u75c7\u72c0\u7684\u7d44\u5408\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f(1)Interstitial lung fibrosis\uff1b(2)primary biliary cirrhosis\uff1b(3)uveitis\uff1b(4)scleritis\uff1b(5) autoimmune hepatitis\uff1b(6)peripheral neuropathy\uff1b(7)acute pancreatitis\uff1b(8)renal tubular acidosis\uff1b(9)amyloidosis\uff1b(10)atopic dermatitis\nA. (1)+(2)+(3)\nB. (2)+(4)+(5)\nC. (1)+(6)+(7)\nD. (4)+(9)+(1)\nE. (5)+(6)+(8)\n": "(E)", "107-1.\n\u4e00\u4f4d32\u6b72\u5a66\u5973\u56e0\u5169\u5074\u96d9\u624b\u53ca\u96d9\u8173\u816b\u75db\u7d042\u9031\u5230\u91ab\u9662\u4f4f\u9662\uff0c\u5979\u6709\u5169\u624b\u65e9\u6668\u50f5\u786c\u73fe\u8c61\uff0c\u6c92\u6709\u5176\u4ed6\u7684\u7279\u5225\u75c5\u53f2\uff0c\u7406\u5b78\u6aa2\u67e5\u986f\u793a\u96d9\u624b\u7b2c\u4e09\u3001\u7b2c\u56db\u53ca\u7b2c\u4e94\u8fd1\u7aef\u6307\u9593\u95dc\u7bc0\u58d3\u75db\u53ca\u816b\u8139\u53ca\u5169\u5074\u7b2c\u4e8c\u3001\u7b2c\u4e09\u638c\u6307\u95dc\u7bc0\u816b\u8139\u53ca\u58d3\u75db\uff0c\u624b\u90e8\u53ca\u8173\u90e8X-\u5149\u6b63\u5e38\uff0c\u4e0b\u5217\u90a3\u4e9b\u6aa2\u67e5\u5c0d\u75c5\u4eba\u662f\u6700\u6709\u5e6b\u5fd9\u8a3a\u65b7\uff1f(1). \u7d05\u8840\u7403\u4e0b\u964d\u901f\u5ea6(ESR) (2). C\u53cd\u61c9\u86cb\u767d(CRP) (3).\u6297\u74dc\u80fa\u9178\u86cb\u767d\u6297\u9ad4(ACPA) (4). \u985e\u98a8\u6fd5\u6027\u56e0\u5b50(RF) (5). \u6297\u6838\u6297\u9ad4(ANA)\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (1)+(5)\n": "(C)", "107-2.\n\u4e00\u4f4d28\u6b72\u5973\u6027\u56e0\u96d9\u624b\u53ca\u96d9\u8173\u816b\u8139\u4e00\u500b\u6708\u5230\u91ab\u9662\u6c42\u8a3a\uff0c\u4e00\u500b\u6708\u524d\u5979\u525b\u751f\u7522\u4e00\u4f4d\u6b63\u5e38\u7537\u5b30\uff0c\u75c5\u4eba\u6c92\u7279\u5225\u75c5\u53f2\uff0c\u7406\u5b78\u6aa2\u67e5\u5728\u96d9\u624b\u53ca\u96d9\u8173\u6709\u58d3\u75db\u53ca\u816b\u8139\u73fe\u8c61\uff0c\u8840\u4e2d\u767d\u8840\u74032,800/mm3\uff0c\u4e2d\u6027\u767d\u8840\u7403\u4f5476.24 %\uff0c\u6dcb\u5df4\u7403\u4f5414.64 %\uff0c\u55ae\u6838\u7d30\u80de(monocyte)8.0%\uff0c\u55dc\u9178\u6027\u7c92\u7d30\u80de(eosinophils)0.74%\uff0c\u55dc\u9e7c\u6027\u7c92\u7d30\u80de(basophils)0.54%\uff0c\u7d05\u8840\u7403(RBC)3.47 x 10^6/mm3\uff0c\u8840\u7d05\u7d20(hemoglobin)9.6 g/dl\uff0c\u8840\u7d30\u80de\u6bd4\u5bb9(hematocrit)28\r%\uff0c\u8840\u5c0f\u677f186,000/mm3\uff0c\uff0c\u7d05\u8840\u7403\u4e0b\u964d\u901f\u5ea6(ESR)80/hr\uff0cc-\u53cd\u61c9\u86cb\u767d(CRP)1.28mg/dl\uff0cANA\u6548\u50f91:1280\u967d\u6027\uff0c\u6297\u96d9\u93c8DNA\u6297\u9ad4(Anti-dsDNA)\u967d\u6027\uff0c\u8840\u4e2d\u88dc\u9ad4C3(2.31mg/dl)\u53caC4\u7686\u4e0b\u964d(5.8mg/dl)\uff0c\u81e8\u5e8a\u8a3a\u65b7\u6700\u53ef\u80fd\u70ba\nA. \u985e\u98a8\u6ebc\u6027\u95dc\u7bc0\u708e(RA)\nB. \u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621\nC. \u5168\u8eab\u6027\u786c\u5316\u75c7\nD. \u4e7e\u71e5\u75c7\nE. \u8840\u7ba1\u708e\n": "(B)", "107-3.\n\u5982\u4e0a\u8ff0\u75be\u75c5\uff0c\u5176\u6700\u6709\u53ef\u80fd\u7684\u7d30\u80de\u6fc0\u7d20\u8b8a\u5316\u662f\uff1a\r(1)\u7b2c\u4e00\u578b\u5e72\u64fe\u7d20(Type\u2160interferon)\r(2)\u4ecb\u767d\u7d20-10(interleukin-10)\r(3)\u4ecb\u767d\u7d20-1 (interleukin- 1)\r(4)\u4ecb\u767d\u7d20-2 (interleukin- 2)\r(5)\u8f49\u8b8a\u751f\u9577\u56e0\u5b50\u03b2(transforming growth factor-\u03b2)\nA. (1)\u589e\u52a0+(2)\u589e\u52a0\nB. (1)\u589e\u52a0+(4)\u589e\u52a0\nC. (3)\u589e\u52a0+(4)\u589e\u52a0\nD. (4)\u589e\u52a0+(5)\u589e\u52a0\nE. (5)\u589e\u52a0+(1)\u589e\u52a0\n": "(A)", "107-4.\n\u4e00\u4f4d28\u6b72\u7537\u6027\u8077\u696d\u8ecd\u4eba\u56e0\u70ba\u4e0b\u80cc\u75db\u67095\u5e74\u6642\u9593\uff0c\u5728\u65e9\u6668\u7761\u9192\u5f8c\u7279\u5225\u53b2\u5bb3\u65e9\u4e0a\u50f5\u786c\u6703\u6301\u7e8c2\u5c0f\u6642\uff0c\u4f46\u904b\u52d5\u5f8c\u4e0b\u80cc\u75db\u6703\u6539\u5584\uff0c\u4f7f\u7528\u6d88\u708e\u85e5\u5f8c\u6703\u6709\u4e00\u9ede\u6539\u5584\uff0c\u6b64\u5916\u6c92\u6709\u4efb\u4f55\u95dc\u7bc0\u554f\u984c\uff0c\u96d9\u89aa\u6c92\u6709\u7279\u5225\u75be\u75c5\uff0c\u4f46\u53d4\u7236\u4e5f\u6709\u9577\u671f\u4e0b\u80cc\u75db\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u6c92\u6709\u7279\u5225\u4e0d\u6b63\u5e38\uff0c\u9664\u5411\u524d\u53ca\u5411\u5f8c\u5f4e\u8170\u6709\u4e00\u4e9b\u9650\u5236\u53ca\u4e0b\u80cc\u58d3\u75db\u5916\uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5\u986f\u793a\uff1a\u7d05\u8840\u7403\u4e0b\u964d\u901f\u5ea6(ESR)48mm/h\uff0cHLA-B27(\u4eba\u985e\u767d\u8840\u7403\u6297\u539f-B27)\u9670\u6027\uff0c\u4e0b\u5217\u6aa2\u67e5\u662f\u6700\u9069\u7576\nA. \u9aa8\u6c0f\u9ac2\u95dc\u7bc0(sacroiliac joint)\u96fb\u8166\u65b7\u5c64(CT)\u6aa2\u67e5\nB. \u9aa8\u6c0f\u9ac2\u95dc\u7bc0(sacroiliac joint)\u6838\u78c1\u5171\u632f(MRI)\u6aa2\u67e5\nC. \u9aa8\u9583\u720d\u986f\u5f71\u6aa2\u67e5(bone scan)\nD. \u8d85\u97f3\u6ce2\u6aa2\u67e5(ultrasonography)\nE. \u95dc\u7bc0\u7d44\u7e54\u5207\u7247\u6aa2\u67e5(join biopsy)\n": "(B)", "107-5.\n\u4e00\u4f4d40\u6b72\u5a66\u5973\u60a3\u6709\u76ae\u808c\u708e(dermatomyositis)2\u5e74\uff0c\u4e14\u75be\u75c5\u63a7\u5236\u5f97\u5f88\u597d\uff0c\u76ee\u524d\u85e5\u7269\u4ee5\u985e\u56fa\u9187(prednisolone)\u53caazathioprine\u6cbb\u7642\uff0c\u8eab\u9ad4\u6aa2\u67e5\u7686\u6b63\u5e38\uff0c\u56db\u80a2\u808c\u8089\u529b\u91cf\u6b63\u5e38\uff0c\u6c27\u6c2398%\u98fd\u548c(O2 saturation)\u76ae\u819a\u6c92\u6709\u7d05\u6591\uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5CK 100\u03bc/L\uff0cANA 1:1280\u500d\u967d\u6027\uff0c\u6297Jo-1\u6297\u9ad4\u967d\u6027\uff0c\u76ee\u524d\u4e0b\u5217\u6aa2\u67e5\u662f\u6700\u9069\u5408\u75c5\u4eba\u4e4b\u6aa2\u67e5\nA. 6\u5206\u9418\u8d70\u8def\u6aa2\u67e5\nB. \u5fc3\u81df\u6838\u78c1\u5171\u632f\u6aa2\u67e5(MRI)\nC. \u80f8\u90e8X\u5149(chest radiography)\nD. \u904b\u52d5\u58d3\u529b\u6aa2\u67e5\nE. \u76ae\u819a\u5207\u7247\u6aa2\u67e5\n": "(C)", "107-6.\n\u4e00\u4f4d28\u6b72\u7537\u6027\u67096\u500b\u6708\u7684\u53f3\u8173\u8ddf\u75db\uff0c\u4f11\u606f\u5f8c\u75bc\u75db\u52a0\u5287\uff0c\u65e9\u6668\u7761\u9192\u6709\u6668\u50f5\u73fe\u8c61\u7d042\u5c0f\u6642\uff0c\u5c0dacetaminophen\u6cbb\u7642\u7121\u6548\uff0c\u904e\u53bb\u773c\u775b\u5e38\u6709\u8461\u8404\u819c\u708e\u767c\u751f\uff0c\u8eab\u9ad4\u6aa2\u67e5\uff0c\u8170\u690e\u7121\u58d3\u75db\uff0c\u8170\u690e\u904b\u52d5\u6b63\u5e38\uff0c\u53f3\u8173\u8ddf\u6709\u58d3\u75db\u53ca\u816b\u8139\uff0c\u5176\u4ed6\u7686\u6b63\u5e38\uff0c\u9aa8\u76c6\u8154\u95dc\u7bc0X\u5149\u6b63\u5e38\uff0c\u53f3\u8173\u8ddfX\u5149\u8edf\u7d44\u7e54\u6709\u816b\u8139\uff0cAchillis\u808c\u8171\u63a5\u5408\u8655\u9aa8\u9abc\u6709\u4fb5\u8755\u73fe\u8c61\uff0c\u4e0b\u5217\u6aa2\u67e5\u662f\u6700\u9069\u5408\u4e4b\u6aa2\u67e5\uff0c\r(1)\u985e\u98a8\u6fd5\u6027\u56e0\u5b50(RF)\r(2)\u6297\u6838\u6297\u9ad4(ANA)\r(3)\u6297\u74dc\u80fa\u9178\u86cb\u767d\u6297\u9ad4(ACPA)\r(4)\u4eba\u985e\u767d\u8840\u7403\u6297\u539fB27\u6aa2\u67e5(HLA-B-27)\r(5)\u7d05\u8840\u7403\u4e0b\u964d\u901f\u5ea6(ESR)\nA. (1)+(2)\nB. (1)+(3)\nC. (4)+(5)\nD. (5)+(2)\nE. (5)+(1)\n": "(C)", "107-7.\n\u4e00\u4f4d42\u6b72\u5a66\u5973\u56e0\u70ba\u5c0d\u7a31\u6027\u8fd1\u7aef\u808c\u8089\u7121\u529b\u67093\u500b\u6708\u5230\u91ab\u9662\u8acb\u6c42\u8a55\u4f30\uff0c\u7406\u5b78\u6aa2\u67e5\u9664\u56db\u80a2\u8fd1\u7aef\u808c\u8089\u7121\u529b\u5916\uff0c\u4e26\u7121\u5176\u4ed6\u7570\u5e38\uff0c\u4e5f\u7121\u76ae\u819a\u75c7\u72c0\uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5\u8840\u6e05\u57fa\u9178\u78f7\u9175\u7d20(CK)2000U/L\uff0c\u7532\u72c0\u817a\u6fc0\u7d20(TSH)\u6b63\u5e38\uff0c\u808c\u96fb\u5716\u986f\u793a\u5728\u8fd1\u7aef\u808c\u8089\u6709\u81ea\u767c\u986b\u52d5(spontaneous fibrillation)\uff0c\u591a\u9805\u6027\u904b\u52d5\u96fb\u4f4d(polyphasic motor unit potential)\u589e\u52a0\uff0c\u6838\u78c1\u5171\u632f(MRI)\u986f\u793a\u817f\u90e8\u56db\u982d\u808c\u6709\u767c\u708e\u6539\u8b8a\uff0c\u4e0b\u5217\u662f\u76ee\u524d\u6700\u5408\u9069\u4e4b\u6cbb\u7642?\nA. \u8b77\u9081(adalimumab)\nB. \u74b0\u5b62\u7d20(cyclosporine)\nC. \u4f86\u6c1f\u7c73\u7279(leflunomide)\nD. \u985e\u56fa\u9187(prednisolone)\nE. \u7fa5\u6c2f\u53e3\u594e(hydroxychloroquine)\n": "(D)", "107-8.\n\u4e00\u4f4d25\u6b72\u5973\u6027\u767c\u71d2\u5026\u6020\u53ca\u96d9\u624b\u624b\u8155\u3001\u96d9\u819d\u53ca\u8173\u8e1d\u75db\u4e00\u9031\uff0c\u5979\u66fe\u7d93\u77ed\u66ab\u6709\u76ae\u819a\u7d05\u75b9\uff0c\u50cf\u662f\u81bf\u5305(pustule)\uff0c\u6c92\u6709\u5c3f\u9053\u75c7\u72c0\u6216\u9670\u9053\u5206\u6ccc\u7269\u3002\u5979\u66fe\u4f7f\u7528\u904e\u975e\u6cd5\u85e5\u7269\u4e14\u6027\u6d3b\u52d5\u6d3b\u8000\uff0c\u4f7f\u7528\u53e3\u670d\u907f\u5b55\u85e5\uff0c\u7406\u5b78\u6aa2\u67e5\u9ad4\u6eab38\u2103\uff0c\u624b\u8155\u6709\u58d3\u75db\uff0c\u5de6\u819d\u53ca\u96d9\u8173\u88f8\u6709\u58d3\u75db\u53ca\u816b\u8139\uff0c\u53ca\u5169\u5074\u8ddf\u8171(Achilles tendon)\u58d3\u75db\uff0c\u96d9\u624b\u53ca\u96d9\u8173\u6709\u7d05\u6591\u76ae\u75c7\uff0c\u5be6\u9a57\u6aa2\u67e5\u8840\u6db2\u767d\u8840\u740313,500/mm3\uff0c\u809d\u814e\u529f\u80fd\u6b63\u5e38\uff0c\u4e0b\u5217\u6aa2\u67e5\u5c0d\u8a3a\u65b7\u662f\u6700\u6709\u5e6b\u52a9?\nA. C\u53cd\u61c9\u86cb\u767d(CRP)\nB. \u5b50\u5bae\u9838\u5206\u6ccc\u7269\u57f9\u990a\nC. \u7d05\u8840\u7403\u4e0b\u964d\u901f\u5ea6(ESR)\nD. \u93c8\u7403\u83cc\u6297\u539f\u6aa2\u67e5\nE. \u624b\u8155\u53ca\u96d9\u819d\u96fb\u8166\u65b7\u5c64(CT scan)\n": "(B)", "107-9.\n\u4e00\u4f4d25\u6b72\u60a3\u67095\u5e74\u4e4b\u7d05\u6591\u6027\u72fc\u7621\uff0c\u6e96\u5099\u61f7\u5b55\uff0c\u904e\u53bb\u4e00\u5e74\u4f86\u4f7f\u7528hydroxychloroquine\u3001mycophenolate mofetil\u53ca\u985e\u56fa\u9187\u63a7\u5236\u7d05\u6591\u6027\u72fc\u7621\uff0c\u75c5\u60c5\u7a69\u5b9a\uff0c\u7406\u5b78\u6aa2\u67e5\u4e00\u5207\u6b63\u5e38\uff0c\u9664\u53f3\u81c9\u6709\u4e00\u4e9b\u7d05\u6591\uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5\u7686\u6b63\u5e38\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u6cbb\u7642\u75c5\u4eba\u6700\u597d\u7684\u5efa\u8b70\nA. \u505c\u6b62\u4f7f\u7528hydroxychloroquine\nB. \u505c\u6b62\u4f7f\u7528mycophenolate mofetil\nC. \u505c\u6b62\u4f7f\u7528\u985e\u56fa\u9187\nD. \u7e7c\u7e8c\u4f7f\u7528\u6240\u6709\u85e5\u7269\nE. \u505c\u6b62\u4f7f\u7528\u6240\u6709\u85e5\u7269\n": "(B)", "107-10.\n\u4e00\u4f4d40\u6b72\u7537\u6027\uff0c\u767c\u71d2\u905439\u2103\uff0c\u9ad4\u91cd\u6e1b\u8f155\u516c\u65a4\uff0c\u808c\u8089\u53ca\u95dc\u7bc0\u75bc\u75db\u53ca\u6dcb\u5df4\u817a\u816b\u8139\u800c\u6c42\u91ab\uff0c\u6709\u4e00\u500b\u6708\u95dc\u7bc0\u75db\u5305\u62ec\u80a9\u90e8\u3001\u624b\u8155\u3001\u96d9\u819d\uff0c\u4e14\u6709\u65e9\u6668\u50f5\u786c\u73fe\u8c61\uff0c\u4e14\u66fe\u5728\u8eab\u9ad4\u53ca\u56db\u80a2\u6709\u7c89\u8272\u7d05\u6591\uff0c\u7406\u5b78\u6aa2\u67e5\u9ad4\u6eab38.8\u2103\uff0c\u9838\u90e8\u6dcb\u5df4\u817a\u816b\u5927\uff0c\u813e\u816b\u5927\uff0c\u8eab\u9ad4\u53ca\u56db\u80a2\u6709\u7d05\u75b9\uff0c\u624b\u8155\u53ca\u96d9\u819d\u816b\u8139\u53ca\u58d3\u75db\uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5ESR 100 mm/h\uff0c\u767d\u8840\u740330,000/mm3\uff0cC\u53cd\u61c9\u86cb\u767d(CRP)18mg/dl\uff0c\u9435\u86cb\u767d(Ferritin)20,000 ng/ml\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u6700\u53ef\u80fd\u4e4b\u8a3a\u65b7?\nA. \u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621(SLE)\nB. \u5168\u8eab\u6027\u786c\u5316\u75c7(SSc)\nC. \u6210\u4eba\u578bStill's \u75c5(Adult Onset Still's Disease)\nD. \u6025\u6027\u9aa8\u9ad3\u767d\u8840\u75c5(AML)\nE. \u50f5\u76f4\u6027\u810a\u690e\u708e(AS)\n": "(C)", "107-1.\n\u4e0b\u5217\u6709\u95dcSLE\u7684\u81ea\u9ad4\u6297\u9ad4\u53ca\u5176\u75be\u75c5\u4f75\u767c\u75c7\u7684\u914d\u5c0d\u7d44\u5408\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Anti-phospholipid\u2500fetal loss\nB. Anti-SSB/La\u2500lupus nephritis\nC. Anti-Sm\u2500malar rash\nD. Anti-RNP\u2500arthritis\nE. Anti-ribosomal P\u2500drug-induced lupus-like syndrome\n": "(A)", "107-2.\n53\u6b72\u5973\u6027\u7684\u4e3b\u8a34\u70ba\u8fd1\u4e8c\u5e74\u4f86\u5929\u51b7\u6642\u96d9\u5074\u624b\u6307\u6703\u8b8a\u767d\u53ca\u8b8a\u7d2b\u3002\u6700\u8fd1\u5169\u624b\u80cc\u7684\u76ae\u819a\u6709\u8b8a\u7c97\u3001\u8b8a\u539a\u3002\u800c\u4e14\u6703\u6709\u4e7e\u54b3\u3001\u808c\u8089\u7121\u529b\u53ca\u6392\u4fbf\u4e0d\u9806\u767c\u751f\u3002\u5230\u67d0\u91ab\u9662\u62bd\u8840\u6aa2\u67e5\u767c\u73fe\uff1aANA 1:1280 speckled+nucleolar pattern, anti-Scl-70 (-), anti-CENP-B (-), RF 62 IU/mL, anti-U1RNP 1284 IU/mL, CK 645 U/L (normal<250 U/L)\u3002\u8acb\u554f\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Systemic sclerosis\nB. MCTD (mixed connective tissue disease)\nC. SLE\nD. RA\nE. Polymyositis/dermatomyositis\n": "(B)", "107-3.\n19\u6b72\u7537\u6027\u5728\u6e05\u6668\u6642\u6703\u6709\u4e0b\u80cc\u50f5\u786c\u53ca\u9178\u75db\u6709\u534a\u5e74\u4e4b\u4e45\u3002\u8d77\u4f86\u904b\u52d530\u5206\u4e4b\u5f8c\u6703\u9010\u6f38\u7de9\u89e3\u3002\u5728\u6b64\u671f\u9593\u66fe\u6709\u4e00\u6b21\u53f3\u8173\u5e95\u8d70\u8def\u5287\u75db\uff0c\u7d93\u670d\u7528\u6d88\u708e\u6b62\u75db\u5291\u5f8c\u9010\u6f38\u6062\u5fa9\u6b63\u5e38\u3002\u7d93\u91ab\u5e2b\u8a73\u7d30\u6aa2\u67e5\u5f8c\u8a3a\u65b7\u70ba\u50f5\u76f4\u6027\u810a\u690e\u708e\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u6700\u6709\u6548\uff1f\nA. Methotrexate\nB. Anti-B cell therapy\nC. Anti-TNF- alpha therapy\nD. MMF (mycophenolate mofetil)\nE. Cyclophosphamide\n": "(C)", "107-4.\n57\u6b72\u7537\u6027\u75c5\u4eba\u57288\u5e74\u524d\u767c\u73fe\u5169\u624b\u7684\u6307\u7532\u6709\u589e\u751f\u80a5\u539a\u53ca\u6613\u8106\u3002\u800c\u8fd1\u534a\u5e74\u4f86\u6642\u5e38\u6709\u4e0b\u80cc\u9178\u75db\u3002\u6700\u8fd1\u767c\u73fe\u591a\u8655\u9060\u7aef\u6307\u9593\u95dc\u7bc0\u6709\u767c\u708e\u816b\u75db\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73feESR 31mm/1h, CRP1.8mg/dL\u3002\u7167X-\u5149\u767c\u73fe\u591a\u8655\u95dc\u7bc0\u6709marginal erosion\u53ca\u9aa8\u982d\u7834\u58de\u3002\u8acb\u554f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Inflammatory osteoarthritis\nB. Rheumatoid arthritis\nC. Reactive arthritis\nD. Tinea on the finger nails\nE. Psoriatic arthritis\n": "(E)", "107-5.\n\u4e0b\u5217\u6709\u95dc\u5404\u985e\u8840\u7ba1\u708e\u53ca\u5176\u81f4\u75c5\u56e0\u5b50\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Hepatitis C virus-associated cryoglobulinemic vascultits\u2500T cell response\nB. Granulomatosis with polyangiitis\u2500cANCA\nC. Eosinophilic granulomatosis with polyangiitis\u2500immune complex deposition\nD. Takayasu arteritis\u2500IgA-associated vasculitis\nE. Microscopic polyangiitis\u2500complement activation\n": "(B)", "107-6.\n\u4e00\u4f4d72\u6b72\u5973\u6027\u6700\u8fd1\u56db\u500b\u6708\u4f86\uff0c\u7a81\u7136\u767c\u751f\u96d9\u5074\u80a9\u8180\u808c\u8089\u5287\u75db\uff0c\u4f34\u96a8\u6709\u5fae\u71d2\u767c\u751f\u3002\u6700\u8fd1\u611f\u89ba\u5728\u9873\u9aa8\u90e8\u4f4d\u6709\u982d\u75db\u4e14\u4f34\u96a8\u8996\u529b\u6a21\u7cca\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73fe: Hb 9.8mg/mL, ESR102mm/1h, CRP 2.1mg/dL, ANA 1:80 speckled, pANCA(-), cANCA (-)\u3002\u7d93\u6bcf\u5929\u670d\u7528prednisolone 40mg \u4e03\u5929\u4e4b\u5f8c\u6709\u660e\u986f\u7642\u6548\u3002\u8acb\u554f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Giant cell arteritis\nB. Migraine\nC. Adhesive capsulitis\nD. Influenza infection\nE. Glaucoma\n": "(A)", "107-7.\n51\u6b72\u5973\u6027\u8fd1\u4e09\u500b\u6708\u4f86\u6709\u767c\u71d2\u96d9\u5074\u7684\u4e0a\u773c\u77bc\u816b\u8139\u53ca\u51fa\u73fe\u7d2b\u7d05\u8272\u6591\u3002\u8d77\u5e8a\u6642\u5927\u817f\u7121\u529b\uff0c\u5fc5\u9808\u4ee5\u96d9\u624b\u652f\u6490\u624d\u80fd\u5750\u8d77\u3002\u6700\u8fd1\u4e00\u9031\u559d\u6c34\u6709\u6642\u6703\u55c6\u5230\u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u96d9\u5074\u5927\u817f\u56db\u982d\u808c\u7121\u529b\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73fe: ANA 1:160 speckled, \u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u6700\u80fd\u53cd\u61c9\u60a3\u8005\u7684\u75be\u75c5\u6d3b\u52d5\u6027\uff1f\nA. CRP\nB. CK\nC. AST\nD. Anti-tRNA synthetase titer\nE. Myoglobulin\n": "(B)", "107-8.\n\u8acb\u554f\u4f7f\u7528color Doppler ultrasound\u53ef\u4ee5\u6aa2\u67e5\u4e0b\u5217\u4f55\u7a2e\u808c\u8089\u9aa8\u9abc\u7684\u75be\u75c5\uff1f (1).\trotator cuff tears (2). bone marrow edema (3). calcium pyrophosphate deposition (4). chronic osteomyelitis (5). spinal stenosis (6). carpal tunnel syndrome (7). avascular bone necrosis (8). septic arthritis (9). HIVD\nA. (2)+(5)+(8)\nB. (1)+(4)+(9)\nC. (1)+(3)+(6)\nD. (3)+(4)+(5)\nE. (7)+(8)+(9)\n": "(C)", "107-9.\n\u8acb\u554f\u4e0b\u5217\u4f55\u7a2e\u75be\u75c5\u6703\u5f15\u8d77acute mono-arthritis\uff1f (1). rheumatoid arthritis (2). gouty arthritis (3). osteoarthritis (4). seronegative spondylarthropathy (5). septic arthritis (6). Lyme disease\r(7). acute rheumatic fever (8). pigmented villonodular synovitis\r(9). traumatic arthritis\nA. (1)+(3)+(4)\nB. (2)+(6)+(7)\nC. (7)+(8)+(9)\nD. (4)+(5)+(6)\nE. (2)+(5)+(9)\n": "(E)", "107-10.\n\u4e0b\u5217\u6709\u95dc2012\u5e74Systemic Lupus International Collaborating Clinic (SLICC) classification criteria\u4e2d\u6240\u5217SLE\u7684\u81e8\u5e8a\u8868\u5fb5\u53ca\u8840\u6e05\u5b78\u6aa2\u67e5\uff0c\u4f55\u8005\u5305\u62ec\u5728\u5167\uff1f (1).\tarthritis with deformity (2). chronic cutaneous LE (3). anti-phospholipid antibodies (4). hemoglobulin< 10g/dL (5). anti-SSA/Ro antibodies (6). ANCAs (7). low serum complement levels (8). uveitis (9). vasculitis\nA. (1)+(2)+(9)\nB. (2)+(3)+(7)\nC. (3)+(4)+(5)\nD. (1)+(6)+(8)\nE. (5)+(6)+(7)\n": "(B)", "108-1.\n\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u6b63\u78ba\uff1f\r(1)\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(RA)\u6613\u808c\u8171\u9aa8\u63a5\u5408\u9ede\u767c\u708e(enthesitis)\uff0c\u4e7e\u766c\u6027\u95dc\u7bc0\u708e(Psoriatic arthritis,PSA)\u6613\u95dc\u7bc0\u6ed1\u819c\u708e(synovitis)\r(2)\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(RA)\u6613\u4fb5\u72af\u9060\u7aef\u6307\u9593\u95dc\u7bc0(Distal interphalangeal joint,DIP)\uff0c\u4e7e\u766c\u6027\u95dc\u7bc0\u708e(PSA)\u6613\u4fb5\u72af\u8fd1\u7aef\u6307\u7aef\u7bc0(proximal interphalangeal join,PIP)\r(3)\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(RA)\u6613\u5f15\u8d77\u9aa8\u4fb5\u8755\uff0c\u4e7e\u766c\u6027\u95dc\u7bc0\u708e(PSA)\u6613\u5f15\u8d77\u808c\u8171\u9aa8\u63a5\u5408\u9ede\u767c\u708e\r(4)\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(RA)\u5927\u90e8\u5206\u6703\u7522\u751f\u81ea\u9ad4\u6297\u9ad4\uff0c\u4e7e\u766c\u6027\u95dc\u7bc0\u708e(PSA)\u5927\u90e8\u5206\u4e0d\u6703\u7522\u751f\u81ea\u9ad4\u6297\u9ad4\r(5)\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(RA)\u4e3b\u8981\u662f\u6a5f\u68b0\u6027\u5f15\u8d77\u4e4b\u767c\u708e(Mechanical inflammation)\uff0c\u4e7e\u766c\u6027\u95dc\u7bc0\u708e(PSA)\u4e3b\u8981\u662f\u81ea\u9ad4\u514d\u75ab\u53cd\u61c9\u9020\u6210(Autoimmune)\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (1)+(5)\n": "(C)", "108-2.\n\u4e0b\u5217\u85e5\u7269\u88ab\u5efa\u8b70\u5728\u6240\u6709\u7d05\u6591\u6027\u72fc\u7621(SLE)\u75c5\u4eba\u9577\u671f\u4f7f\u7528\uff1f\nA. endoxan\nB. hydroxychloroquine\nC. azathioprine\nD. \u9ad8\u5291\u91cf\u985e\u56fa\u9187glucocorticoid\nE. \u6297\u751f\u7d20\u4ee5\u9810\u9632\u611f\u67d3\n": "(B)", "108-3.\n\u4e0b\u5217\u6297\u9ad4\u5e38\u5408\u4f75\u9593\u8cea\u80ba\u75be\u75c5(interstitial lung disease)\u4e26\u5feb\u901f\u5f71\u97ff\u751f\u547d\u5371\u96aa\uff1f\nA. anti- melanoma differentiation-associated protein 5(MDA5)Ab\nB. anti-Sm Ab\nC. anti-RNP Ab\nD. anti-dsDNA Ab\nE. anti histone Ab\n": "(A)", "108-4.\n\u4e00\u4f4d65\u6b72\u5973\u6027\u56e0\u5168\u8eab\u7121\u529b\u53ca\u865b\u5f31\uff0c\u6df1\u8910\u8272\u5c0f\u4fbf\u53ca\u541e\u56a5\u56f0\u96e3\u800c\u4f4f\u9662\uff0c\u4e09\u5341\u4e94\u5e74\u524d\u75c5\u4eba\u63a5\u53d7\u8b8a\u6027\u624b\u8853\u5f9e\u7537\u8b8a\u5973\uff0c\u6b64\u5f8c\u5c31\u9577\u671f\u4f7f\u7528\u96cc\u6fc0\u7d20\uff0c\u4e00\u5e74\u534a\u524d\u6709\u5fc3\u81df\u5f15\u8d77\u7684\u8166\u4e2d\u98a8\u5f8c\u958b\u59cb\u670d\u7528atorvastatin\u53caAspirin\u53ca\u5229\u5c3f\u5291\uff0c\u8eab\u9ad4\u6aa2\u67e5\u986f\u793a\u4e0a\u4e0b\u80a2\u8fd1\u7aef\u808c\u8089\u7121\u529b\uff0c\u4e0b\u5217\u4e3b\u8981\u6aa2\u67e5\u5c07\u6700\u6709\u53ef\u80fd\u65bc\u75be\u75c5\u8a3a\u65b7\u6b64\u75c5? (1)CK (2)anti-HMGCR (3)anti-sm (4)anti-topoisomerase 1  (5)anti-Ro Ab\nA. (1)+(2)\nB. (1)+(3)\nC. (1)+(4)\nD. (1)+(5)\nE. (2)+(5)\n": "(A)", "108-5.\n\u627f\u63a5\u4e0a\u984c\uff0c\u6b64\u75c5\u4eba\u6700\u6709\u53ef\u80fd\u60a3\u6709\uff1f\nA. \u7d05\u6591\u6027\u72fc\u7621(SLE)\nB. \u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(RA)\nC. \u611f\u67d3\u5fc3\u5167\u819c\u708e\nD. \u85e5\u7269\u5f15\u8d77\u808c\u708e\nE. \u786c\u76ae\u75c7\n": "(D)", "108-6.\n\u4e00\u4f4d60\u6b72\u7537\u6027\u56e0\u6025\u6027\u75db\u98a8\u591a\u6b21\u4f4f\u9662\uff0c\u4ed6\u6709\u814e\u7d50\u77f3\u3001\u6162\u6027\u814e\u75c5\u4e4b\u75c5\u53f2\uff0c\u7d93\u6aa2\u67e5\u5c6c\u65bc\u5c3f\u9178\u88fd\u9020\u589e\u52a0\u4e4b\u75c5\u4eba\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba?\r(1)\u6700\u597d\u7684\u964d\u5c3f\u9178\u85e5\u7269\u70baallopurinol\r(2)\u6b64\u75c5\u4eba\u76ee\u524d\u6025\u6027\u75db\u98a8\u767c\u4f5c\u61c9\u53ef\u99ac\u4e0a\u7d66\u4e88allopurinol 300mg/day\r(3)\u75c5\u4eba\u958b\u59cb\u4f7f\u7528\u964d\u5c3f\u9178\u85e5\u6642\uff0c\u53ef\u540c\u6642\u7d66\u4e88colchicine\u9810\u9632\u767c\u4f5c\r(4)\u6b64\u75c5\u4eba\u6700\u597d\u7684\u964d\u5c3f\u9178\u85e5\u7269\u662fbenzbromarone\r(5)\u6b64\u75c5\u4eba\u61c9\u9577\u671f\u670d\u7528\u964d\u5c3f\u9178\u85e5\nA. (1)+(2)\nB. (1)+(3)\nC. (1)+(4)\nD. (2)+(4)\nE. (2)+(5)\n": "(B)", "108-7.\n\u4e00\u4f4d45\u6b72\u5973\u6027\u56e0\u624b\u6307\u53ca\u8173\u8dbe\u816b\u75db\u4e09\u5e74\uff0c\u5176\u5169\u8173\u5927\u62c7\u6307\u53ca\u53f3\u8173\u7b2c\u4e8c\u8173\u8dbe\u53ca\u5de6\u7b2c\u4e09\u8173\u8dbe\u70ba\u50cf\u9999\u8178\u6a23\u7684\u816b\u8139(Sausage-like)\uff0canti-CCP\u6297\u9ad4\u53ca\u985e\u98a8\u6fd5\u6027\u56fa\u7686\u9670\u6027\uff0c\u5979\u7684\u8173\u8ddf\u8171(Achilles tendon)\u9577\u671f\u816b\u8139\u53ca\u75bc\u75db\uff0c\u6b64\u75c5\u4eba\u6700\u6709\u53ef\u80fd\u4e4b\u8a3a\u65b7\u70ba \uff1f\nA. \u985e\u98a8\u6ebc\u6027\u95dc\u7bc0\u708e(RA)\nB. \u7d05\u6591\u6027\u72fc\u7621(SLE)\nC. \u4e7e\u766c\u6027\u95dc\u7bc0\u708e(PSA)\nD. \u786c\u76ae\u75c7(SSc)\nE. \u591a\u767c\u6027\u808c\u708e(Polymyositis)\n": "(C)", "108-8.\n\u514d\u75ab\u6291\u5236\u5291\u5e38\u7528\u65bc\u6cbb\u7642\u81ea\u9ad4\u514d\u75ab\u75be\u75c5\u53ca\u5668\u5b98\u79fb\u690d\u75c5\u4eba\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u70ba\u6b63\u78ba? (1)\u985e\u56fa\u9187(corticosteroid)\u5e38\u5f15\u8d77\u9aa8\u8cea\u758f\u9b06(Osteoporosis) (2)Tacrolimus\u53cacyclosporine\u6703\u5f15\u8d77\u808c\u8089\u6e1b\u5c11 (3)\u4f7f\u7528\u514d\u75ab\u6291\u5236\u5291\u8f03\u5c11\u5f15\u8d77\u611f\u67d3 (4)\u4f7f\u7528\u514d\u75ab\u6291\u5236\u5291\u8f03\u4e0d\u6703\u5f15\u8d77\u4e7e\u766c (5)\u4f7f\u7528\u514d\u75ab\u6291\u5236\u5291\u8f03\u4e0d\u6703\u9020\u6210\u814e\u81df\u7834\u58de\nA. (1)+(2)\nB. (1)+(3)\nC. (1)+(4)\nD. (1)+(5)\nE. (2)+(4)\n": "(A)", "108-9.\n\u4e00\u4f4d30\u6b72\u5973\u6027\u60a3\u6709\u7d05\u6591\u6027\u72fc\u7621(SLE)\u591a\u5e74\uff0c\u6700\u8fd1\u6709\u4e09\u6b21\u6d41\u7522\u4e26\u88ab\u8a3a\u65b7\u6709\u6297\u78f7\u8102\u6297\u9ad4\u75c7\u5019\u7fa4(Antiphospholipid Syndrome)\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba? (1)\u53ef\u4ee5Aspirin 100mg/day \u6cbb\u7642 (2)\u53ef\u4ee5Aspirin 330mg/day \u6cbb\u7642 (3)\u53ef\u4ee5\u670d\u7528\u907f\u5b55\u85e5 (4)\u62bd\u7159\u4e0d\u5f71\u97ff\u75c5\u60c5 (5)\u518d\u6b21\u61f7\u5b55\u6642\u53ef\u6253\u4f4e\u5291\u91cf(heparin)\nA. (1)+(3)\nB. (1)+(4)\nC. (1)+(5)\nD. (2)+(3)\nE. (2)+(5)\n": "(C)", "108-10.\n\u786c\u76ae\u75c7\u814e\u5371\u6025(scleroderma renal crisis, SRC)\u662f\u56b4\u91cd\u4e14\u81f4\u547d\u4e4b\u6025\u75c7\u5176\u9996\u9078\u4e4b\u6cbb\u7642\u85e5\u7269\uff1f\nA. ACE-inhibitors (angiotensin-converting enzyme inhibitor)\nB. corticosteroids\nC. endoxan (cyclophosphamide)\nD. Immuran (azathioprine)\nE. methotrexate (MTX)\n": "(A)", "108-1.\n\u4e0b\u5217\u6709\u95dc SLE\u81ea\u9ad4\u6297\u9ad4\u8207\u81e8\u5e8a\u8868\u73fe\u4e4b\u9593\u7684\u76f8\u95dc\u6027\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Anti-dsDNA\u8207disease activity\u6709\u6b63\u76f8\u95dc\nB. Anti-SSB\u8207nephritis\u6709\u6b63\u76f8\u95dc\nC. Anti-cardiolipin\u8207neonatal lupus\u7684\u767c\u751f\u6709\u95dc\nD. Anti-ribosomal P\u8207mononeuritis multiplex\u6709\u6b63\u76f8\u95dc\nE. Anti-histone\u8207thrombocytopenia\u6709\u6b63\u76f8\u95dc\n": "(A)", "108-2.\n\u4e0b\u5217\u4f55\u7a2e\u6297\u9ad4\u5728\u8a3a\u65b7rheumatoid arthritis\u6700\u5177\u7279\u7570\u6027\uff1f\nA. Anti-IgG\nB. Anti-EB viral nuclear protein\nC. Anti-collagen type II\nD. Anti-CCP\nE. Anti-proteoglycan\n": "(D)", "108-3.\n\u4e0b\u5217\u6709\u95dcsystemic sclerosis\u7684\u63cf\u8ff0\u4e2d,\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. \u6700\u5e38\u51fa\u73fe\u7684\u6297\u9ad4\u70baanti-centromere antibodies\nB. Anti-Jo-1\u8207interstitial lung disease\u7121\u95dc\nC. Anti-topoisomerase 1 antibodies\u70ba\u5176\u751f\u7269\u6a19\u8a8c\nD. \u53e3\u670d\u9ad8\u91cf\u985e\u56fa\u9187\u70ba\u6cbb\u7642\u76ae\u819a\u786c\u5316\u7684\u9996\u9078\u85e5\u7269\nE. Raynaud's phenomenon\u70ba\u5728\u672b\u671f\u624d\u6703\u51fa\u73fe\n": "(C)", "108-4.\n\u4e0b\u5217\u6709\u95dcSjogren's syndrome\u7684extra-glandular manifestations\u7684\u63cf\u8ff0\u4e2d,\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Erosive arthritis\nB. Iritis/uveitis\nC. Leukocytoclastic vasculitis\nD. Oral cavity carcinoma\nE. Primary biliary cholangitis\n": "(E)", "108-5.\n\u4e0b\u5217\u6709\u95dc\u98a8\u6fd5\u514d\u75ab\u75be\u75c5\u7684\u75c5\u56e0\u8207\u7d50\u679c\u7684\u52fe\u914d\u95dc\u4fc2\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Anti-myeloperoxidase\u5f15\u8d77lupus nephritis\nB. Anti-proteinase 3\u5f15\u8d77granulomatosis with polyangiitis\nC. Viral infection\u5f15\u8d77Takayasu's arteritis\nD. Immune complex\u5f15\u8d77giant cell arteritis\nE. IgG4\u5f15\u8d77 microscopic polyangiitis\n": "(B)", "108-6.\n\u4e0b\u5217\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u8a3a\u65b7polyarteritis nodosa\u6700\u6709\u5e6b\u52a9\uff1f\nA. Anti-elastase antibodies\nB. Inflammatory parameters\nC. Angiography\nD. Anti-neutrophil cytoplasmic antibodies\nE. Renal function test\n": "(C)", "108-7.\n\u4e0b\u5217\u6709\u95dcinflammatory muscle diseases\u7684\u63cf\u8ff0\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Inclusion body myositis\u6703\u5f15\u8d77\u672b\u7aef\u808c\u8089\u7684\u7121\u529b\nB. \u76ae\u808c\u708e\u8207\u816b\u7624\u8f03\u7121\u95dc\u806f\u6027\nC. \u591a\u767c\u6027\u808c\u708e\u8207B\u7d30\u80de\u7522\u751f\u6297\u9ad4\u6709\u5f88\u5927\u7684\u95dc\u4fc2\nD. \u672c\u985e\u75be\u75c5\u5e38\u5e38\u5f15\u8d77\u6025\u6027\u808c\u8089\u7121\u529b\nE. \u80c3\u8178\u9053\u7684\u8815\u52d5\u5e38\u53d7\u5230\u5f71\u97ff\n": "(A)", "108-8.\n\u4e0b\u5217\u6709\u95dcSLE\u7684\u5206\u985e\u57fa\u6e96\u9805\u76ee\u7684\u7d44\u5408\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba? (1)chronic cutaneous vasculitis  (2)  RBC casts in urinalysis (3)    anti-SSA/Ro (4) anti-phospholipid (5) positive direct Coomb's test (6) low serum complements (7) Raynaud's phenomenon (8) malar skin rash\nA. (1)+(2)+(3)+(4)\nB. (5)+(6)+(7)+(8)\nC. (2)+(4)+(5)+(8)\nD. (3)+(5)+(6)+(7)\nE. (4)+(6)+(7)+(8)\n": "(C)", "108-9.\n\u4e0b\u5217\u6709\u95dcrheumatoid arthritis \u7684extra-articular manifestations\u4e2d\uff0c \u4f55\u8005\u6700\u70ba  \u6b63\u78ba\uff1f\r (1)Uveitis (2)cervical myelopathy (3)oral mucosa ulcer (4)Felty's  syndrome (5)mechanical hand (6)rheumatoid nodule (7)inflammatory bowel diseases (8)episcleritis\nA. (2)+(4)+(8)\nB. (1)+(2)+(3)\nC. (4)+(5)+(6)\nD. (6)+(7)+(8)\nE. (2)+(3)+(6)\n": "(A)", "108-10.\n\u4e0b\u5217\u6709\u95dcaxial spondyloarthritis\u7684\u767c\u708e\u6027\u4e0b\u80cc\u75db\u5206\u985e\u57fa\u6e96\u7684\u7d44\u5408\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\r (1)\tAge>40 year-old (2) HLA-B27 (+)  (3) acute lumbago (4) relief after exercise (5)\u534a\u591c\u6216\u6e05\u6668\u7684\u9178\u75db\u50f5\u786c>30\u5206 (6) \u767d\u5929\u4f11\u606f\u4e4b\u5f8c\u6703\u548c\u7de9 (7) \u8170\u90e8\u810a\u690e\u6703\u8b8a\u76f4 (8)\u7167MRI\u5e6b\u52a9\u4e0d\u5927\nA. (1)+(2)+(3)\nB. (4)+(5)+(7)\nC. (2)+(4)+(8)\nD. (3)+(6)+(7)\nE. (6)+(7)+(8)\n": "(B)", "109-140.\u4e00\u4f4d55\u6b72\u7537\u6027\u4e8c\u5929\u524d\u7a81\u7136\u53f3\u8173\u8e1d\u75db\u53ca\u816b\u8139 \uff0c\u75c5\u4eba\u670920\u5e74\u62bd\u83f8\u7fd2\u6163 \uff0c\u5076\u723e\u559d\u9152 \uff0c\u4e8c\u5468\u524d\u4e26\u66fe\u6709\u5c0f\u4fbf\u5fae\u75db\u53ca\n\u707c\u71b1\u611f\uff0c\u4e0b\u5217\u6aa2\u9a57\u5c0d\u75c5\u4eba\u6700\u6709\u5e6b\u52a9 \uff1f(1) \u6297\u6838\u6297\u9ad4 (antinuclear antibody )\uff1b(2) \u4eba\u985e\u767d\u8840\u7403\u6297\u539f -B27 \n(HLA-B27)\uff1b(3) \u5c3f\u9178\uff1b(4) \u6297\u74dc\u80fa\u9178\u86cb\u767d\u6297\u9ad4 (ACPA)\uff1b(5) \u6297\u55dc\u4e2d\u6027\u767d\u8840\u7403\u7d30\u80de\u8cea\u6297\u9ad4 (ANCA)   \nA.(1)+(5)\nB.(1)+(4)\nC.(2)+(3)\nD.(2)+(4)\nE.(3)+(5)\n": "[C]", "109-141.\u9ad8\u5c3f\u9178\u8840\u75c7\u60a3\u8005\uff0c\u4e0b\u5217\u4f55\u60c5\u6cc1\u4e0d\u9808\u4ee5\u964d\u5c3f\u9178\u85e5\u7269\u6cbb\u7642\uff1f    \nA.\u6709\u75db\u98a8\u77f3\nB.X-ray\u6709\u56e0\u5c3f\u9178\u7834\u58de\u95dc\u7bc0\u6216\u9aa8\u75c5\u8b8a\nC.\u7d93\u5e38\u75db\u98a8\u767c\u4f5c\nD.\u8840\u4e2d\u5c3f\u9178\u5927\u65bc7mg/dL\nE.\u814e\u81df\u56e0\u5c3f\u9178\u5f15\u8d77\u4e4b\u814e\u75c5\u8b8a\n": "[D]", "109-142.\u5168\u7403\u65b0\u51a0\u80ba\u708e\u75c5\u6bd2 (Covid-19)\u611f\u67d3\u5df2\u8d85\u904e\u4e00\u4edf\u67d2\u767e\u842c\u4eba \uff0c\u6b7b\u4ea1\u4eba\u6578\u8d85\u904e\u516d\u5341\u516b\u842c (\u81f3109\u5e747\u6708)\uff0c \u547c\u5438\u8870\u7aed\n\u70ba\u6700\u5927\u6b7b\u4ea1\u539f\u56e0 \uff0c\u5176\u80ba\u90e8\u75c5\u7406\u8b8a\u5316\u6700\u5927\u7279\u5fb5\u70ba\u4f55 \uff1f   \nA.\u5ee3\u6cdb\u80ba\u90e8\u8840\u7ba1\u6813\u585e\u53ca\u80ba\u90e8\u5fae\u8840\u7ba1\u75c5\u8b8a (thrombosis \u53camicroangiopathy)\nB.\u5ee3\u6cdb\u80ba\u8840\u7ba1\u51fa\u8840\nC.\u80ba\u816b\u7624\nD.\u80ba\u52d5\u8108\u9ad8\u8840\u58d3\nE.\u5ee3\u6cdb\u80ba\u8840\u7ba1 B\u7d30\u80de\u6d78\u6f64\n": "[A]", "109-143.\u4e0a\u8ff0\u65b0\u51a0\u80ba\u708e\u75c5\u6bd2 (Covid-19)\u9032\u5165\u4eba\u9ad4\u7d30\u80de\u662f\u7d50\u5408\u4f55\u7a2e\u5206\u5b50\u800c\u611f\u67d3\uff1f    \nA.\u8840\u7ba1\u6536\u7e2e\u7d20-\u8f49\u63db\u9175\u7d201 (Angiotensin-converting enzyme 1)   \nB.\u8840\u7ba1\u6536\u7e2e\u7d20-\u8f49\u63db\u9175\u7d202 (Angiotensin-converting enzyme 2)\nC.\u8840\u7ba1\u6536\u7e2e\u7d20-\u8f49\u63db\u9175\u7d203 (Angiotensin-converting enzyme 3)\nD.\u8840\u7ba1\u6536\u7e2e\u7d20-\u8f49\u63db\u9175\u7d204 (Angiotensin-converting enzyme 4)\nE.\u8840\u7ba1\u6536\u7e2e\u7d20-\u8f49\u63db\u9175\u7d205 (Angiotensin-converting enzyme 5)\n": "[B]", "109-144.\u4e00\u4f4d45\u6b72\u5973\u662f\u4e3b\u8a34\u96d9\u8173\u6162\u6162\u51fa\u73fe\u7d2b\u6591 \uff0c\u8840\u6e05\u6aa2\u67e5\u6709type II\u51b7\u51dd\u7403\u86cb\u767d\u8840\u75c7 (cryoglobulinemia )\uff0c\u6b64\u75c5\u6700\u5e38\u898b\n\u4e4b\u539f\u56e0\u70ba \uff1f   \nA.\u80ba\u7d50\u6838\u611f\u67d3\nB.C\u809d\u75c5\u6bd2\u611f\u67d3\nC.\u6885\u6bd2\u611f\u67d3\nD.\u6dcb\u75c5\u611f\u67d3\nE.\u5ff5\u73e0\u83cc\u611f\u67d3\n": "[B]", "109-145.B\u7d30\u80de\u5f15\u8d77\u6dcb\u5df4\u589e\u6b96\u75be\u75c5 (B cell lymphoproliferative disorder )\u4e3b\u8981\u5f15\u8d77\u4e4b\u51b7\u51dd\u86cb\u767d\u8840\n\u75c7(cryoglobulinemia )\u662f   \nA.\u7b2c\u4e00\u578b\nB.\u7b2c\u4e8c\u578b\nC.\u7b2c\u4e09\u578b\nD.\u7b2c\u56db\u578b\nE.\u7b2c\u4e94\u578b\n": "[A]", "109-146.\u4e00\u4f4d55\u6b72\u5973\u6027\u4e3b\u8a34\u6709\u5de6\u8170\u75bc\u75db 4\u500b\u6708\uff0c\u7406\u5b78\u6aa2\u67e5\u9664\u5de6\u8170\u89f8\u75db\u5916\u4e26\u672a\u767c\u73fe\u5176\u4ed6\u4e0d\u6b63\u5e38\u73fe\u8c61 \uff0c\u96fb\u8166\u65b7\u5c64\u986f\u793a\u5728\n\u5f8c\u8179\u8154\u6709\u4e00\u500b\u816b\u7624 \uff0c\u4e14\u58d3\u8feb\u8f38\u5c3f\u7ba1\u53ca\u814e\u81df \uff0c\u5207\u7247\u6aa2\u67e5\u70ba\u514d\u75ab\u7403\u86cb\u767dIg G 4\u76f8\u95dc\u75be\u75c5 (IgG4RD)\uff0c\u4e0b\u5217\u4f55\u7a2e\u6aa2\n\u67e5\u662f\u6700\u4e0d\u9069\u5408\u8a3a\u65b7IgG 4RD\uff1f\n(1) \u8840\u6e05IgG 4\u6fc3\u5ea6\u5347\u9ad8   \n(2) \u7d44\u7e54\u5207\u7247\u6aa2\u67e5\u6709\u6dcb\u5df4\u539f\u5f62\u8cea\u7d30\u80de (Lymphoplasmic )\u7d30\u80de\u6d78\u6f64\n(3) \u7d44\u7e54\u5207\u7247\u6aa2\u67e5\u6709plasma\u7d30\u80de\u6d78\u6f64   \n(4) \u7d44\u7e54\u5207\u7247\u6aa2\u67e5\u6709\u4e2d\u6027\u767d\u8840\u7403\u6d78\u6f64 (Neutrophia )\n(5) \u8840\u6e05anti dsDNA\u5347\u9ad8   \nA.(1)+(2)\nB.(1)+(3)\nC.(2)+(3)\nD.(4)+(5)\nE.(2)+(4)\n": "[D]", "109-147.IgG4\u76f8\u95dc\u75be\u75c5(IgG4RD)\u70ba\u4e00\u7a2e\u7e96\u7dad\u5316\u767c\u708e\u75be\u75c5\uff0c\u6700\u5c11\u4fb5\u72af\u4e0b\u5217\u54ea\u7a2e\u5668\u5b98\uff1f    \nA.\u6dda\u817a\nB.\u80ba\nC.\u553e\u6db2\u817a\nD.\u5f8c\u8179\u8154\nE.\u9ad6\u95dc\u7bc0   \n": "[E]", "109-148.\u4e00\u4f4d48\u6b72\u5bb6\u5ead\u4e3b\u5a66\u4e3b\u8a34\u5728\u65e9\u4e0a\u8d77\u5e8a\u5f8c\u56db\u80a2\u50f5\u786c\u6709\u4e03\u500b\u6708 \uff0c\u6bcf\u5929\u50f5\u786c\u6642\u9593\u8d85\u904e\u4e8c\u5c0f\u6642 \uff0c\u4e09\u500b\u6708\u524d\u5979\u958b\u59cb\u6709\u96d9\n\u80a9\u75bc\u75db\u4e14\u975e\u5e38\u75b2\u5026 \uff0c\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u96d9\u624b\u8fd1\u7aef\u6307\u9593\u95dc\u7bc0 (PIP)\u53ca\u624b\u638c\u6307\u95dc\u7bc0 (MCP)\u53ca\u624b\u8155(wrist)\u6709\u816b\u53ca\u58d3\n\u75db\uff0c\u4e0b\u5217\u6aa2\u67e5\u5c0d\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9 \uff1f\n(1) \u7d05\u8840\u7403\u6c89\u6fb1\u901f\u5ea6 (ESR)\n(2) \u808c\u9178\u9176(CK)\n(3) \u4e73\u9178\u53bb\u6c2b\u9176 (LDH)   \n(4) \u985e\u98a8\u6fd5\u6027\u56e0\u5b50 (RF)\n(5) IL-10   \nA.(1)+(2)\nB.(1)+(3)\nC.(1)+(4)\nD.(1)+(5)\nE.(2)+(5)\n": "[C]", "109-149.\u627f\u63a5\u4e0a\u984c\uff0c\u75c5\u4eba\u6700\u6709\u53ef\u80fd\u4e4b\u8a3a\u65b7\u70ba\uff1f    \nA.PM \u591a\u767c\u6027\u808c\u708e\nB.RA \u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\nC.AS \u50f5\u76f4\u6027\u810a\u690e\u708e\nD.SSC \u786c\u76ae\u75c7\nE.SLE \u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621\n": "[B]", "109-150.\u5341\u4e5d\u6b72\u7684\u6797\u5c0f\u59d0 \uff0c\u6700\u8fd1\u534a\u5e74\u4f86\u6709\u5fae\u71d2 \u3001\u5026\u6020\u3001\u53ca\u5169\u624b\u591a\u6578\u95dc\u7bc0\u9178\u75db \u3002\u8840\u6db2\u5e38\u898f\u6aa2\u67e5\u767c\u73fe \uff1aHb 9.8 g/dL, \nplatelet count 86 ,000/uL, WBC 3450 /uL with normal differential count, ESR 11 mm /1hr, CRP< 0.5 \nmg/dL, proteinuria (++) \u3002\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u75be\u75c5\u7684\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9 \uff1f   \nA.Rheumatoid factors\nB.Sonogram of bilateral hands\nC.Autoantibody profile\nD.Viral screen tests\nE.Bone marrow examination\n": "[C]", "109-151.\u56db\u5341\u4e00\u6b72\u7684\u9673\u592a\u592a\u662f B\u809d\u5e36\u539f\u8005 \u3002\u6700\u8fd1\u4e09\u500b\u6708\u5728\u6668\u9192\u4e4b\u5f8c\u611f\u89ba\u5169\u624b \u3001\u5169\u8155\u3001\u53ca\u5169\u8098\u95dc\u7bc0\u50f5\u786c\u9178\u75db \u3002\u62bd\u8840\u6aa2\n\u67e5\u767c\u73fe\uff1a\u8840\u6db2\u5e38\u898f\u6b63\u5e38 \uff0cESR 34mm /1hr, CRP 2.4 mg/dL. ANA 1:160 speckled pattern (normal< 1:40), \n\u96d9\u624bX-\u5149\u6aa2\u67e5\u7121\u7570\u5e38 \u3002\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u75be\u75c5\u7684\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9 \uff1f   \nA.Sonogram of the affected joints\nB.RFs\nC.Cryoglobulin\nD.Complements\nE.Anti-CCP\n": "[E]", "109-152.\u4e00\u4f4d54\u6b72\u4e2d\u5e74\u5a66\u5973\u4e3b\u8a34\u70ba\u8fd1\u4e09\u5e74\u4f86 \uff0c\u5728\u51ac\u5929\u5169\u624b\u6307\u6703\u8b8a\u767d \u3002\u6700\u8fd1\u4e09\u9031\u5c62\u6709\u4e7e\u54b3\u53ca\u904b\u52d5\u6642\u547c\u5438\u56f0\u96e3 \uff0c\u559d\u6c34\u6642\n\u5076\u800c\u6703\u55c6\u5230 \u3002\u5c31\u8a3a\u6642\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe: \u5169\u624b\u80cc\u7684\u76ae\u819a\u6697\u6c89\u53ca\u7a0d\u786c \u3002\u8840\u6e05\u5b78\u6aa2\u67e5\u767c\u73fe: ANA 1:1280 nucleolar \npattern, pulmonary function test\u5448\u73femoderate restrictive pattern, DLCO: 54% of normal value \u3002\u8acb\u554f\u6700\n\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u4f55 \uff1f   \nA.SLE   \nB.Sjogren\u2019s syndrome\nC.Systemic sclerosis\nD.Polymyositis\nE.Anti-phospholipid syndrome\n": "[C]", "109-153.\u4e00\u4f4d51\u6b72\u7684\u7537\u6027\u60a3\u8005 \uff0c\u6700\u8fd1\u4e00\u5e74\u4f86\u6709\u773c\u4e7e\u53ca\u53e3\u4e7e\u75c7\u72c0 \u3002\u904e\u53bb\u4e5f\u6709\u591a\u5e74\u7684\u904e\u654f\u6027\u9f3b\u708e\u767c\u751f \u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\n\u73fe:\u4e0b\u984e\u90e8\u6709\u5c0d\u7a31\u6027\u7684\u816e\u817a\u816b\u584a\u5b58\u5728 \u3002\u96d9\u5074\u773c\u76ae\u6d6e\u816b \u3002\u4f46\u662f\u514d\u75ab\u5b78\u6aa2\u67e5\u767c\u73feanti -SSA/Ro(-)\u53ca \nanti-SSB/La(-)\u3002\u5176\u65e2\u5f80\u6b77\u4e2d\u6709\u88ab\u8178\u80c3\u79d1\u5c08\u79d1\u91ab\u5e2b\u8a3a\u65b7\u70ba\u80f0\u81df\u708e \u3002\u8acb\u554f\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4e0b\u5217\u4f55\u8005 \uff1f   \nA.Sicca syndrome\nB.IgG4-related disease\nC.Chronic pancreatitis\nD.Lymphoma\nE.Sacoidosis\n": "[B]", "109-154.\u4e0b\u5217\u6709\u95dcaxial spondyloarthritis\u7684\u63cf\u8ff0\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f    \nA.HLA-B27 (+)\nB.ANA (+)\nC.RFs (+)\nD.\u8170\u9178\u80cc\u75db\u5728\u904b\u52d5\u6642\u6703\u52a0\u5287\nE.Anti-TNF-alpha\u6297\u9ad4\u6cbb\u7642\u7121\u6548\n": "[A]", "109-155.\u4e0b\u5217\u6709\u95dc\u8840\u7ba1\u708e\u75c7\u5019\u7fa4(vasculitis syndrome)\u53ca\u5176\u81e8\u5e8a\u5be6\u52d9\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f    \nA.Granulomatosis with polyangiitis\u2501serum pANCA(+)\u5c45\u591a\nB.Henoch-Schonlein purpura\u2501serum IgA\u4e0a\u5347\u5c45\u591a\nC.Eosinophilic granulomatosis with polyangiitis\u2501serum cANCA(+)\u5c45\u591a\nD.Giant cell arteritis\u2501\u5c0f\u65bc50\u6b72\u7684\u60a3\u8005\u5c45\u591a\nE.Polyarteritis nodosa\u2501\u76ae\u819a\u5e38\u6703\u5448\u73feleukocytoclastic vasculitis\n": "[B]", "109-156.\u4e0b\u5217\u6709\u95dcosteoarthritis\u7684\u63cf\u8ff0\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f    \nA.\u624b\u90e8\u6aa2\u67e5\u6642\u5e38\u53ef\u767c\u73feHeberden\u2019s nodules\nB.\u6700\u5e38\u767c\u751f\u65bc\u624b\u8155\u95dc\u7bc0\nC.\u8840\u4e2d\u767d\u8840\u7403\u8a08\u6578\u5e38\u5e38\u6703\u5347\u9ad8\nD.X-\u5149\u6aa2\u67e5\u5e38\u6703\u6709\u9aa8\u982d\u4fb5\u8755\u767c\u751f\nE.\u9577\u671f\u670d\u7528\u5c11\u91cf\u985e\u56fa\u9187\u6700\u70ba\u6709\u6548\n": "[A]", "109-157.\u4e0b\u5217\u6709\u95dc\u6676\u9ad4\u8a98\u767c\u6027\u95dc\u7bc0\u708e(crystal-associated arthropathies)\u7684\u63cf\u8ff0\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f    \nA.Calcium pyrophosphate deposition disease\u901a\u5e38\u767c\u751f\u5728\u5e74\u8f15\u4eba\nB.Calcium apatite\u7d50\u6676\u5728\u504f\u6975\u5149\u986f\u5fae\u93e1\u89c0\u5bdf\u4e0b\u5448\u73fe\u8ca0\u96d9\u5c48\u5149\u6027(negative birefringency)\nC.Calcium oxalate\u7d50\u6676\u7684\u5f62\u6210\u8207\u809d\u529f\u80fd\u7570\u5e38\u6709\u95dc\nD.\u4f7f\u7528allopurinol\u6cbb\u7642\u75db\u98a8\u6642\u5fc5\u9808\u5148\u78ba\u5b9aHLA-B*5801(-)\nE.\u79cb\u6c34\u4ed9\u7d20\u5177\u6709\u964d\u5c3f\u9178\u7684\u6548\u679c   \n": "[D]", "109-158.\u4e00\u4f4d65\u6b72\u5973\u6027\u56e0\u6709\u80ba\u90e8\u611f\u67d3 \uff0c\u7d93\u670d\u7528\u6297\u751f\u7d20\u4e00\u5929\u4e4b\u5f8c \uff0c\u5169\u4e0b\u817f\u90e8\u6709\u6414\u7662\u53ca\u7d05\u8272\u5c0f\u9ede\u51fa\u73fe \u3002\u5c31\u8a3a\u6642\u767c\u73fe\u4e0a\u8ff0\n\u76ae\u819a\u9664\u4e86\u81a8\u9686\u4e4b\u5916 \uff0c\u4ee5\u624b\u6307\u58d3\u4e4b\u4e0d\u6703\u8b8a\u767d \u3002\u91ab\u5e2b\u8a3a\u65b7\u70bavasculitic urticaria \u3002\u8acb\u554f\u6700\u9069\u7576\u7684\u85e5\u7269\u6cbb\u7642\u70ba\u4e0b\u5217\n\u4f55\u8005\uff1f   \nA.Anti-histamine injection\nB.Oral colchicine\nC.Hydroxychloroquine\nD.Dapsone\nE.Systemic corticosteroids\n": "[E]", "109-159.\u6709\u95dcAnti-phospholipid syndrome\u7684\u8a3a\u65b7\u57fa\u6e96\u4e2d \uff0c\u4e0b\u5217\u7684\u90a3\u4e9b\u7d44\u5408\u6700\u70ba\u6b63\u78ba \uff1f\n(1) Deep vein thrombosis (2) cutaneous petechia (3) fetal loss (4) hemolytic anemia (5) \nanti-beta2-GPI\u6297\u9ad4\u967d\u6027 (6) prolong bleeding time (7) premature delivery (8) anti-platelet antibody\u967d\u6027 \n(9) epilepsy (10) arthritis (11) leukocytosis (12) pulmonary hypertension   \nA.(1)+(3)+(5)\nB.(2)+(4)+(8)\nC.(3)+(5)+(10)\nD.(5)+(11)+(12)\nE.(6)+(7)+(9)\n": "[A]", "110-113.60\u6b72\u7684\u5973\u75c5\u60a3\u4e3b\u8a34\u53f3\u819d\u95dc\u7bc0\u816b\u8139\u53ca\u8f15\u5fae\u75bc\u75db\u5df2 2\u9031\u3002\u62bd\u51fa\u95dc\u7bc0\u6db2\u6aa2\u9a57 \uff0c\u5176\u5916\u8868\u9ec3\u8272\u900f\u660e \uff0c\u9ecf\u7a20\n\u5ea6\uff08viscosity \uff09\u9ad8\uff0c\u767d\u8840\u7403\u6fc3\u5ea6\u70ba300 cells /mm\u00b3\u3002\u6700\u9069\u5b9c\u7684\u8a3a\u65b7\u70ba\u4f55 \uff1f   \nA.\u75db\u98a8\u6027\u95dc\u7bc0\u708e\u3002\nB.\u9000\u5316\u6027\u95dc\u7bc0\u708e\u3002\nC.\u7d30\u83cc\u6027\u95dc\u7bc0\u708e\u3002\nD.\u4e7e\u766c\u6027\u95dc\u7bc0\u708e\u3002\nE.\u7d05\u6591\u6027\u72fc\u7621(SLE)\u3002\n": "[B]", "110-114.50\u6b72\u5973\u75c5\u4eba\u4e3b\u8a34\u5169\u5074\u624b\u8155\u95dc\u7bc0\u53ca\u624b\u6307\u95dc\u7bc0\u816b\u75db\u5df2 3 \u500b\u591a\u6708 \u3002\u62bd\u8840\u6aa2\u67e5 \uff0cESR \u53ca CRP \u7686\u660e\u986f\u4e0a\u5347 \uff0c\u4e14\u985e\n\u98a8\u6fd5\u56e0\u5b50\u4e5f\u5448\u967d\u6027 \u3002\u96d9\u624bX \u5149\u4e5f\u767c\u73fe\u95dc\u7bc0\u908a\u7de3\u6027\u8150\u8755\u73fe\u8c61 \u3002\u6b64\u6642\uff0c\u9664\u7d66\u4e88\u6d88\u708e\u6b62\u75db\u5291 \uff08NSAID\uff09\u5916\uff0c\u6700\u9069\n\u5b9c\u518d\u7d66\u4e88\u7684\u85e5\u7269\u70ba\u4e0b\u5217\u90a3\u4e00\u7a2e \uff1f   \nA.methotrexate\u3002\nB.cyclosporine\u3002\nC.cyclophosphamide\u3002   \nD.azathioprine\u3002\nE.Mycophenolate mofetil (MMF)\u3002\n": "[A]", "110-115.\u4e00\u4f4d26\u6b72\u7d05\u6591\u6027\u72fc\u7621\u5973\u6027\u75c5\u4eba \uff0c\u56e0\u9ad8\u71d2\u53ca\u76ae\u819a\u7d05\u75b9\u4f4f\u9662 \uff0c\u7030\u6f2b\u6027\u7d05\u6591\u5206\u5225\u5728\u81c9\u53ca\u80f8\u90e8 \uff0ccomputed \ntomography scan\u986f\u793a\u814b\u4e0b \u3001\u9838\u90e8\u53ca\u4e0a\u9396\u9aa8\u6709\u6dcb\u5df4\u817a\u816b\u8139 \uff0c\u9aa8\u9ad3\u5207\u7247\u6709hemophagocytic cells \uff0c\u4e0b\u5217\u6aa2\u67e5\n\u5c0d\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9 \uff1fa. \u88dc\u9ad4 b. Ferritin (\u9435\u86cb\u767d) c. ANA\u6297\u6838\u6297\u9ad4 d. \u4e73\u9178\u812b\u6c2b\u9176 (lactate \ndehydrogenase ,LDH)  e. \u4e19\u80fa\u9178\u8f49\u80fa\u9176Alanine transaminase (ALT)   \nA.a+b\u3002\nB.a+c\u3002\nC.b+c\u3002\nD.b+d\u3002\nE.c+d\u3002\n": "[D]", "110-116.\u4e00\u540d27\u6b72\u7537\u6027\u6709\u767c\u71d2 \u3001\u547c\u5438\u9053\u611f\u67d3 \u3001\u904b\u52d5\u6027\u547c\u5438\u56f0\u96e3\u4e09\u500b\u6708 \uff0c\u7d93\u6297\u751f\u7d20\u6cbb\u7642\u5f8c \uff0c\u6709\u8f15\u5fae\u6539\u5584 \uff0c\u4f46\u547c\u5438\u56f0\u96e3\n\u6301\u7e8c\uff0c\u9ad8\u89e3\u6790\u5ea6\u96fb\u8166\u65b7\u5c64\u986f\u793a\u4e8c\u5074\u4e0b\u80babilateral ground -glass Haziness (\u5ee3\u6cdb\u6bdb\u73bb\u7483\u6a23\u6a21\u7cca )\u4e8c\u500b\u6708\u5f8c\u4ed6\u958b\n\u59cb\u7121\u6cd5\u5f9e\u5ea7\u6905\u53ca\u8e72\u8e1e\u7ad9\u8d77\u4f86 \uff0c\u4e0b\u5217\u6aa2\u67e5\u5c0d\u8a3a\u65b7\u7279\u5225\u6709\u5e6b\u52a9 \uff1f   \nA.\u4e19\u80fa\u9178\u8f49\u80fa\u9176Alanine transaminase (ALT)\u3002\nB.\u4e73\u9178\u812b\u6c2b\u9176(lactate dehydrogenase,LDH)\u3002\nC.\u808c\u9178\u78f7\u5316\u9175\u7d20Creatine phosphokinase (CPK)\u3002\nD.\u6297\u6838\u6297\u9ad4 (ANA)\u3002\nE.\u8840\u4e2d\u88dc\u9ad4\u3002\n": "[C]", "110-117.\u627f\u63a5\u4e0a\u984c\uff0c\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u6703\u51fa\u73fe\u4e0b\u5217\u5178\u578b\u6297\u9ad4\uff1f    \nA.Anti-RNP\u6297\u9ad4\u3002\nB.Anti-Jo1 \u6297\u9ad4\u3002\nC.Anti-histone \u6297\u9ad4\u3002\nD.Anti-dsDNA\u3002\nE.Anti-Ku \u6297\u9ad4\u3002\n": "[B]", "110-118.\u4e00\u4f4d58\u6b72\u7537\u6027\u56e0\u54b3\u8840 8\u5929\u5f8c\u958b\u59cb\u904b\u52d5\u6027\u547c\u5438\u56f0\u96e3 \uff0c\u80f8\u90e8X\u5149\u986f\u793a\u897f\u5074\u80ba\u90e8\u6709\u6d78\u6f64 \uff0c\u8840\u7d05\u7d205.4g/d\uff0c \u5c0f\u4fbf\u6709\u5927\n\u91cf\u86cb\u767d\u5c3f\u53ca\u51fa\u8840 \uff0c\u808c\u9178\u9150\uff08creatinine \uff097.2mg/dl\uff0c\u4e0b\u5217\u6aa2\u67e5\u6700\u5408\u9069 \uff1f\na. \u4e19\u80fa\u9178\u8f49\u80fa\u9176Alanine transaminase (ALT) \nb. \u6297\u55dc\u4e2d\u6027\u767d\u8840\u7403\u7d30\u80de\u8cea\u6297\u9ad4Anti -neutrophil cytoplasmic antibodies (ANCA)\nc. \u6297\u814e\u7d72\u7403\u57fa\u5e95\u819c\u6297\u9ad4Anti -glomerular basement membrane antibody / GBM Antibody \nd. \u6297\u6838\u6297\u9ad4 (ANA) \ne. \u6297\u5fc3\u78f7\u8102\u6297\u9ad4anticardiolipin antibody   \nA.a+b\u3002\nB.b+c\u3002\nC.c+d\u3002\nD.d+e\u3002\nE.e+a\u3002   \n": "[B]", "110-119.\u627f\u63a5\u4e0a\u984c \uff0c\u6cbb\u7642\u6700\u597d\u7684\u9078\u64c7\u70ba \uff1a\na.\u764c\u5fb7\u661fCyclophosphamide (Endoxan) \nb. \u963f\u65af\u5339\u6797Aspirin low dose\nc.\u79cb\u6c34\u4ed9\u7d20Colchicine\nd.\u985e\u56fa\u9187\u8108\u885d\u6cbb\u7642methyl -prednisolone pulse therapy \ne.\u6297\u751f\u7d20Antibiotics   \nA.a+b\u3002\nB.a+c\u3002\nC.a+d\u3002\nD.a+e\u3002\nE.b+c\u3002\n": "[C]", "110-120.\u4e00\u4f4d58\u6b72\u5973\u6027\u6709\u4e09\u5e74\u5de6\u5074\u7b2c\u4e09\u624b\u6307\u816b\u75db \uff0c\u5de6\u624b\u7b2c\u4e94\u6307\u4e5f\u6709\u816b\u8139 \uff0c\u816b\u8139\u662f\u5f9e\u638c\u6307\u95dc\u7bc0 (MCP)\u5230\u8fd1\u7aef\u6307\u9593\u95dc\n\u7bc0(PIP)\u53ca\u8fd1\u7aef\u6307\u9593\u95dc\u7bc0 (PIP)\u5230\u9060\u7aef\u6307\u9593\u95dc\u7bc0 (DIP)\u4e4b\u9593\uff0c\u5979\u7684\u6307\u7532\u6709\u9ede\u72c0\u51f9\u9677 (pittiy)\uff0c\u6307\u7532\u8b8a\u5f62\u840e\u7e2e\u53ca\u5206\n\u96e2(dystrophy onycholysis )\uff0c\u985e\u98a8\u6fd5\u56e0\u5b50 (RF)\u53caCCP\u6297\u9ad4\u7686\u9670\u6027 \uff0cHLA-B27\u4e5f\u70ba\u9670\u6027 \uff0c\u6b64\u75c5\u4eba\u6700\u6709\u53ef\u80fd\u8a3a\n\u65b7\u70ba\uff1f   \nA.\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(RA)\u3002\nB.\u4e7e\u766c\u6027\u95dc\u7bc0\u708e(PsA)\u3002\nC.\u50f5\u76f4\u6027\u810a\u690e\u708e(AS)\u3002\nD.\u75db\u98a8\u6027\u95dc\u7bc0\u708e (gouty arthritis)\u3002\nE.\u9000\u5316\u6027\u95dc\u7bc0\u708e (osteoarthritis)\u3002\n": "[B]", "110-121.\u514d\u75ab\u7403\u86cb\u767d G\u975c\u773d\u6ce8\u5c04(Intravenous immunoglobulin G injection)\u5c0d\u65bc\u4e0b\u5217\u4f55\u7a2e\u75be\u75c5\u6700\u70ba\u6709\u6548\uff1f    \nA.Nephrotic syndrome\u3002\nB.Fulminant hepatitis\u3002\nC.Immune thrombocytopenia\u3002\nD.Thyroid storm\u3002\nE.Acute pulmonary hemorrhage\u3002\n": "[C]", "110-122.\u4e0b\u5217\u6709\u95dc\u75be\u75c5\u8207HLA\u6297\u539f\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u7684\u76f8\u95dc\u6027\u6700\u5927\uff1f    \nA.Rheumatoid arthritis\u2501HLA-DR4\u3002\nB.SLE\u2501HLA-B8\u3002\nC.Behcet\u2019s disease\u2501HLA-DR3\u3002\nD.Sjogren\u2019s syndrome\u2501HLA-B27\u3002\nE.Allopurinol hypersensitivity\u2501HLA-DR2\u3002\n": "[A]", "110-123.21\u6b72\u4e4b\u5973\u6027\u60a3\u8005\u4e3b\u8a34\u70ba\u591a\u767c\u6027\u95dc\u7bc0\u75bc\u75db\u53ca\u53e3\u4e7e\u6709\u4e09\u500b\u6708\u4e4b\u4e45 \uff0c\u670d\u7528\u6d88\u708e\u6b62\u75db\u5291\u6709\u6548 \u3002\u6c42\u8a3a\u5f8c\u624b\u90e8 X-\u5149\u6aa2\u67e5\n\u7121\u7570\u5e38\u6216\u9aa8\u982d\u7834\u58de\u8de1\u8c61 \u3002\u8840\u6e05\u5b78\u6aa2\u67e5\u767c\u73fe: ANA 1: 160X speckled pattern, anti -cardiolipin antibody (+), \nanti-dsDNA antibody (-), ESR 48mm /mL, CRP 0.8 mg/dL, RF 94 IU /mL (normal <20 IU/mL), blood \nroutine: platelet count: 88 ,000/uL, AST 24 U/L, ALT 58 U/L\u3002\u8acb\u554f\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4e0b\u5217\u4f55\u8005 \uff1f   \nA.RA\u3002\nB.SLE\u3002\nC.Ankylosing spondylitis\u3002   \nD.Sjogren\u2019s syndrome\u3002\nE.Autoimmune hepatitis\u3002\n": "[B]", "110-124.48\u6b72\u4e2d\u5e74\u5a66\u5973\u81ea\u53bb\u5e74\u51ac\u5929\u958b\u59cb\u6709\u624b\u6307\u982d\u8b8a\u767d \u3001\u8b8a\u7d2b\u767c\u751f \u3002\u800c\u6700\u8fd1\u66f4\u6709\u6ea2\u9178 \uff0c\u6613\u55c6\u53ca\u541e\u56a5\u56f0\u96e3\u767c\u751f \u3002\u8840\u6e05\u5b78\n\u6aa2\u67e5\u767c\u73fe: ANA : 1:640 speckled pattern\u3002 \u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6297\u9ad4\u6aa2\u67e5\u5c0d\u75be\u75c5\u7684\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9 \uff1f   \nA.Anti-dsDNA\u3002\nB.Anti-phospholipid\u3002\nC.Anti-SSA\u3002\nD.Anti-neutrophil cytoplasmic antibodies\u3002\nE.Anti-Scl-70\u3002\n": "[E]", "110-125.53\u6b72\u7537\u6027\u8fd1 1\u5e74\u4f86\u6709\u773c\u4e7e\u53ca\u53e3\u4e7e\u767c\u751f \u3002\u800c\u4e14\uff0c\u767c\u73fe\u5169\u5074\u816e\u817a\u816b\u5927\u53ca\u773c\u76ae\u6d6e\u816b \u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73fe \uff1aANA :1: 40 \n(-), CRP 6.4 mg/dL, anti-SSA (-), anti -SSB(-), amylase 354 U/L, lipase 69 U/L\u3002\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u5c0d\n\u75be\u75c5\u7684\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9 \uff1f   \nA.\u816e\u817a\u6d78\u6f64\u6dcb\u5df4\u7403\u7684IgG4\u67d3\u8272\u3002\nB.Serum IgG-RFs\u3002\nC.Serum cryoglobulin M\u5b9a\u91cf\u3002\nD.Anti-EB viral antibody\u3002\nE.Sialoscintigraphy\u6aa2\u67e5\u3002\n": "[A]", "110-126.\u4e0b\u5217\u6709\u95dc\u8840\u7ba1\u708e\u53ca\u5176\u75c5\u7406\u6a5f\u5236\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f    \nA.Microscopic polyangiitis \u2501 immune complex deposition\u3002\nB.Eosinophic granulomatosis with polyangiitis\u2501MPO-ANCA (-)\u3002\nC.Granulomatosis with polyangiitis \u2501 proteinase 3-ANCA (+)\u3002\nD.Henoch-Schonlein purpura\u2501IgM cryoglobulinemia-induced\u3002\nE.Giant cell arteritis\u2501chronic hepatitis C infection\u3002\n": "[C]", "110-127.\u4e0b\u5217\u4f55\u7a2e\u81e8\u5e8a\u8868\u5fb5\u53ca\u5be6\u9a57\u5ba4\u6aa2\u67e5\u7570\u5e38 \uff0c\u53ef\u4ee5\u4f5c\u70baSLE\u7684\u5206\u985e\u57fa\u6e96 (classification criteria )?(1) discoid skin \nrash (2) erosive arthritis (3) anti-beta 2 glycoprotein I antibody  (4) pleural effusion  (5) acute uveitis  (6) \nleukocytosis  (7) bipolar mental disorder (8) acute renal tubular acidosis   \nA.(2)+(4)+(5)\u3002\nB.(3)+(5)+(7)\u3002\nC.(1)+(6)+(8)\u3002\nD.(4)+(5)+(6)\u3002\nE.(1)+(3)+(4)\u3002\n": "[E]", "110-128.\u4e0b\u5217\u4f55\u8005\u662fRheumatoid arthritis\u7684\u95dc\u7bc0\u5916\u75c7\u72c0 (extra-articular manifestations )?(1) xerostomia  (2) \nepiscleritis  (3) osteophyte  (4) hyperthyroidism (5) secondary amyloidosis (6) periodontitis (7) vasculitis  \n(8) polycythemia vera   \nA.(1)+(3)+(4)\u3002\nB.(5)+(6)+(8)\u3002\nC.(2)+(5)+(8)\u3002\nD.(2)+(6)+(7)\u3002   \nE.(4)+(7)+(8)\u3002\n": "[D]", "111-113.\u4e00\u4f4d30\u6b72\u5973\u6027\u6253\u5b8cCOVID -19\u75ab\u82d710\u5929\u5f8c\u958b\u59cb\u982d\u75db \uff0c\u7d93\u6aa2\u67e5\u5f8c\u78ba\u5b9a\u6709\u75ab\u82d7\u5f15\u8d77\u8840\u6813\u585e (thrombosis )\uff0c\u4e0b\u5217\n\u4f55\u7a2e\u75ab\u82d7\u8f03\u6613\u5f15\u8d77\u6b64\u526f\u4f5c\u7528 \uff1f      \nA.\u6838\u9178\u75ab\u82d7(mRNA Vaccine)\u3002\nB.\u75c5\u6bd2\u8f09\u9ad4\u75ab\u82d7(Viral Vector Vaccine)\u3002\nC.\u86cb\u767d\u8cea\u6b21\u55ae\u4f4d\u75ab\u82d7(Protein Subunit Vaccine)\u3002\nD.\u4e0d\u6d3b\u52d5\u75ab\u82d7(Inactivated Vaccine)\u3002\nE.\u6e1b\u6bd2\u75ab\u82d7(Live- Attenuated Vaccine)\u3002\n": "[B]", "111-114.\u627f\u63a5\u4e0a\u984c\uff0c\u6b64\u75c5\u4eba\u56e0\u75ab\u82d7\u5f15\u8d77\u7684\u6813\u585e\u5176\u6a5f\u8f49\u8207\u4e0b\u5217\u4f55\u7a2e\u8840\u6db2\u7d30\u80de\u7684\u6210\u4efd\u6297\u9ad4\u6709\u95dc\uff1f    \nA.\u767d\u8840\u7403(Leukocyte)\u3002\nB.\u8840\u5c0f\u677f(Platelet)\u3002\nC.\u6dcb\u5df4\u7403(Lymphocyte)\u3002\nD.\u5de8\u566c\u7d30\u80de(Macrophage)\u3002\nE.\u55dc\u4f0a\u7d05\u6027\u767d\u8840\u7403(Eosinophil)\u3002\n": "[B]", "111-115.\u4e00\u4f4d30\u6b72\u5973\u6027\u767c\u71d2\u4e00\u500b\u6708\u5408\u4f75\u591a\u8655\u95dc\u7bc0\u75db\u53ca\u53e3\u8154\u6f70\u760d \uff0c\u4f9d\u64da2019 EULAR /ACR\u8a3a\u65b7\u7d05\u6591\u6027\u72fc\u7621\u4e4b\u689d\n\u4ef6\uff0c\u4e0b\u5217\u6297\u9ad4\u6aa2\u67e5\u5c07\u6709\u5e6b\u52a9\u8a3a\u65b7 \uff1f   \nA.\u6297RNP\u6297\u9ad4(Anti-RNP Antibody)\u3002\nB.\u6297\u78f7\u8102\u6297\u9ad4(Anti-Phospholipid Antibody)\u3002\nC.\u6297SS-A/RO\u6297\u9ad4(Anti-SS-A/RO Antibody)\u3002\nD.\u6297SS-B/LA\u6297\u9ad4(Anti-SS-B/LA Antibody)\u3002\nE.\u6297\u7d44\u7e54\u86cb\u767d\u6297\u9ad4(Anti-histone Antibody)\u3002\n": "[B]", "111-116.\u4e00\u4f4d60\u6b72\u5973\u6027\u4e3b\u8a34\u591a\u8655\u95dc\u7bc0\u708e \uff0c\u5305\u62ec\u624b\u8155 \u3001\u8fd1\u7aef\u624b\u6307\u95dc\u7bc0\u708e\u53ca\u819d\u95dc\u7bc0\u708e \uff0c\u4e0b\u5217\u5169\u7a2e\u5be6\u9a57\u5ba4\u6aa2\u67e5\u5df2\u6210\u70ba\u8a3a\u65b7\n\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\u4e4b\u5e38\u7528\u6aa2\u67e5 \uff1f\n(1) \u6297\u6838\u6297\u9ad4   \n(2) \u985e\u98a8\u6fd5\u6027\u56e0\u5b50   \n(3) \u6297SS-A/RO\u6297\u9ad4   \n(4) \u6297\u74dc\u6c28\u9178\u6297\u9ad4 (Anti-citrullinated protein Antibodies)   \n(5) \u6297SS-B/LA\u6297\u9ad4   \nA.(1)+(2)\u3002\nB.(1)+(3)\u3002\nC.(1)+(4)\u3002\nD.(2)+(3)\u3002\nE.(2)+(4)\u3002\n": "[E]", "111-117.\u4e00\u4f4d30\u6b72\u7537\u6027\u4e3b\u8a34\u4e0b\u80cc\u75db\u4e00\u5e74 \uff0c\u6700\u8fd1\u5de6\u819d\u95dc\u7bc0\u816b\u4e8c\u500b\u6708 \uff0c\u904e\u53bb\u6709\u524d\u8461\u8404\u819c\u708e (anterior uveitis )\u75c5\u53f2\uff0c\u75c5\u4eba\n\u6709\u62bd\u83f8\u4e00\u5929\u4e00\u5305\u5df2\u7d93\u62bd\u83f8\u4e94\u5e74 \uff0c\u4e0b\u5217\u6aa2\u67e5\u5c0d\u6b64\u75c5\u4eba\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f \n(1) \u6297\u6838\u6297\u9ad4 (ANA)   \n(2) \u7279\u5225\u4eba\u985e\u767d\u8840\u7403\u6297\u539f\u6aa2\u67e5 (HLA)   \n(3) C-\u53cd\u61c9\u86cb\u767d (CRP)   \n(4) \u6297RNP\u6297\u9ad4   \n(5) \u5c3f\u9178\u6aa2\u6e2c   \nA.(1)+(2)\u3002\nB.(2)+(3)\u3002\nC.(3)+(4)\u3002   \nD.(4)+(5)\u3002\nE.(1)+(5)\u3002\n": "[B]", "111-118.\u4e00\u4f4d50\u6b72\u5973\u6027\u4e3b\u8a34\u773c\u4e7e\u53ca\u53e3\u4e7e \uff0c\u904e\u53bb\u66fe\u6709\u816e\u817a\u816b\u5927\u4e4b\u75c5\u53f2 \uff0c\u88ab\u8a3a\u65b7\u70ba\u4e7e\u71e5\u75c7 \uff0c\u4e0b\u5217\u4f55\u8005\u7570\u5e38\u6700\u6709\u53ef\u80fd\u6703\u7522\n\u751f\u6dcb\u5df4\u7624 \uff1f   \nA.\u7d05\u8840\u7403\u4e0b\u964d\u901f\u5ea6\u589e\u52a0(ESR)\u3002\nB.\u8ca7\u8840\u3002\nC.\u9577\u671f\u816e\u817a\u816b\u5927\u3002\nD.\u95dc\u7bc0\u75db\u3002\nE.\u809d\u529f\u80fd\u7570\u5e38\u3002\n": "[C]", "111-119.\u4e00\u4f4d45\u6b72\u7537\u6027\u7a81\u7136\u53f3\u8173\u8e1d\u816b\u75db\uff0c\u7121\u6cd5\u8d70\u8def\uff0c\u75c5\u4eba\u7121\u53d7\u50b7\u4e4b\u75c5\u53f2\uff0c\u4e0b\u5217\u6aa2\u67e5\u6700\u6709\u5e6b\u52a9\u8a3a\u65b7\uff1f    \nA.\u985e\u98a8\u6fd5\u6027\u56e0\u5b50\u3002\nB.\u6297\u6838\u6297\u9ad4\u3002\nC.X-Ray\u6aa2\u67e5\u3002\nD.\u95dc\u7bc0\u8154\u6db2\u6aa2\u67e5\u3002\nE.\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u3002\n": "[D]", "111-120.\u4e00\u4f4d55\u6b72\u5973\u6027\u4e3b\u8a34\u547c\u5438\u56f0\u96e3\u4e8c\u9031 \uff0c\u516d\u500b\u6708\u524d\u5728\u773c\u77bc\u6709\u7d05\u6591\u5408\u4f75\u6c34\u816b \uff0c\u81c9\u90e8\u53ca\u524d\u80f8\u4e5f\u6709\u7d05\u6591 \uff0c\u5728\u624b\u80cc\u3001\u6307\u95dc\n\u7bc0\u6709\u812b\u5c51\u76ae\u75b9 \uff0c\u4e0b\u80a2\u808c\u8089\u7121\u529b \uff0c\u75c5\u4eba\u56e0\u547c\u5438\u56f0\u96e3\u4f4f\u9032ICU\u4f7f\u7528\u547c\u5438\u5668 \uff0c\u4e0b\u5217\u6297\u9ad4\u6aa2\u67e5\u5c0d\u75c5\u4eba\u4e4b\u8a3a\u65b7\u53ca\u75c5\u60c5\n\u9810\u5f8c\u6700\u6709\u5e6b\u52a9 \uff1f   \nA.\u6297RNP\u6297\u9ad4\u3002\nB.\u6297MDA5\u6297\u9ad4\u3002\nC.\u6297Scl-70\u6297\u9ad4\u3002\nD.\u6297SS-A/RO\u6297\u9ad4\u3002\nE.\u6297SS-B/LA\u6297\u9ad4\u3002\n": "[B]", "111-121.\u4e0b\u5217\u6709\u95dcHLA loci\u8207\u514d\u75ab\u76f8\u95dc\u75be\u75c5\u4e4b\u9593\u7684\u95dc\u806f\u6027\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u5f37\u70c8\uff1f    \nA.SLE\u2014HLA-DR2\u3002\nB.Ankylosing spondylitis \u2014HLA-B27\u3002\nC.Myasthenia gravis \u2014HLA-B8\u3002\nD.Behcet's disease \u2014HLA-B51\u3002\nE.Chronic active hepatitis \u2014HLA-DR3\u3002\n": "[B]", "111-122.\u4e0b\u5217\u6709\u95dc\u81ea\u9ad4\u514d\u75ab\u75be\u75c5\u8207\u81ea\u9ad4\u6297\u9ad4\u4e4b\u9593\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f    \nA.Hashimoto's thyroiditis \u2014anti-TSH receptor antibody\u3002\nB.Granulomatosis with polyangiitis--anti-proteinase 3 antibody\u3002\nC.Systemic lupus erythematosis (SLE) \u2014anti-C3 antibody\u3002\nD.Rheumatoid arthritis (RA) \u2014anti-IgM antibody\u3002\nE.Systemic sclerosis \u2014anti-epidermal cadhedin antibody\u3002\n": "[B]", "111-123.\u4e0b\u5217\u4f55\u8005\u662frheumatoid arthritis\u6700\u5e38\u898b\u7684\u95dc\u7bc0\u5916\u8868\u73fe\uff1f    \nA.Vasculitis\u3002   \nB.Non-specific Interstitial pneumonia\u3002\nC.Subcutaneous nodule\u3002\nD.Cervical myelopathy\u3002\nE.Uveitis\u3002\n": "[C]", "111-124.\u4e0b\u5217\u6709\u95dcsystemic sclerosis\u7684\u81e8\u5e8a\u75c7\u72c0\u63cf\u8ff0\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f    \nA.\u76ae\u819a\u5e38\u6703\u51fa\u73fe\u6ebc\u75b9\u6027\u8b8a\u5316\u3002\nB.\u6613\u767c\u751f\u5fc3\u8840\u7ba1\u75c5\u8b8a\u3002\nC.\u5e38\u6703\u5f15\u8d77\u9593\u8cea\u6027\u814e\u708e\u3002\nD.\u80ba\u764c\u7684\u6bd4\u4f8b\u589e\u52a0\u3002\nE.\u6700\u5e38\u898b\u7684\u521d\u59cb\u75c7\u72c0\u70baRaynaud's phenomenon\u3002\n": "[E]", "111-125.\u4e0b\u5217\u4f55\u8005\u662fSjogren's syndrome\u7684\u817a\u9ad4\u5916(extra-glandular)\u4f75\u767c\u75c7\u4e4b\u4e00\uff1f    \nA.Uveitis\u3002\nB.Chronic pancreatitis\u3002\nC.Retroperitoneal fibrosis\u3002\nD.Renal tubular acidosis\u3002\nE.Anemia\u3002\n": "[D]", "111-126.\u6cbb\u7642axial spondyloarthritis\u7684\u6700\u6709\u6548\u7684\u85e5\u7269\u70ba\u4e0b\u5217\u4f55\u8005\uff1f    \nA.Salazopyrin\u3002\nB.Methotrexate\u3002\nC.Anti-TNF-alpha therapy\u3002\nD.Corticosteroids\u3002\nE.Cyclosporine\u3002\n": "[C]", "111-127.SLE\u7684\u8a3a\u65b7\u662f\u6839\u64da\u81e8\u5e8a\u75c7\u72c0\u53ca\u514d\u75ab\u8840\u6e05\u5b78\u6aa2\u67e5\u5169\u90e8\u5206 \u3002\u8acb\u554f\u4e0b\u5217\u7684\u90a3\u4e9b \u9805\u76ee\u5305\u62ec\u5728\u5167 \uff1f\n(1) Oral mucosa ulcer (2) scaring alopecia (3) discoid skin lesion (4) pleural effusion (5) myalgia (6) \nschizophrenia (7) low serum complements (8) anti-Sm antibody (9) anti-beta glycoprotein I antibody (10) \nhemolytic anemia (11) anti-ribonuclear protein antibody (12) thrombocytopenia   \nA.(1)+(2)+(7)\u3002\nB.(3)+(4)+(11)\u3002\nC.(5)+(8)+(9)\u3002\nD.(3)+(7)+(10)\u3002\nE.(3)+(11)+(12)\u3002\n": "[D]", "111-128.\u4e0b\u5217\u4f55\u7a2e\u75be\u75c5\u5c6c\u65bcanti -neutrophil cytoplasmic antibody (ANCA)\u967d\u6027\u7684\u8840 \u7ba1\u708e\u75c7\u5019\u7fa4 \uff1f\n(1) granulomatosis with polyangiitis (2) hepatitis C virus -associated vasculitis (3) microscopic \npolyangiitis (4) eosinophilic granulomatosis with polyangiitis (5) lupus vasculitis (6) giant cell arteritis (7) \ndrug-induced vasculitis (8) Behcet's disease (9) IgA-induced vasculitis (10) Takayasu arteritis   \nA.(3)+(4)+(5)\u3002\nB.(6)+(7)+(8)\u3002\nC.(1)+(2)+(6)\u3002   \nD.(7)+(8)+(9)\u3002\nE.(1)+(3)+(4)\u3002\n": "[E]"}